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Abstract 
 
Active vitamin D3 metabolites play an essential role in the maintenance of calcium and 
phosphorus homeostasis. The conventional chemical synthesis of this metabolite is time-
consuming, environmentally unfriendly and often results in low yield. Therefore, the 
biotechnological production of active vitamin D3 metabolites is of great importance to the 
pharmaceutical industry. Hereby, cytochrome P450 enzymes have the potential to achieve 
this goal. 
The present work reports on the optimization of a biotechnological process in Bacillus 
megaterium MS941 for the production of vitamin D3 metabolites. On that account, two 
cytochrome P450 enzymes were used as biocataylsts, namely CYP109E1 and CYP109A2 
from the Gram-positive bacterium Bacillus megaterium DSM319. Both enzymes were 
subjected for functional and structural characterization in order to optimize their activity 
and/or regio-selectivity towards vitamin D3. In terms of hydroxylation activity, it has been 
shown that the conversion of vitamin D3 with CYP109E1 results in the formation of several 
derivatives, while CYP109A2 shows clearly a higher regio-selectivity towards 25-
hydroxylation. The elucidation of the crystal structure of both enzymes provides detailed 
insights into the geometry of these enzymes. By means of molecular docking, site-directed 
mutagenesis was successfully performed, resulting in the creation of mutants with higher 
regio-selectivity compared to the wild type, in particular when using CYP109E1. The 
enhancement of the regio-selectivity of this P450 resulted in a higher yield of the valuable 
metabolite 25-hydroxyvitamin D3. A two-fold increase of the 25-hydroxyvitamin D3 yield 
was achieved after the substitution of I85 by tryptophan or alanine. The engineering of 
CYP109A2 resulted also in a slight increase in the 25-hydroxyvitamin D3 yield compared to 
the wild type. Summarizing, it has been shown that CYP109E1-I85W, CYP109A2-, - or 
CYP109-T103A-based whole-cell systems are a competitive methods for the production of 
25-hydroxyvitamin D3 among the previously established biotechnological processes. 
 
 
 
II 
 
Zusammenfassung 
 
Aktive Vitamin-D3-Metaboliten spielen eine wesentliche Rolle bei der Aufrechterhaltung 
der Calcium- und Phosphor-Homöostase. Die herkömmliche chemische Synthese dieser 
Metaboliten ist zeitaufwendig, umweltschädlich und führt oft zu geringer Ausbeute. Daher 
ist die biotechnologische Herstellung von aktiven Vitamin-D3-Metaboliten für die 
pharmazeutische Industrie von großer Bedeutung. Der Einsatz von Cytochromen P450 gilt 
hierbei als vielversprechend. 
Die vorliegende Arbeit beschäftigt sich mit der Optimierung eines biotechnologischen 
Prozesses in Bacillus megaterium MS941 zur Produktion von Vitamin-D3-Metaboliten. Als 
Biokatalysatoren wurden zwei Cytochrome-P450-Enzyme verwendet, nämlich CYP109E1 
und CYP109A2 aus dem Gram-positiven Bakterium Bacillus megaterium DSM319. Beide 
Enzyme wurden einer funktionellen und strukturellen Charakterisierung unterzogen, um ihre 
Aktivität und / oder Regio-Selektivität gegenüber Vitamin-D3 zu optimieren. Bezüglich der 
Hydroxylierungsaktivität wurde gezeigt, dass die Umwandlung von Vitamin-D3 mit 
CYP109E1 zur Bildung mehrerer Derivate führt, während CYP109A2 deutlich eine höhere 
Regio-Selektivität bezüglich einer 25-Hydroxylierung zeigt. Die Aufklärung der 
Kristallstruktur beider Enzyme liefert detaillierte Einblicke in die Geometrie dieser Enzyme. 
Mit Hilfe des molekularen Dockings wurde eine ortsgerichtete Mutagenese erfolgreich 
durchgeführt, wodurch im Vergleich zum Wildtyp, insbesondere von CYP109E1, Mutanten 
mit höherer Regio-Selektivität hergestellt wurden. Die Optimierung der Regio-Selektivität 
dieses P450 führte zu einer höheren Ausbeute des wertvollen Metaboliten 25-
Hydroxyvitamin-D3. Die Produktion von 25-Hydroxyvitamin-D3 konnte durch die 
Substitution von I85 durch Tryptophan oder Alanin verdoppelt werden. Die Optimierung 
von CYP109A2 führte ebenfalls zu einem leichten Anstieg der 25-Hydroxyvitamin-D3-
Ausbeute im Vergleich zum Wildtyp. Zusammenfassend wurde gezeigt, dass CYP109E1-
I85W-, CYP109A2-, oder CYP109-T103A-basierte Ganzzellsysteme eine 
wettbewerbsfähige Methode zur Herstellung von 25-Hydroxyvitamin-D3 unter den bisher 
etablierten biotechnologischen Verfahren darstellen. 
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1. Introduction 
 
1.1. Protein engineering 
‘Enzymes as catalysts are of key importance in biotechnology, similar to the role of nucleic 
acids as carriers of genetic information’ (Buchholz et al., 2005). They are widely used in the 
industrial production of bulk chemicals and pharmaceuticals. The conventional chemical 
synthesis often requires complex procedures under harsh conditions; in contrast, enzymes 
perform their reactions with high specificity and enantio-, regio- and stereo-selectivity under 
mild conditions. Despite their attractive features, enzymes often do not meet the requirement 
of an industrial process and, therefore, different enzyme properties usually have to be 
improved. Out of this necessity, a new multidisciplinary field named protein engineering 
was born, which comprises different science areas: molecular biology, biochemistry, 
crystallography, bioinformatics and biotechnology. 
Generally, there are two basic approaches for protein engineering: directed evolution and 
rational design. The first one involves different molecular biology methods that mimic the 
natural evolution via random mutagenesis (e.g. chemical mutagenesis, error prone PCR) 
and/or DNA recombination (e.g. gene shuffling, staggered extension process (StEP)) (Zhao 
et al., 2002). In iterative cycles, mutations are randomly introduced to create a library of 
genes followed by screening to identify enzyme variants that exhibit the desired function. 
The advantage of this strategy is that no structural information of the protein is needed. On 
the other hand, the screening procedure could be as difficult as looking for a needle in a 
haystack. However, directed evolution has been successfully applied to optimize 
biocatalysts in terms of their specificity, stability, activity. Successful applications have been 
reviewed by (Arnold, 2017; Böttcher and Bornscheuer, 2010; Zhao et al., 2002). 
In rational protein design, mutations are introduced to specific protein sites (site-directed 
mutagenesis) and, therefore, the availability of the enzyme structure and knowledge about 
structure-function relationship is required. The advanced progress in protein crystallography 
and computational methods can enhance the potential of protein engineering via site-
directed mutagenesis (Illanes et al., 2012; Röthlisberger et al., 2008). Rational design has 
been successfully used to overcome the enzyme limitations in industrial applications. The 
thermostability of α-amylase from Bacillus licheniformis and formate dehydrogenase from 
Pseudomonas sp. 101 has been improved by removal of asparagine residues and 
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introduction of additional hydrophobic contacts, respectively (Declerck et al., 2000; Rojkova 
et al., 1999). Further examples for successful protein engineering via site-directed 
mutagenesis are reviewed by (Böttcher and Bornscheuer, 2010). Recently, the combination 
of directed evolution and rational design techniques supported by computer-aided methods 
opens new possibilities for protein engineers (Li and Cirino, 2014). 
In recent years, the cytochrome P450 monooxygenases (CYP or P450) has been recognized 
as potential biocatalyst for pharmaceutical and biotechnological industries since they can 
catalyze the oxidation of inactivated hydrocarbons in a stereo-selective manner (Bernhardt, 
2006; Bernhardt and Urlacher, 2014; Hazel M Girvan & Andrew W Munro, 2016).  
However, P450s enzymes have some properties that limit their industrial applications to few 
examples (Julsing et al., 2008). For this reason, cytochrome P450 enzymes have been 
engineered by directed evolution and rational design to improve their activities, expression 
levels, stabilities and substrate specificities as well as regio- and stereo-selectivities. In this 
context, the most investigated cytochrome P450 enzymes is the bacterial fatty acid 
hydroxylase CYP102A1 (P450 BM3) from Bacillus megaterium. CYP102A1 has been 
engineered to catalyze the hydroxylation of non-natural substrates as diverse as 
pharmaceuticals, terpenes and alkanes. CYP102A1-F87A was generated by site-directed 
mutagenesis, which is able to catalyze the hydroxylation of fatty acids at the position ω-4. In 
contrast, the wild type enzyme catalyzes the hydroxylation at ω-1, ω-2 and ω-3 (Oliver et 
al., 1997). An overview of CYP102A2 mutants can be found in (Whitehouse et al., 2012). 
Numerous protein engineering studies have been performed with cytochrome P450 
enzymes, providing different examples where different enzyme properties have been 
successfully improved and in other cases they have not. Further examples for P450s 
engineering are reviewed in (Gillam, 2008; Kumar, 2010; McIntosh et al., 2014; Yasuda et 
al., 2018). 
1.2. Vitamin D3 
The fat-soluble vitamin D3 is a secosterol, which is synthesized from the precursor 7-
dehydrocholesterol (7-DHC) during exposure to sunlight (Holick et al., 1980). The 
photolytic conversion of 7-DHC results in the formation of previtamin D3 that is further 
converted to vitamin D3 by heat-induced isomerization (Okano et al., 1977; Holick et al., 
1977) (Figure. 1.1). Vitamin D3 can also be obtained naturally from the diet. Nevertheless, 
only a few natural sources contain significant amounts of this important compound. The 
flesh of fatty fish such as salmon and tuna as well as the fish liver oils count to the best 
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naturally sources for vitamin D3. Although more and more foods are fortified with vitamin 
D3, the sunlight-dependent endogenous synthesis of vitamin D3 remains the main source for 
most populations (Calvo et al., 2005). Therefore, environmental factors such as latitude and 
weather conditions affect vitamin D3 synthesis (Spiro and Buttriss, 2014). Moreover, 
individual characteristic, such as skin pigmentation, age and outdoor activity can also 
influence vitamin D3 status.  Due to this, vitamin D3 insufficiency exists worldwide 
including Europe (Duso et al., 2004; Spiro and Buttriss, 2014).  
 
 
 
 
 
 
 
 
 
 
 
The consequences of low vitamin D3 level in the blood are mainly remarkable in bone 
formation and mineralization, because vitamin D3 metabolites are principle factors in 
calcium and phosphorus homeostasis. In absence of vitamin D3, only 10 to 15% of dietary 
calcium and about 60% of phosphorus could be absorbed (DeLuca, 2004; Hossein-nezhad 
and Holick, 2013), resulting in rickets among children and osteomalacia among adults 
(Underwood and DeLuca, 1984; Heaney et al., 2003). Furthermore, vitamin D3 metabolites 
play a key role in several physiological processes such as cell growth, apoptosis, modulation 
of immune response and renin-angiotensin system (Abe et al., 1981; Wagner et al., 2003; Li, 
2003; Di Rosa et al., 2011). Therefore, worldwide there has been growing interest in the 
physiological and therapeutic aspects of vitamin D3. Several studies have linked vitamin D3 
Figure 1.1. Vitamin D3 synthesis in the skin. The photolytic 
conversion of 7-dehydrocholesterol into previtamin D3 is 
followed by heat-induced isomerization producing vitamin D3.  
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deficiency to the development of different chronic diseases such as cardiovascular and 
autoimmune diseases, neuromuscular dysfunction, diabetes mellitus, different cancers and 
gynecological disorders (Deluca and Cantorna, 2001; Grant, 2002; Holick, 2004). 
 
1.3. Metabolism of vitamin D3 
Apart from the origin of vitamins D3, this molecule is biologically inert. Two sequential 
hydroxylation steps, the first one at C-25 and the second at C-1, are required to produce the 
hormonally active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2VD3) (Figure 
1.2). These reactions are catalyzed by different enzymes of the same family, namely 
cytochrome P450 (CYP or P450). 
Studies on the 25-hydroxylase in human and animals showed that several cytochrome P450 
enzymes, such as CYP2R1, CYP27A1, CYP2J2, CYP2D25 and CYP3A4, can act as 
vitamin D3 25-hydroxylases (Prosser and Jones, 2004; Schuster, 2011). However, only 
CYP2R1 is considered as the physiologically relevant enzyme (Cheng et al., 2004). The 25-
hydroxylation of vitamin D3 occurs primarily in the liver, producing 25-hydroxyvitamin D3 
(25(OH)VD3), also known as calcidiol. It also has been shown that 25(OH)D3 is produced in 
other tissues such as kidney and intestine (Horsting and DeLuca, 1969; Holick et al., 1972; 
Tucker et al., 1973). 25(OH)VD3 is the major circulating vitamin D3 metabolite and, for this 
reason, its plasma level is considered as the best indicator for vitamin D3 status. Among 
experts, there is no consensus on the optimal plasma level of this indicator. However, a 
25(OH)VD3 concentration less than 20 ng/mL
 
(50 nmol/L) is related with vitamin D3 
deficiency (Bischoff-Ferrari et al., 2006; Holick, 2007). The Clinical Practice Guideline of 
the Endocrine Society distinguishes between vitamin D deficiency (< 20 ng/mL), 
insufficiency (21 to 29 ng/mL) and sufficiency (30 ng/mL), whereas a concentration 
between 40 and 60 ng/mL
 
is recommended (Holick et al., 2011). 25(OH)VD3 is not only 
interesting for its task as an indicator for vitamin D3 status, but also as therapeutic agent. It 
has been found that supplementation of 25(OH)VD3 has a preventive, therapeutic effect 
against  chronic kidney disease, Crohn’s and cholestatic liver disease (Leichtmann et al., 
1991; Jean et al., 2008). In addition, anti-proliferative activity of this metabolite has been 
shown (Munetsuna et al., 2014). 25(OH)VD3 is also used as supplement in animal food, as it 
has been found that this metabolite is the most active form of vitamin D3 capable of 
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supporting both cellular functions and embryonic development in chickens and turkeys 
when fed as the sole source of vitamin D3 (Soares et al., 1995).  
The second step in vitamin D3 activation, 1α-hydroxylation, occurs mainly in the kidneys by 
the mitochondrial enzyme CYP27B1 producing the secosteroid hormone 1α,25-
dihydroxyvitamin D3 (1α,25(OH)2D3), also known as calcitriol, which is the most active 
form of vitamin D3. Most of vitamin D3 physiological functions rely on the action of this 
active metabolite. More detailed information on biological functions of 1α,25(OH)2D3 can 
be found in (Brown et al., 2002; DeLuca, 2004; Deluca and Cantorna, 2001; Duso AS. et al., 
2004; Sutton and MacDonald, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Vitamin D3 activation and inactivation. Liver 25-hydroxylase 
converts vitamin D3 into 25(OH)VD3, the most circulating metabolite of 
vitamin D3. The second activation step occurs primarily in the kidney 
producing the most active metabolite, 1α.25(OH)2VD3. Vitamin D3 
inactivation is performed by 24-hydroxylase (CYP24A1) after a series of 
oxidation reactions resulting in calcitroic acid or 1α,25(OH)2VD3-26,23-
lactone. The metabolite 24,25(OH)2VD3 is produced from 25(OH)VD3 by 
CYP24A1. Figure is taken from (Prosser and Jones, 2004). 
5
  Introduction 
 
 
The inactivation of vitamin D3 is carried out by the mitochondrial enzyme CYP24A1, which 
is involved in two catabolic pathways; (i) the carbon-24 oxidation pathway from 
1α,25(OH)2VD3 to calcitroic acid (ii) the lactone pathway from 1α,25(OH)2VD3 to 
1α,25(OH)2VD3-26,23-lactone (Figure 1.2) (Prosser and Jones, 2004). In addition, 
CYP24A1 has an activating role in vitamin D3 metabolism as it catalyze the formation of the 
metabolite 24,25(OH)2VD3, which has been proposed to play a biological role in bone 
fracture repair or cartilage maturation (Seo et al., 1997). 
1.4. Action of the hormone 1α,25-dihydroxyvitamin D3 
The secosteroid hormone, 1α,25(OH)2VD3, accomplishes its biological functions, like other 
steroid hormone, through intracellular receptors that function as transcription factors (Tsai 
and O’Malley, 1994). The hormone 1α,25(OH)2VD3 binds to the nuclear vitamin D receptor 
(VDR), which is present in most tissues and cells. The complex consisting of 1,25(OH)2VD3 
and VDR  forms then a heterodimer with the retinoic acid X receptor (RXR) that binds to 
specific short repeating hexameric nucletide sequences in the genome known as vitamin D 
response elements (VDREs) (Ozono et al., 1990; Barletta et al., 2002). The VDREs are 
usually located upstream in the promotor of the target gene (Gamble and Freedman, 2002).  
As a result of ligand-induced conformational change of the VDR-RXR heterodimer, co-
repressor proteins such as the nuclear receptor co-repressor (NCoR) are dissociated from the 
complex and interactions with different co-activators are created (Haussler et al., 1998). This 
complex has the ability to recruit a large coregulatory complex into the transcriptional 
preinitiation complex of the target gen resulting in enhancement or suppression of gene 
transcription (Pike and Meyer, 2010; Sutton and MacDonald, 2003). 
1.5. Cytochrome P450 monooxygenases  
Cytochromes P450 (CYPs or P450s) are heme-containing enzymes, which are found 
throughout the three biological kingdoms (Nelson, 2011). The earliest insight into P450 
research began in 1958, when a carbon-monoxide binding pigment was isolated from rat and 
pig liver microsomes (Garfinkel, 1958; Klingenberg, 1958). Later, Omura and Sato 
demonstrated the presence of iron-protoporphyrin IX in this pigment, which was named 
cytochrome P450 (Omura and Sato, 1964). Such name is uncommon for enzymes, which are 
normally named after their function. The terminology of cytochromes P450 describes the 
nature and characteristic feature of this enzyme class; cytochrome stands for hemoprotein, 
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the letter P for ‘Pigment’ and the number 450 relates the characteristic absorption peak at 
450 nm when the enzyme is complexed with carbon monoxide (CO). 
P450 enzymes are classified into families and subfamilies based on the sequence identity. 
According to the widely used P450 nomenclature system (Nelson, 2009), members of the 
same family share an amino acid sequence identity of more than  40%, and those with more 
than 55% identity are assigned to the same subfamily. The conventional name of 
cytochrome P450 enzymes starts with the abbreviation CYP followed by an Arabic number 
for the P450 family, a letter for the subfamily and a second Arabic number for the individual 
gene, for instance, CYP109E1 is a member of the family 109 and the subfamily E. The 
function of P450 enzymes is the activation of molecular oxygen for the metabolism of 
different chemical structures (e.g. steroids, fatty acids, xenobiotics and terpenes). They can 
introduce one oxygen atom of the molecular oxygen into an allylic position, double bond 
and non-activated C-H bond, while the second oxygen atom is reduced to water. The most 
common reaction of P450s is a hydroxylation reaction (Figure 1.3). However, P450s are 
able to catalyze a variety of reactions including epoxidation, sulfoxidation, N-, O-, S-
dealkylation, and C-C bond cleavage. An overview of the reactions catalyzed by P450s is 
given by (Sono et al., 1996; Bernhardt, 2006; Guengerich and Munro, 2013).  
 
 
 
 
 
The heme-iron plays a central role in the multi-step catalytic cycle of P450s, which changes 
between two oxidation states, the Fe III (ferric) and the Fe II (ferrous). At the beginning of 
each cycle, the heme iron adopts an inactive state, low spin Fe (III), which is six-coordinated 
by four nitrogen atoms of protoporphyrin IX ring (equatorial), the sulphur atom from 
cysteine and a water molecule (axial) (Figure. 1.4) (1). The substrate binding causes a 
displacement of the water molecule producing a five coordinated high-spin Fe (III) (2). The 
first electron delivered by the redox partners is used to reduce the ferric iron into its ferrous 
form (Fe (II)) (3). In the next step, molecular oxygen is bound, resulting in a ferrous dioxy 
Figure 1.3. General hydroxylation reaction catalyzed by P450 enzymes. 
Adapted from (Urlacher et al., 2004). 
7
  Introduction 
 
 
species (4). A second reduction followed by a proton delivery results in an iron-hydroperoxo 
intermediate (5). This complex undergoes heterolytic cleavage, producing the putative iron-
oxo ferryl species named “Compound I” (6). According to the oxygen rebound mechanism, 
compound I abstracts a hydrogen atom from the closely bound substrate forming the 
intermediate compound II and a substrate radical (7) (Groves, 2006). Through radical 
recombination, the hydroxylated product is formed and finally released. The enzyme returns 
to its initial state (low-spin ferric form) and the cycle can start again.  
During the catalytic cycle reactive oxygen species (ROS) are produced, which can lead to an 
inactivation of P450 enzymes. Interestingly, some P450s can oxidize their substrates using 
peroxides as electron and oxygen donor (shunt pathway) (Nordblom et al., 1976; Bernhardt, 
1996). This peroxidase-like mechanism allows P450s to function without the cost-expensive 
cofactor NADPH and electron transport proteins. The usage of peroxide instead of NADPH 
results, however, in a decrease of reaction rates (Bernhardt and Urlacher, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Catalytic cycle of cytochromes P450. Figure is taken from  
(Ener et al., 2010). 
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1.6. Electron transfer in cytochrome P450 systems 
As mentioned above, P450s require sequential delivery of two electrons in order to facilitate 
their activity, which are usually obtained from the pyridine nucleotide coenzyme NADPH.  
The transport of these two electrons from NADPH to P450 is performed by means other 
protein (s), redox partner (s). Concerning the involved redox partners, P450s were classified 
after their discovery into two main classes, the mitochondrial class I and microsomal class II 
(Omura et al., 1966; Lu et al., 1969). Since then, several cytochrome P450 systems have 
been reported, which could be classified into ten classes (Hannemann et al., 2007). 
However, the most commonly classes are class I and class II (Figure 1.5). Most of bacterial 
and the mitochondrial cytochrome P450 systems belong to class I, consisting of three 
distinct proteins: (i) a FAD-containing ferredoxin reductase, which is soluble in case of 
bacteria and associated to the inner mitochondrial membrane in eukaryotes. (ii) a soluble 
ferredoxin, which receives the electrons one by one from the reductase and shuttles them to 
the last component of the system, (iii) the cytochrome P450 itself, which is soluble in case 
of bacteria and bound to the inner mitochondrial membrane in eukaryotes (Figure 1.5 A, B). 
The class II systems are commonly present in eukaryotes and known as microsomal 
systems, since their two components, the P450 and the NADPH-cytochrome P450 reductase 
(CPR), are bound to the membrane of the endoplasmic reticulum (Figure 1.5 C). CPR 
includes the prosthetic groups FAD and FMN. 
 
1.7. Structure of P450 enzymes 
Despite the low sequence identity among the members of the P450 family (< 20%), P450 
enzymes share a common structural fold and topology, which is essential for their function. 
The conserved overall structure of P450s consists of approximately 13 α-helices (named A-
L) and five β-sheets (1-5) with the heme group in a buried substrate binding pocket, forming 
the so called P450 fold (Graham and Peterson, 1999) (Figure 1.6). The most conserved 
structural elements of the P450 fold include a four-helix bundle (helices D, E, I, and L) and 
the J- and K-helices. The prosthetic heme group is found between the I- and L-helices 
binding to the Cys-heme-ligand loop containing the P450 signature sequence 
FxxGx(H/R)xCxG. Herby, the highly conserved cysteine is bound to the heme iron as fifth 
ligand, while in other cytochromes like hemoglobin, a histidine residue is coordinating the 
heme iron (Denisov et al., 2005). 
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The linkage of the heme iron to the cysteine thiolate is the origin of the characteristic Soret 
absorption at 450 nm when carbon monoxide is bound to the ferrous form of the enzyme. 
The longest helix (I-helix) is located in the immediate vicinity of the heme and contains a 
highly conserved threonine and an acidic residue known as acid-alcohol pair, which is 
supposed to be involved in oxygen activation and proton delivery (Imai et al., 1989; 
Martinis et al., 1989). Characteristic feature of the I-helix is the local split in the H-bonding 
pattern of α-helix near the conserved threonine. This helical deformation is critical for the 
oxygen activation. It is known that the K-helix contains the conserved ExxR motif, which is 
suggested to be important for stabilizing the core structure. 
Figure 1.5. Scheme of different cytochrome P450 systems. (A) class I, 
bacterial system containing three soluble proteins, ferredoxin reductase 
(FdR), ferredoxin (Fdx) and P450. (B) Class I, mitochondrial system. (C) 
Class II, microsomal system. Figures modified according to (Hannemann 
et al., 2007). 
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However, there are variable regions in P450 structures providing the individual properties. 
Regions in P450s responsible for substrate recognition and binding, known as substrate 
recognition sites (SRSs), were first identified by Gotoh (Gotoh, 1992), consisting usually of 
variable residues allowing the conversion of an enormous number of different substrates 
(Peterson and Graham, 1998). On the basis of sequence or structure comparison, the 
individual SRSs can be determined for each P450 (Gotoh, 1992; Gricman et al., 2015). 
Generally, P450 structures contain six SRSs (Figure 1.7): SRS1 is located on the BC loop, 
SRS2, 3 and 4 are located on the F-, G- and I-helices, respectively, and SRS5 is located on 
β1-4 and SRS6 spans over β 4-1 and β 4-2. The residues located in the SRSs interact directly 
with a ligand molecule, or determine the structure or flexibility of the binding site. SRS2 and 
3 are located on the entrance channel leading from the bulk to the binding pocket, whereas 
SRS1, 4, 5, and 6 form the access to the heme. 
Figure 1.6. Topological illustration of P450 structure. The 
structural elements α-helices and β-sheets are presented as green 
tube and blue arrows, respectively. Figure is taken from (Peterson 
and Graham, 1998). 
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The number of obtained P450 structures has been increased during the last decades 
providing significant information about structure-function relationship. It is known that 
P450s possess flexible structures in order to allow substrate entry followed by closing of the 
active site. The first indications of the open/closed forms of P450 structures were based on 
the comparison of BM3 substrate-free and –bound complexes (Li and Poulos, 1997). In the 
substrate-free form, the F-G loop defines the access channel to the active site, while the F- 
and G- helices are positioned so that the active site is wide open. Upon substrate binding, 
remarkable conformational changes occur in the F- and G-helices leading to closure of the 
active site. Besides the open/closed forms of P450 structures, the active site can adopt 
different shapes depending on the structure of bound ligands. Such induced fit was firstly 
observed in CYP119 by the elucidation of its crystal structure with two different ligands; 
phenylimidazole and imidazole (Yano et al., 2000). The structural flexibility of P450 throws 
light on the question how the same P450 fold can bind and convert a broad range of different 
substrates. 
 
 
Figure 1.7. The six substrate recognistion sites in P450s are shown by arrwos 
(SRS) and represented here for the crystal strcuture of CYP109A2 (PDP: 5OFQ). 
The α-helices are labeled following the common P450 nommenclatur (A-L). 
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1.8. Cytochrome P450s for the production of active vitamin D3 metabolites 
In recent years, P450 biocatalysts have been used for the synthesis of bulk chemicals and 
pharmaceuticals (Bernhardt, 2006; Bernhardt and Urlacher, 2014; Hazel M Girvan & 
Andrew W Munro, 2016; Sakaki, 2012; Urlacher et al., 2004). The production of pravastatin 
from compactin through 6β-hydroxylation catalyzed by CYP105A3 is one of the most 
successful applications of P450 enzymes (Watanabe et al., 1995). Another successful 
industrial application of cytochrome P450 is the bioconversion of vitamin D3 to 1α-25-
dihydroxyvitamin D3. Firstly, Sasaki et al. showed that two Streptomyces strains are capable 
of converting 25(OH)VD3 and 1α-(OH)VD3, respectively, to 1α-25(OH)2VD3 (Sasaki et al., 
1991). However, the conversion of vitamin D3 to 25(OH)VD3 was not detected. 
Subsequently, the conversion of vitamin D3 to 1α-25(OH)2VD3  via 25(OH)VD3 was 
reported using Amycolata autotrophica FERM BP-1573 (now renamed to Pseudonocardia 
autotrophica) (Sasaki et al., 1992).  Using this strain, a preparative-scale conversion of 
vitamin D3 (200 L tank fermenter) yielded 8.3 mg 25(OH)VD3/L culture and 0.17 mg 1α-
25(OH)2VD3/L culture after 120 h (Sasaki et al., 1992).  Afterwards, the identification of 
vitamin D3 25-hydroxylase from this strain was reported, which has been classified as 
CYP105A2 (Kawauchi et al., 1994). Using recombinant Streptomyces lividans cells 
expressing CYP105A2, the maximum yield of 25(OH)VD3 was 20 mg/L culture after 72 h 
cultivation time. In addition, a vitamin D3 hydroxylase from P. autotrophica has been 
identified and classified as CYP107 (known as Vdh), which can convert vitamin D3 to 1α-
25(OH)2VD3 via 25(OH)VD3 (Fujii et al., 2009). Another vitamin D3 hydroxylase from 
Streptomyces griseolus has been identified, namely CYP105A1 (Sawada et al., 2004). 
CYP107 and CYP105A1 are currently applied in the biotechnological production of active 
vitamin D3 metabolites (Sakaki et al., 2011). Using site-directed mutagenesis and directed 
evolution, the catalytic activity of CYP107 and CYP105A1 towards vitamin D3 has been 
enhanced (Hayashi et al., 2008; Yasutake et al., 2013). To the best of our knowledge, only 
these two P450s are employed in a biotechnological process for the production of the active 
vitamin D3 metabolites, 25(OH)VD3 and/or 1α-25-dihydroxyvitamin D3, demonstrating the 
necessity of further biotechnological alternative. 
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1.9. Aim of this work 
Bacillus megaterium (B. megaterium) is considered as an ideal industrial organism (Vary et 
al., 2007). It has been industrially employed to produce proteins like penicillin acylase 
(Martín et al., 1995), various amylases (Hebeda et al., 1988) and glucose dehydrogenase 
(Kittsteiner-Eberle et al., 1989). In addition, it has been used for the production of different 
biotechnological interesting substances like pyruvate and vitamin B12 (Hollmann and 
Deckwer, 2004; Raux et al., 1998). Previously, the genome sequence of B. megaterium 
DSM319 has been published and it was shown to contain four open reading frames encoding 
four P450s; CYP102A1, CYP106A1, CYP109E1 and CYP109A2. 
This work focuses on the two members of the family CYP109 from B. megaterium DSM319 
and their application as vitamin D3 hydroxylase. The biotechnologically important B. 
megaterium strain MS941 was used as expression and conversion host. The goal of the 
presented work is the production of active vitamin D3 metabolites, mainly 25-
hydroxyvitamin D3. For this purpose, the action of these two P450s on vitamin D3 has to be 
firstly determined. In order to increase the yield of our target product, 25-hydroxyvitamin 
D3, protein engineering methods should be applied to improve the activity and/or regio-
selectivity of the selected P450s towards vitamin D3. Hereby, the crystal structures of 
CYP109E1 and CYP109A2 have to be elucidated in collaboration with the laboratory of 
biophysical chemistry at the University of Groningen. By means of molecular docking and 
structural comparison, functionally important residues of both enzymes have to be predicted. 
Based on this, site-directed mutagenesis should be performed to create a focused mutant 
library. The enzyme mutants should be screened for higher product formation. 
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a  b  s  t  r  a  c  t
In this  study  the ability  of CYP109E1  from  Bacillus  megaterium  to metabolize  vitamin  D3 (VD3) was  inves-
tigated.  In an  in  vitro  system  using  bovine  adrenodoxin  reductase  (AdR)  and  adrenodoxin  (Adx4-108),
VD3 was  converted  by CYP109E1  into  several  products.  Furthermore,  a whole-cell  system  in  B. mega-
terium  MS941  was established.  The  new  system  showed  a  conversion  of 95% after 24 h.  By  NMR analysis
it  was found  that  CYP109E1  catalyzes  hydroxylation  of VD3 at carbons  C-24  and  C-25,  resulting  in  the
formation  of  24(S)-hydroxyvitamin  D3 (24S(OH)VD3),  25-hydroxyvitamin  D3 (25(OH)VD3)  and  24S,25-
dihydroxyvitamin  D3 (24S,25(OH)2VD3). Through  time  dependent  whole-cell  conversion  of  VD3,  we
identiﬁed  that  the  formation  of 24S,25(OH)2VD3 by CYP109E1  is derived  from  VD3 via the  intermediate
24S(OH)VD3. Moreover,  using  docking  analysis  and site-directed  mutagenesis,  we identiﬁed  important
active  site residues  capable  of  determining  substrate  speciﬁcity  and regio-selectivity.  HPLC  analysis  of  the
whole-cell  conversion  with the  I85A-mutant  revealed  an increased  selectivity  towards  25-hydroxylation
of  VD3 compared  with  the  wild  type  activity,  resulting  in an  approximately  2-fold  increase  of  25(OH)VD3
production  (45  mg  l−1 day−1) compared  to wild  type  (24.5 mg  l−1 day−1).
©  2017  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Cytochromes P450 (P450s) are heme-containing enzymes found
in all domains of life (Nelson, 2011). They are involved in many
metabolic processes, including the biosynthesis of steroids and
fatty acids, the metabolism of drugs and the detoxiﬁcation of
xenobiotics (Bernhardt, 2006). P450 monooxygenases are gain-
ing importance as enzymes for industrial biotechnology since they
have the ability to introduce oxygen into non-activated C H bonds
of various compounds in a regio- and stereo-selective manner
under mild conditions (Bernhardt and Urlacher, 2014; Urlacher and
Girhard, 2012).
Vitamin D3 (VD3) is a fat-soluble prohormone, which is synthe-
sized in the presence of ultraviolet radiation from the precursor
7-dehydrocholestrol (Holick et al., 1979; Kametani and Furuyama,
1987). The activation of VD3 is achieved by different P450s: the
mitochondrial CYP27A1 mediates hydroxylation of VD3 at carbon
∗ Corresponding authors.
E-mail addresses: f.hannemann@mx.uni-saarland.de (F. Hannemann),
ritabern@mx.uni-saarland.de (R. Bernhardt).
25, producing 25-hydroxyvitamin D3 (25(OH)VD3), which is then
further hydroxylated by CYP27B1 resulting in the most active form
of VD3, i.e., 1,25-dihydroxyvitamin D3 (1-25(OH)2VD3) (Prosser
and Jones, 2004; Schuster, 2011). It was  found that other P450s such
as the microsomal CYP2R1, CYP3A4 and CYP2J3 can also hydroxy-
late VD3 at C-25 (Cheng et al., 2014; Gupta et al., 2004).
The active form of VD3, 1-25(OH)2VD3, is involved in the reg-
ulation of the calcium and phosphate metabolism, amongst other
physiological processes (Sakaki et al., 2005; Demay, 2006; Jurutka
et al., 2007). However, sufﬁcient levels of the precursor 25(OH)VD3
are required for the regulatory action of 1-25(OH)2VD3 (Di Rosa
et al., 2011). Moreover, 25(OH)VD3 represents the most abundant
VD3 circulating metabolite and, therefore, is used clinically as an
indicator for the VD3 status of patients (Hollis, 2005).
During the last years there has been a growing interest in the
biotransformation of VD3 to its active metabolites, 25(OH)VD3
and 1-25(OH)2VD3. Thereby, recent research activity focused on
microbial P450s (Sakaki et al., 2011). However, only few bacte-
rial P450s are known to produce these active metabolites such as
CYP105A1 from S. griseolus (Sasaki et al., 1991) and CYP107 (Vdh)
from P. autotrophica (Fujii et al., 2009). Therefore, the identiﬁcation
http://dx.doi.org/10.1016/j.jbiotec.2016.12.023
0168-1656/© 2017 Elsevier B.V. All rights reserved.
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of new microbial P450s with 1- and/or 25-hydroxylation activity
towards VD3 is of great interest.
Recently, CYP109E1 from Bacillus megaterium DSM319 was
identiﬁed and characterized in our group (Józ´wik et al., 2016). It was
shown that CYP109E1 has a 16-hydroxylation activity towards
testosterone. In addition, the X-ray crystal structures of CYP109E1
were solved for substrate-free protein and in complexes with
testosterone or corticosterone. In the absence of bound steroids,
CYP109E1 contains a large, open active site pocket at the distal side
of the heme. The testosterone-bound CYP109E1 structure shows a
different conformation, in which the active site pocket is more nar-
row (closed state of CYP109E1) (Józ´wik et al., 2016), which likely
reﬂects the protein’s functionally relevant state and therefore was
applied in this study for vitamin D3 docking calculations.
In this study, the substrate speciﬁcity of CYP109E1 was  inves-
tigated for VD3. Herein, for the ﬁrst time we present the results
demonstrating that CYP109E1 from B. megaterium exhibits hydrox-
ylation activity towards VD3. In addition, whole-cell conversion
of VD3 was carried out using B. megaterium. Furthermore, site-
directed mutagenesis based on docking simulations of CYP109E1
and VD3 was performed in order to optimize the regio-selectivity
of CYP109E1 towards 25-hydroxylation. The effect of the mutations
on the conversion of VD3 was examined in the whole-cell system.
2. Materials and methods
2.1. Chemicals
VD3, 25(OH)VD3, 1-25(OH)2VD3, (2-hydroxypropyl)--
cyclodextrin and saponin (from quillaja bark) were purchased
from Sigma-Aldrich Chemie GmbH (Steinheim, Germnay). Iso-
propyl -d-1-thiogalactopyranoside (IPTG) and 5-aminolevulinic
acid were purchased from Carbolution chemicals (Saarbruecken,
Germany). Bacterial media were purchased from Becton Dickinson
(Heidelberg, Germany). All other chemicals were from standard
sources and of highest purity available.
2.2. Bacterial strains and plasmids
Cloning experiments were carried out with E. coli Top10 (Invit-
rogen, San Diego, USA). The E. coli strain C43 (DE3) for the
heterologous protein expressions was purchased from Lucigen
Corporation (Wisconsin, USA). Whole-cell conversions were car-
ried out using B. megaterium MS941 (Wittchen and Meinhardt,
1995; Stammen et al., 2010). pET17b (Merck Bioscience, Bad Soden,
Germnay) and pSMF2.1 (Bleif et al., 2012) were used for expression
purposes in E. coli and B. megaterium, respectively.
2.3. Cloning of CYP109E1
The coding region for CYP109E1 (GenBank GeneID 9119265)
was ampliﬁed by polymerase chain reaction (PCR) using genomic
DNA of B. megaterium MS941 as template. The coding region of
CYP109E1 was cloned into the SpeI and KpnI restriction sites of
pSMF2.1, yielding pSMF2.1.CYP109E1. The gene of CYP109E1 with
a hexahistidine tag at the C-terminus was cloned into NdeI and KpnI
restriction sites of pET17b, yielding pET17b.CYP109E1.
2.4. Site-directed mutagenesis
The mutants of CYP109E1 were generated by the
QuikChange site-directed mutagenesis method using the plasmid
pSMF2.1.CYP109E1 as template and Phusion DNA polymerase
(Thermo Fisher Scientiﬁc GmbH, Dreireich, Germany). The PCR
primers (MWG-Biotech AG, Ebersberg, Germany) were designed
Table 1
Oligonucleotides used in PCR to generate CYP109E1 mutants.
Primer name oligonucleotides
I85A-for 5′-ACGAGCCTAGCTAATATTGATCCGCCTAAG-3′
I85A-rev 5′-CTTAGGCGGATCAATATTAGCTAGGCTCGT-3′
I168A-for 5′-TCGGATATTGCCGTAGCCGGTCCTTCTAATAACGAACGT-3′
I168A-rev 5′-ACGTTCGTTATTAGAAGGACCGGCTACGGCAATATCCGA-3′
V169A-for 5′-GATATTATCGCAGCCGGTCCTTCTAATAACGAACGT-3′
V169A-rev 5′-ACGTTCGTTATTAGAAGGACCGGCTGCGATAATATC-3′
K187A-for 5′-CTCCAGCAAGAGGCAATGAAAGCAAATGATGAGC-3′
K187A-rev 5′-GCTCATCATTTGCTTTCATTGCCTCTTGCTGGAG-3′
I241A-for 5′-CTATTTTGCTACTGGCTGCTGGAAACGAAACAACCAC-3′
I241A-rev 5′-GTGGTTGTTTCGTTTCCAGCAGCCAGTAGCAAAATAG-3′
to introduce point mutation at the desired positions. The oligonu-
cleotide primers for mutagenesis are shown in Table 1. The
reactions were performed in a 50 l volume using a gradient
cycler (PTC-200 DNA Engine cycler). 20 cycles were carried out
as follows: initial denaturation at 95 ◦C for 30 s, denaturation at
95 ◦C for 30 s, annealing at 58 ◦C for 30 s and extension at 72 ◦C for
4 min. Correct generation of the desired mutations was conﬁrmed
by DNA sequencing, carried out by Euroﬁnes-MWG (Ebersberg,
Germany).
2.5. Heterologous expression in E. coli and puriﬁcation
To express CYP109E1 and its mutants, E. coli C43 (DE3) cells
were transformed with the corresponding expression plasmids
(pET17b.CYP109E1) and cultured overnight in Luria-Bertani (LB)
medium containing ampicillin (100 g ml−1) at 37 ◦C and 140 rpm.
The seed culture was  used to inoculate a 200 ml  Terriﬁc Broth (TB)
medium containing ampicillin 100 g ml−1 (1:100 dilution) in a 2-
l bafﬂed ﬂask. The main culture was grown at 37 ◦C and 140 rpm.
When the OD600 reached 0.5, the expression was induced with
1 mM IPTG. 0.5 mM delta-aminolevulinic acid served as heme pre-
cursor. The cultures were shifted to 30 ◦C and 120 rpm for 24 h.
The E. coli cells were harvested by centrifugation at 4500 rpm for
30 min, and the cell pellets were stored at −20 ◦C until puriﬁca-
tion. All puriﬁcation steps were performed at 4 ◦C. The cell pellets
were resuspended in 50 mM potassium phosphate buffer (pH 7.4)
containing 300 mM NaCl and 20% glycerol. Phenylmethylsulphonyl
ﬂuoride (PMSF) was added to a ﬁnal concentration of 1 mM and the
suspension was  sonicated with a T13-sonotrode for 15 min with an
amplitude of 12% and consisted of repeated intervals of 15 s pulse
and 15 s pause. Cell free extract was  obtained by ultracentrifugation
at 30,000 rpm for 30 min. The supernatant was applied to an immo-
bilized metal ion afﬁnity chromatography column (TALON, Takara
Bio Europe, Saint-Germain-en-Laye, France) that had been equili-
brated with 50 mM potassium phosphate buffer (pH 7.4) containing
300 mM NaCl and 20% glycerol. The column was washed with 5
column volumes of 50 mM potassium phosphate buffer (pH 7.4)
containing 300 mM NaCl, 20 mM imidazole and 20% glycerol. The
tagged protein was eluted with 50 mM potassium phosphate buffer
(pH 7.4) containing 300 mM NaCl, 150 mM imidazole and 20% glyc-
erol. The bovine Adx4-108 and AdR were expressed and puriﬁed as
described elsewhere (Sagara et al., 1993; Uhlmann et al., 1994).
2.6. Carbon monoxide (CO) difference spectroscopy
The reduced CO difference spectra of P450 were measured with
a double-beam spectrophotometer (UV-2101PC, Shimadzu, Japan).
The concentration of P450 was estimated using a molar extinction
coefﬁcient of 450-490 = 91 mM−1 cm−1 referred to the method of
Omura and Sato (1964).
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2.7. In vitro conversion of VD3
A reconstituted in vitro system containing CYP109E1 (1 M),
AdR (3 M),  Adx4-108 (20 M),  MgCl2 (1 mM), and a cofac-
tor regenerating system with glucose-6-phosphate (5 mM)  and
glucose-6-phosphate dehydrogenase (1 U) was used in a ﬁnal vol-
ume  of 250 l in potassium phosphate buffer (20 mM,  pH 7.4). The
substrate was dissolved in 2-hydroxypropyl--cyclodextrin (2.25%
w/v) and added to a ﬁnal concentration of 200 M.  The reaction was
started by addition of 0.5 mM NADPH. After 1 h at 30 ◦C the reac-
tion was stopped and extracted twice with 2 vol of ethyl acetate.
The organic phases were combined, evaporated to dryness and
prepared for analysis by high-performance liquid chromatography
(HPLC).
2.8. Whole-cell conversion of VD3
The whole-cell conversions were performed in B. mega-
terium MS941. The cells were transformed with the corre-
sponding pSMF2.1.CYP109E1 plasmid using the polyethylene
glycol-mediated protoplast transformation method (Barg et al.,
2005). The seed culture was prepared with LB medium (10 g/ml
tetracycline). The main culture (50 ml  TB medium, 10 g/ml tetra-
cycline) was inoculated with 500 l of seed culture (dilution 1:100)
in 300 ml  bafﬂed ﬂasks and incubated at 37 ◦C, 140 rpm. The culture
was grown to OD578 of 0.4 and recombinant gene expression was
induced with xylose (5 mg/ml). The culture was grown further at
30 ◦C for 24 h with shaking at 140 rpm.
For whole-cell conversion experiments, VD3 was dissolved in
45% 2-hydroxypropyl--cyclodextrin and 4% Quillaja Saponin as
membrane solubilizing agent. After 24 h of protein expression,
2.5 ml  of the substrate solution were added to the 50 ml  culture.
A ﬁnal substrate concentration of 200 M was used for all conver-
sion experiments. Afterwards, the conversion was  performed for
the indicated time at 30 ◦C and 120 rpm in 300 ml  bafﬂed ﬂasks.
500 l samples of the cultures were taken after deﬁned time peri-
ods, extracted and prepared for HPLC analysis.
Large scale whole-cell conversions for puriﬁcation of VD3
metabolites were performed in 2 l bafﬂed ﬂasks using 250 ml  of
main culture. Cultivation of bacteria as well as the whole-cell con-
version and extraction were accomplished as mentioned above.
After extraction, organic phases were dried using solvent evapo-
rator and stored at −20 ◦C under protection from UV light until
product puriﬁcation by HPLC.
2.9. High-performance liquid chromatography (HPLC)
The HPLC was carried out on a Jasco system (Pu-980 HPLC pump,
AS-950 sampler, UV-975 UV/visible detector, LG-980-02 gradient
unit; Jasco, Gross-Umstadt, Germany) equipped with a Nucle-
odur 100-5 C18 column (125 × 4 mm;  Macherey-Nagel, Düren,
Germany). The column temperature was adjusted to 40 ◦C. The
samples were dissolved in 200 l acetonitrile. The ﬂow rate was
1 ml/min with a linear gradient of 60–100% aqueous acetonitrile
for 15 min  followed by 100% acetonitrile for 15 min. The UV detec-
tion of the substrate and products was accomplished at 265 nm.  The
absorption properties of the products did not differ from the sub-
strate and, therefore, the product formation was calculated from
the relative peak area (area%) of the HPLC chromatograms, dividing
each respective product peak area by the sum of all peak areas.
2.10. Product puriﬁcation
Puriﬁcation of the products was carried out with reversed-
phase HPLC using a preparative column VP 250/8 NUCLEODUR
100-5 C18ec (Macherey-Nagel, Düren, Germany). First, the dried
extract was dissolved in an acetonitrile/water mixture and ﬁltered
through the Rotilabo syringe ﬁlters (0.22 m,  Carl Roth GmbH,
Karlsruhe, Germany). For puriﬁcation of product P2, a linear gra-
dient of 80–100% acetonitrile aqueous solution as a mobile phase
for 17 min  was  applied (UV detection: 265 nm; ﬂow rate: 3.5 −
4 ml/min; column temperature: 40 ◦C). Products P4 and P5 were
puriﬁed isocratically using a 65% acetonitrile aqueous solution
as a mobile phase for 40 min (UV detection: 265 nm; ﬂow rate:
2.5 ml/min; column temperature: 40 ◦C). Collected product frac-
tions were combined, evaporated to dryness and analyzed by NMR
characterization.
2.11. NMR characterization of the metabolites
The NMR  spectra were recorded in CDCl3 with a Bruker Avance
500 NMR  spectrometer at 298 K. The chemical shifts were relative
to CHCl3 at ı 7.26 (1H NMR) and CDCl3 at ı 77.00 (13C NMR) using
the standard  notation in parts per million. The 1D NMR  (1H and
13C NMR) and the 2D NMR  spectra (gs-HH-COSY and gs-HSQCED)
were recorded using the BRUKER pulse program library.
2.12. Molecular docking
Vitamin D3 (ligand) was  docked into the active site of CYP109E1
(receptor) in its closed conformation (PDB: 5L94, CYP109E1-TES)
with the use of Autodock Vina 1.1.2 (Trott and Olson, 2010). The
testosterone molecule and all waters were removed, and the result-
ing model was  used as a template for the docking experiments.
Coordinates for the ligand were taken form an available crystal
structure (PDB: 3VRM); six bonds were kept rotatable as con-
ﬁrmed by manual inspection in AutoDockTools 1.5.6. Hydrogens
and Gasteiger charges were also added in AutoDockTools 1.5.6. The
protein was kept rigid during docking. The simulation cell was lim-
ited to a grid box centered at the heme iron with sides adjusted to
cover the whole distal heme pocket (x:28 Å, y:34 Å, z:48 Å). Docking
simulations were done in triplicate and twenty docking poses were
generated for each simulation. The binding poses were analyzed
according to lowest binding energies and distances of the target
carbon atom (C-25) to the heme iron. Ligand binding residues were
identiﬁed by analysis done with LigPlot+ (Laskowski and Swindells,
2011) and further visualized with ViewDock tool in UCSF Chimera
(Pettersen et al., 2004).
3. Results
3.1. Bioconversion of vitamin D3 by CYP109E1
CYP109E1 from B. megaterium was previously cloned and char-
acterized in our laboratory (Józ´wik et al., 2016). In order to identify
new substrates for this enzyme, screening of a focused library
consisting of different steroids was  carried out. Hereby, VD3 was
identiﬁed as new substrate for CYP109E1. In an in vitro reconsti-
tuted system containing CYP109E1, AdR and Adx4-108, about 90% of
200 M VD3 was  converted within 1 h into 7 products with the fol-
lowing distribution: 3%, 15%, 8%, 22%, 42%, 5% and 5% of product 1 to
product 7 (P1-P7), respectively (Fig. 1A). Over time, it was  observed
that the increase in the formation of P2 is related to a correspond-
ing decrease of P5. Therefore, we  assumed that P5 is converted
by CYP109E1 into P2. Through comparison of the retention time
(tR) of the detected products with that of available authentic stan-
dards, P1 (tR = 4.8 min) and P4 (tR = 11.6 min) were identiﬁed as
1-25(OH)2VD3 and 25(OH)VD3, respectively (data not shown).
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Fig. 1. HPLC chromatogram of the CYP109E1 catalyzed VD3 conversion. (A) in vitro VD3 conversion, using bovine Adx4-108 (20 M) and AdR (3 M)  and CYP109E1 (1 M).
The  reaction was  carried out in a ﬁnal volume of 250 l at 30 ◦C for 1 h. (B) CYP109E1-dependent whole-cell conversion of VD3 in B. megaterium MS941. The reaction was
carried  out in 50 ml  TB medium for 24 h at 30 ◦C. Substrate was added at a ﬁnal concentration of 200 M.  The peaks of detected products and substrate are labeled with
(P1–P7)  and VD3, respectively. The authentic standard of 200 M VD3 (grey) was detected with the same HPLC method.
Fig. 2. Product distribution of VD3 whole-cell conversion in B. megaterium. Reac-
tions were carried out in 50 ml  TB medium for 48 h at 30 ◦C. Samples of the cultures
were taken after deﬁned time points (2, 4, 6, 8, 24 and 48 h) and analyzed by HPLC as
described in “Materials and methods“. Labeling of the products (P1–P7) corresponds
to that in Fig. 1. The vertical bars indicate the standard deviation values of the mean
from two independent experiments.
3.2. Whole-cell conversion of VD3 in B. megaterium
After successful in vitro conversion of VD3, a whole-cell con-
version system was established. Fig. 1B shows an HPLC proﬁle of
VD3 whole-cell conversion in B. megaterium demonstrating a simi-
lar pattern as for the in vitro conversion. After 24 h, 95% conversion
of 200 M substrate was achieved (Fig. 2). The product distribution
after 24 h conversion was as follows: 6%, 37%, 14%, 33%, 6%, 2% and
2% for products P1-P7, respectively.
For further characterization, we analyzed the time course of
product formation during whole-cell conversions, which showed
that the product distribution changed over time (Fig. 2). In the ﬁrst
2 h of the reaction, P5 was found to be the main product with 44% of
total share (40 mg  l−1 day−1). Afterwards, P5 constituted only 5% of
total share (4.3 mg  l−1 day−1). Accompanied by the decrease of P5,
an increase of P2 was observed (Fig. 2). The results obtained thus
indicate that P2 formation is dependent on the action of CYP109E1
on P5. Therefore, we  hypothesized that CYP109E1 has the potency
to hydroxylate VD3 at different positions. To further test, this we
decided to identify the main products by nuclear magnetic reso-
nance (NMR) spectroscopy.
3.3. Large scale conversion of VD3 and product identiﬁcation
In order to obtain sufﬁcient amounts of VD3 metabolites for fur-
ther characterization by NMR  spectroscopy, whole-cell conversions
with a total culture volume of 750 ml  were performed. Three prod-
ucts were obtained with sufﬁcient purity and amounts (5–25 mg)
for structural characterization via NMR  spectroscopy.
In contrast to vitamin D3, its conversion product P4 showed res-
onances of an additional tertiary hydroxyl group in the 13C NMR
spectrum (C 71.15) and the resonances of the methyl groups C-
26 and C-27 appeared both as singlets (H 1.19 s, 6H) in the 1H
NMR  spectrum. This cleary indicated hydroxylation at position C-
25 and led to the structure of 25(OH)VD3 for P4. The data were in
accordance with those reported in literature (Helmer et al., 1985;
Mizhiritskii et al., 1996):
1H NMR  (CDCl3, 500 MHz): ı 0.52 (s, 3xH-18), 0.92 (d, J = 6.5 Hz,
3xH-21), 1.02 (m,  H-22a), 1.06 (m,  H-22b), 1.19 (s, 6H, 3xH-26 and
3xH-27), 1.20 (m,  H-23a), 1.24 (m,  H-16a), 1.28 (m,  H-17), 1.29 (m,
H-12a), 1.36 (m,  H-24a), 1.39 (m,  H-23b), 1.45 (m,  2H, H-11a and H-
24b), 1.51 (m,  H-20), 1.52 (m,  2H, H-11b and H-15a), 1.60 (m,  H-2a),
1.63 (m,  H-15b), 1.69 (m,  H-9a), 1.86 (m, H-16b), 1.94 (m,  H-14),
1.96 (m,  H-2b), 1.98 (m,  H-12b), 2.16 (dd, J = 13.5, 8.5 and 5.0 Hz, H-
1a), 2.26 (dd, J = 13.0 and 7.5 Hz, H-4a), 2.38 (ddd, J = 13.5, 7.5 and
4.6 Hz, H-1b), 2.55 (dd, J = 13.0 and 4.0 Hz, H-4b), 2.82 (m, H-9b),
3.92 (m,  H-3), 4.80 (d, J = 2.5 Hz, H-19a), 5.03 (m,  H-19b), 6.01 (d,
11.3 Hz, H-7), 6.21 (d, 11.3 Hz, H-6). 13C NMR  (CDCl3, 125 MHz): ı
11.99 (CH3, C-18), 18.81 (CH3, C-21), 20.82 (CH2, C-23), 22.24 (CH2,
C-11), 23.56 (CH2, C-15), 27.67 (CH2, C-16), 29.07 (CH2, C-9), 29.29
(CH3, C-26), 29.34 (CH3, C-27), 31.92 (CH2, C-1), 35.16 (CH2, C-2),
36.10 (CH2, C-22), 36.40 (CH, C-20), 40.53 (CH2, C-12), 44.39 (CH2,
C-24), 45.85 (C, C-13), 45.92 (CH2, C-4), 56.33 (CH, C-14), 56.53 (CH,
C-17), 69.21 (CH, C-3), 71.15 (C, C-25), 112.40 (CH2, C-19), 117.51
(CH, C-7), 122.45 (CH, C-6), 135.00 (C, C-5), 142.89 (C, C-8), 145.09
(C, C-10).
The NMR  spectra of P5 revealed an additional secondary
hydroxyl group (H 3.34 m,  C 77.41 CH). Its position at C-24 was
obvious by vicinal correlations of its proton to the isopropyl proton
H-25 (H 1.69 m)  in the HHCOSY and to the methyls C-26 (16.69,
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CH3) and C-27 18.93, CH3) in the HMBC. Comparison of the data
with those of an authentic sample (Xi et al., 2014) supported these
ﬁndings. Especially the chemical shifts of C-1 to C-19 ﬁtted perfectly
to each other, whereas the resonances for the side chain slightly
differed. This might originate from a different sterochemistry at C-
24 in our sample and its epimer from literature. Unfortunately the
authors gave no hint to the stereochemistry at C-24 and our sample
decomposed within one day in solution. Therefore, the assignment
of the absolute conﬁguration at C-24 could not be solved by subse-
quent NMR  measurements, such as Mosherı´s method. But as was
found for closely related 24-hydroxylated steroids the 24(R)- and
24(S)-isomers showed characteristic differences in the 13C NMR
(Koizumi et al., 1979). Applying these observations to our problem
led to the identiﬁcation of the 24(S)-form for our molecule and to
the 24(R)-form for the epimer reported by Xi et al. (2014):
NMR  (CDCl3, 500 MHz): ı 0.57 (s, 3xH-18), 0.92 (d, J = 6.9 Hz,
3xH-26), 0.95 (d, J = 6.9 Hz, 3xH-27), 0.97 (d, J = 6.5 Hz, 3xH-21), 1.08
(m,  H-22a), 1.28 (m,  H-23a), 1.33 (m,  H-16a and H-17), 1.34 (m,  H-
12a), 1.43 (m,  H-20), 1.51 (m,  H-11a), 1.56 (m,  H-15a), 1.58 (m,
H-23b), 1.59 (m,  H-11b), 1.64 (m,  H-22b), 1.68 (m,  H-2a), 1.69 (m,
H-25), 1.70 (m,  H-15b), 1.72 (m,  H-9a), 1.93 (m,  H-16b), 1.96 (m,
H-2b), 2.01 (m,  H-14), 2.03 (m,  H-12b), 2.20 (dd, J = 13.5, 8.5 and
5.0 Hz, H-1a), 2.30 (dd, J = 13.0 and 7.5 Hz, H-4a), 2.42 (ddd, J = 13.5,
7.8 and 4.6 Hz, H-1b), 2.60 (dd, J = 13.0 and 4.0 Hz, H-4b), 2.86 (m,
H-9b), 3.34 (m,  H-24), 3.97 (m,  H-3), 4.86 (d, J = 2.5 Hz, H-19a), 5.07
(dt, J = 2.5 and 1.3 Hz, H-19b), 6.06 (d, 11.3 Hz, H-7), 6.26 (d, 11.3 Hz,
H-6). 13C NMR  (CDCl3, 125 MHz): ı 12.00 (CH3, C-18), 16.69 (CH3,
C-26), 18.93 (CH3, C-27), 19.05 (CH3, C-21), 22.23 (CH2, C-11), 23.55
(CH2, C-15), 27.62 (CH2, C-16), 28.99 (CH2, C-9), 30.74 (CH2, C-23),
31.91 (CH2, C-1), 32.16 (CH2, C-22), 33.15 (CH, C-25), 35.14 (CH2, C-
2), 36.29 (CH, C-20), 40.50 (CH2, C-12), 45.84 (C, C-13), 45.90 (CH2,
C-4), 56.30 (CH, C-14), 56.37 (CH, C-17), 69.20 (CH, C-3), 77.41 (CH,
C-24), 112.44 (CH2, C-19), 117.51 (CH, C-7), 122.43 (CH, C-6), 135.07
(C, C-5), 142.21 (C, C-8), 145.05 (C, C-10).
P2 was found to be a dihydroxylated conversion product of
vitamin D3. The NMR  spectra revealed resonances for a supplemen-
tary secondary (C 79.55 CH) and a tertiary (C 73.15C) hydroxyl
function. 2D NMR  HHCOSY, HSQCED and HMBC measurements
revealed their positions as immediate neighbours at C-24 and
C-25. According to P5, C-24 in P2 was expected to be in (S)-
conﬁguration. However, we wanted to prove this assumption in
an independent manner. Both epimers were known from litera-
ture but no comparative NMR  studies were available. Therefore, we
performed a comparison of the NMR  data of their synthetic precur-
sors, the 24(R)- and 24(S)-forms of de-A,B-cholesta-8,24,25-triol
(Pérez Sestelo et al., 2002). Analysis of the 13C NMR  data for the
side chain of P2 and comparison with those of the C-24 epimeric
de-A,B-cholestanes gave a clear and unambiguous evidence for
24S,25(OH)2VD3 as structure for P2:
NMR  (CDCl3, 500 MHz): ı 0.55 (s, 3xH-18), 0.95 (d, J = 6.5 Hz,
3xH-21), 1.04 (m,  H-22a), 1.14 (m,  H-23a), 1.17 (s, 3xH-26), 1.22
(s, 3xH-27), 1.28 (m,  H-17), 1.29 (m,  H-16a), 1.31 (m,  H-12a), 1.41
(m,  H-20), 1.49 (m,  2H, H-11a and H-11b), 1.54 (m,  H-15a), 1.57 (m,
H-23b), 1.68 (m,  H-2a and H-15b), 1.69 (m,  H-9a), 1.77 (m,  H-22b),
1.89 (m,  H-16b), 1.94 (m,  H-2b), 1.98 (m,  H-14), 2.00 (m,  H-12b),
2.21 (m,  H-1a), 2.30 (dd, J = 13.0 and 7.5 Hz, H-4a), 2.41 (ddd, J = 13.5,
7.8 and 4.6 Hz, H-1b), 2.58 (dd, J = 13.0 and 4.0 Hz, H-4b), 2.83 (m,  H-
9b), 3.29 (d, J = 10.1 and 2.0 Hz, H-24), 3.94 (m,  H-3), 5.05 (dt, J = 2.5
and 1.3 Hz, H-19b), 4.82 (d, J = 2.5 Hz, H-19a), 6.03 (d, 11.3 Hz, H-7),
6.23 (d, 11.3 Hz, H-6). 13C NMR  (CDCl3, 125 MHz): ı 12.00 (CH3, C-
18), 18.94 (CH3, C-21), 22.23 (CH2, C-11), 23.17 (CH3, C-26), 23.54
(CH2, C-15), 26.51 (CH3, C-27), 27.61 (CH2, C-16), 28.34 (CH2, C-23),
28.99 (CH2, C-9), 31.95 (CH2, C-1), 33.22 (CH2, C-22), 35.19 (CH2, C-
2), 36.26 (CH, C-20), 40.51 (CH2, C-12), 45.83 (C, C-13), 45.94 (CH2,
C-4), 56.28 (CH, C-14), 56.39 (CH, C-17), 69.20 (CH, C-3), 73.17 (C, C-
25), 79.55 (CH, C-24), 112.42 (CH2, C-19), 117.56 (CH, C-7), 122.33
(CH, C-6), 135.21 (C, C-5), 142.08 (C, C-8), 145.09 (C, C-10).
These results conﬁrmed our assumption, that CYP109E1 can
hydroxylate VD3 at different positions. As shown above, the ratio of
P2 (24S,25(OH)2VD3) increased inversely proportional to the ratio
of P5 (24S(OH)VD3) over time, indicating that CYP109E1 has 25-
hydroxylation activity towards VD3 as well as 24S(OH)VD3. The
reaction pathway of VD3 conversion by CYP109E1 is shown in Fig. 3.
3.4. Molecular docking of VD3 to CYP109E1
Unfortunately soaking/co-crystallization trials to obtain the
structure of the CYP109E1-VD3 complex proved unsuccessful,
therefore docking of the VD3 molecule was  performed to identify
potential substrate-binding residues. A structural comparison of
CYP109E1 to other P450s converting VD3 found in the PDB, revealed
that the closed conformer of CYP109E1 (PDB: 5L94) is highly sim-
ilar to the closed state observed for CYP107 (Vdh) crystallized in
com plex with VD3 (PDB: 3A50, Yasutake et al., 2010, r.m.s.d of
1.23 Å for 347 C atoms). Therefore, the closed conformation of
CYP109E1 likely reﬂects the functionally relevant conformational
state of the protein and was chosen in this study for the substrate
docking calculations. Among the calculated VD3 conformations, the
one showing a suitable distance of the C-25 atom to the heme iron
and the lowest predicted free energy of binding was chosen for fur-
ther analysis. The docked pose places the aliphatic side chain of VD3
close to the heme iron, productively for 25-hydroxylation (C-25-Fe
distance of 3.7 Å), and is well in agreement with the crystallo-
graphically observed VD3 binding mode in CYP107 (Vdh) (C-25-Fe
distance of 4.6 Å). The only hydrophilic group (3-OH group at the
A-ring) of VD3 is solvent exposed, predicted not to interact with any
of the protein side chains; the rest of the VD3 molecule interacts
with hydrophobic residues lining the active site pocket, similarly as
in Vdh. Since VD3 hydroxylation is of outstanding importance for
sustainable biotransformation process of the production of active
VD3, we were interested to improve the yield of 25(OH)VD3. Four
amino acids predicted to interact with VD3 were mutated to ala-
nine to determine their roles in CYP109E1 activity and selectivity
towards VD3: I85 (BC-loop, substrate recognition site 1, SRS1), I168
and V69 (F-helix, SRS2) and I241 (I-helix, SRS4) Additionally, one
more residue was chosen for mutagenesis, K187 (SRS3), since its
mutation to alanine in CYP109E1 was  previously shown to cause a
slight decrease in testosterone conversion activity. Thus we consid-
ered the possibility that this ﬂexible residue, located at the top of
the active site (G helix), might also take part in VD3 binding (Fig. 4).
3.5. Conversion of VD3 by CYP109E1 mutants
To investigate the effect of selected mutations on activity and
regio-selectivity of CYP109E1 towards VD3 directly in the whole-
cell system, B. megaterium cells were transformed with the plasmid
pSMF2.1.CYP109E1 containing the corresponding CYP109E1 muta-
tions. The results clearly showed that all CYP109E1 mutants still
maintained VD3 hydroxylation activity. However, activity or/and
selectivity of CYP109E1 was  affected by the amino acid replace-
ments (Fig. 5).
While the K187A mutant showed the same conversion ratio
(97%) as compared with wild type, the activity of CYP109E1 was
changed by selected mutations (Fig. 6). All other mutants showed
decreased activity in the ﬁrst 8 h of the reaction. However, the activ-
ity in case of I85A, I168A, V169A and I241A mutants was  increased
afterwards. After 24 h conversion, the I168A mutant exhibited a
comparable conversion (96%) as the wild type and the I85A mutant
showed a maximum conversion of 87%. On the other hand, a sig-
niﬁcant decrease of the activity was observed in case of V169A and
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Fig. 3. Reaction pathway of VD3 by CYP109E1 from B. megaterium.
Fig. 4. Docking model of VD3 in the active site of CYP109E1. The suitable confor-
mation of VD3 for 25-hydroxylation is shown (in magenta), and compared to the
crystallographically observed VD3 binding mode in CYP107 (Vdh) (in green). Heme
is  in red coloured sticks. Amino acids selected for site-directed mutagenesis are
shown in orange sticks. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
I241A mutants, displaying only 76% and 54% conversion, respec-
tively.
Additionally, the effect of the point mutations on the regio-
selectivity of CYP109E1-dependent VD3 conversion was  studied
(Table 2). Compared to wild type, the formation of 24S(OH)VD3
was decreased over time in case of the I85A and I168A mutants,
which, as a consequence, led to reduced amounts of the derived
product 24S,25(OH)2VD3. On the other hand, the 25-hydroxylation
activity towards VD3 was  strongly preferred in the reactions cat-
alyzed by the I85A and I168A mutants resulting in 63% and 49%
of total products, respectively (Table 2). Moreover, mutant I85A
displayed a signiﬁcant reduction in the number of products Con-
sequently, an increase of the absolute 25(OH)VD3 production was
observed with these mutants, compared to the wild type (Fig. 7).
These results indicate that the side chains of amino acids I85 and
I168 are essential for determining the regio-selectivity of CYP109E1
towards VD3. Compared to wild type, the regio-selectivity of the
K187A mutant was also slightly changed towards 25-hydroxylation
(Table 2). Furthermore, it was observed that the 24S,25(OH)2VD3
production decreased in the whole-cell conversion with the K187A
mutant, compared to wild type. In contrast to the decrease in the
24S,25(OH)2VD3 production, an accumulation of 24S(OH)VD3 was
observed, suggesting that the K187A mutant has less speciﬁcity
towards 24S(OH)VD3, compared to wild type.
Furthermore, signiﬁcant changes of the speciﬁcity and regio-
selectivity of CYP109E1 were determined in whole-cell conversions
with the V169A and I241A mutants. Compared to the wild
type, it was observed that reactions of variant V169A showed a
decreased 25-hydroxylation activity of 24S(OH)VD3, whereas the
25-hydroxylation of VD3 was enhanced (Table 2). In addition, no
formation of P1, P3 and P7 was  observed with this mutant. In
whole-cell conversions with the V169A mutant, the product dis-
tribution was  as follows: 24S(OH)VD3 (40%), 25(OH)VD3 (47%),
24S,25(OH)2VD3 (3%) and P6 (10%). It was further observed that
the substitution of I241 to alanine shifts the regio-selectivity of
CYP109E1 towards 24-hydroxylation (60% of total products). In
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Fig. 5. HPLC chromatograms of VD3 whole-cell conversions by B. megaterium expressing different variants of CYP109E1. The reactions were carried out in 50 ml  TB medium
for  24 h at 30 ◦C. The substrate was added at a ﬁnal concentration of 200 M.  The authentic standard of 200 M VD3 (grey) was detected with the same HPLC method.
contrast, a decrease of 24S,25 (OH)2VD3 was observed (only 3%
of total products) indicating that the 25-hydroxylation activity
of this mutant of CYP109E1 towards 24S(OH)VD3 is dramatically
decreased.
4. Discussion
During the past years bioconversion processes, including
speciﬁc hydroxylations, have gained increasing interest, since
chemical synthesis often requires complex procedures and envi-
ronmentally unfriendly conditions. The ability of P450s to
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Table  2
Comparison of products distribution of 24 h whole-cell conversions of VD3 by different variants of CYP109E1.
Enzyme variant Conversion [%] Number of products Major product(s) [%]a
Wild type 95 7 24S,25(OH)2VD3 (37%)
25(OH)VD3 (33%)
I85A  87.3 3 25(OH)VD3 (63%)
I168A 94 7 24S,25(OH)2VD3 (20%)
25(OH)VD3 (49%)
V169A 75.4 3 25(OH)VD3 (47%) 24S(OH)VD3
(42%)
K187A  96.8 7 25(OH)VD3 (45%) 24S(OH)VD3
(22%)
I241A  53.8 4 25(OH)VD3 (27%) 24S(OH)VD3
(58%)
a Only products with a ratio of ≥20% of total products are deﬁned here as major products.
Fig. 6. Effect of selected mutations in CYP109E1 on the conversion of VD3. Reac-
tions were performed using B. megaterium MS941 in 50 ml  TB medium at 30 ◦C. The
substrate was  added at a ﬁnal concentration of 200 M.  Samples of the cultures
were taken after deﬁned time points (2, 4, 6, 8, 24 and 48 h) and analyzed by HPLC
as described in “Materials and methods“. The vertical bars indicate the standard
deviation values of the mean from three independent whole-cell experiments.
Fig. 7. Production of 25(OH)VD3 in B. megaterium overexpressing different variants
of CYP109E1. Reactions were performed in 50 ml  TB medium for 24 h at 30 ◦C. The
substrate was added at a ﬁnal concentration of 200 M.  The amount of 25(OH)VD3
was  measured by HPLC as described in “Materials and methods“. The vertical bars
indicate the standard deviation values of the mean from three independent whole-
cell experiments.
hydroxylate a broad range of compounds makes them suitable as
versatile biocatalysts (Bernhardt, 2006; Bernhardt and Urlacher,
2014).
It is known that VD3 is activated in kidneys and liver by different
P450s such as mitochondrial cytochromes CYP27A1 and CYP27B1
as well as the microsomal enzymes CYP2R1, CYP3A4 and CYP2J3.
However, low activity and stability of mammalian P450s compared
with those of bacterial origin are important factors limiting their
industrial applications (Julsing et al., 2008). As a result of such lim-
itation, bacterial P450s constitute an attractive alternative for the
industrial production of different valuable products, including VD3
metabolites. Until now, only a few studies have reported the usage
of bacterial P450s for the production of VD3 metabolites such as
CYP105A1 and CYP107 (Vdh) (Sakaki et al., 2011). Therefore, the
identiﬁcation of new bacterial P450s with hydroxylation activity
towards VD3 is of a great interest for the industry. In particular, B.
megaterium offers a great potential, both as a source and expression
host, for such new bacterial P450s. It has been used since many
decades for the production of different industrial enzymes (Vary
et al., 2007; Korneli et al., 2013). It offers an advantage that replica-
tive plasmids are stable and maintained (Stammen et al., 2010). In
addition, B. megaterium lacks external alkaline proteases and, there-
fore, is suitable for heterologous protein expression. Moreover, B.
megaterium can grow on simple media utilizing a broad spectrum
of carbon sources (Vary, 1994).
Therefore, the establishment of B. megaterium-based whole
cell system using a bacterial P450 as biocatalyst for the pro-
duction of active VD3 metabolites, such as 25(OH)VD3, is an
interesting alternative for the industrial production. Recently, B.
megaterium was used in our laboratory for the conversion of the
steroid hormone precursor cholesterol to pregnenolone and for
the hydroxylation of 11-keto--boswellic acid (KBA) (Gerber et al.,
2015; Bleif et al., 2012; Brill et al., 2014). Moreover, a CYP27A1-
based whole-cell system was  established in B. megaterium
allowing efﬁcient production of valuable pharmaceuticals such
as 27-hydroxycholesterol, 26/27-hydroxy-7-dehydrocholesterol,
25(OH)VD3 and 25-hydroxy-7-dehydrocholesterol (Ehrhardt et al.,
2016).
In this study, we  demonstrated for the ﬁrst time the conversion
of VD3 by a member of the CYP109 family, namely CYP109E1 from
B. megaterium DSM319. We  showed that CYP109E1 can convert
VD3 into different products, in both enzyme-based and whole-
cell-based assays. The new whole-cell system converts more than
90% of the added substrate (200 M)  within 24 h supporting its
promising potential as VD3 hydroxylase. The two main products
of CYP109E1-dependent conversion of VD3 were identiﬁed by
NMR  analysis as 25(OH)VD3 (33%) and 24S, 25 (OH)2VD3 (37%)
with yields of 24.5 mg  l−1 day−1 and 28.6 mg  l−1 day−1, respec-
tively. In addition, the product P5 was  identiﬁed by NMR  analysis
as 24S(OH)VD3. For further characterization of product formation,
time-dependent whole-cell conversions were performed. It was
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shown that both, 24S(OH)VD3 (P5) and 25(OH)VD3 (P4), are ini-
tially detected as major products (Fig. 3). Nevertheless, a decrease
in the 24S(OH)VD3 ratio was observed in correlation with the for-
mation of 24S,25(OH)2VD3 (P2). In contrast, the ratio of 25(OH)VD3
was relatively constant over time (30–33% of total products). Thus
we conclude that the formation of 24S,25(OH)2VD3 from VD3
proceeds via the intermediate 24S(OH)VD3. This is to the best
of our knowledge a novel reaction pathway of VD3 leading to
24S,25(OH)2VD3 via 24S(OH)VD3. In addition, these results demon-
strate that CYP109E1 has a 25-hydroxylation activity towards VD3
as well as 24S(OH)VD3.
It is known that the hydroxylation of VD3 at C-25 is the ﬁrst step
of the VD3 activation (Prosser and Jones, 2004; Sakaki et al., 2005;
Schuster, 2011). 25(OH)VD3 is the best indicator of the nutritional
status of VD3 in the circulation (Hollis, 2005). This compound has
been gaining importance in recent years as it was shown to be a
better therapeutic agent for several diseases than VD3 itself, due
to its direct biological effect and better intestinal absorption (Jean
et al., 2008; Leichtmann et al., 1991). It was found that supplemen-
tation of 25(OH)VD3 has a preventive, therapeutic effect against
diseases such as hyperglycemia, chronic kidney disease, Crohn’s
and cholestatic liver disease (Jean et al., 2008; Leichtmann et al.,
1991). In addition to applications of this metabolite for human
health, it is used as supplement in animal feed (Soares et al., 1995).
Whereas speciﬁc biological activities for the natural VD3 metabolite
24R,25(OH)2VD3 were identiﬁed (Norman et al., 1983; St-Arnaud
and Glorieux, 1998; Yamato et al., 1989), so far no functions are
known for its unnatural epimer 24S,25(OH)2VD3, which was iden-
tiﬁed here in the CYP109E1-based whole cell conversion of VD3.
Our aim in the next step of this study was the enhancement
of the 25(OH)VD3 production yield by CYP109E1. Since the crys-
tal structure of a VD3-bound CYP109E1 complex is not available,
the putative substrate-binding residues were predicted with dock-
ing simulations. It is anticipated that VD3 binds with its aliphatic
side chain close to the heme iron and the C-25 atom is in a suit-
able distance for hydroxylation (Fig. 4). High similarity of the
CYP109E1-VD3 model with the experimental CYP107 (Vdh)-VD3
crystal structure gives credence to the reliability of our docking
results. A similar set of hydrophobic residues is predicted to interact
with VD3 in CYP109E1, including I85, I241, I168 and V169, which
correspond to I88, I235, L171, and V172 in Vdh (Yasutake et al.,
2010). To test their potential role in VD3 binding and conversion
in CYP109E1, these four residues were targeted for mutation to
alanines. In addition, residue K187 was chosen for mutagenesis,
to test whether this ﬂexible residue may  play a role in substrate
binding by interacting with the 3-OH group of VD3. Previously, it
was shown that mutation of this residue to an alanine slightly low-
ers the conversion rate of testosterone by CYP109E1 (Józ´wik et al.,
2016). However, our results show that considering VD3 hydroxyla-
tion, the mutation of K187 to alanine does not inﬂuence CYP109E1
activity (Fig. 6). Thus, residue K187 plays no role in VD3 binding by
CYP109E1, in accordance with the docking results and with the lack
of substrate binding interactions by the equivalent residue (K180)
in the VD3-bound crystal structure of Vdh.
Mutagenesis of the other four residues (I85, I168, V169 and
I241) ultimately yielded an improved regio-selectivity of CYP109E1
towards VD3. It has been found that all mutants, except I241A,
exhibited a higher selectivity towards 25-hydroxylation than the
wild type (Table 2). This enhancement of the regio-selectivity
resulted in an increase of the 25(OH)VD3 production upon
whole-cell conversion of VD3 (Fig. 7). Compared to the wild
type, approximately a 2-fold increase of the 25(OH)VD3 yield
was achieved with the I85A mutant, 45 mg  l−1 day−1 compared
to 24.5 mg  l−1 day−1. In the literature, the conversion yield of
25(OH)VD3 by the most widely investigated P450 for vitamin D3
hydroxylation, CYP105A1, had been initially very low and was
later signiﬁcantly improved by protein engineering (Sasaki et al.,
1991). The most productive mutant of CYP105A1 (R73A/R84A) is
reported to produce 8.3 mg  l−1 day−1 of 25(OH)VD3 (Hayashi et al.,
2010; Sakaki et al., 2011). Residue I85 of CYP109E1, as mentioned
above, is located in SRS1, in the close vicinity of the heme, and is
one of the most investigated residues in P450s. The correspond-
ing position in different P450s was described to interact with the
P450s ligands and, therefore, to affect the activity and selectiv-
ity of the enzyme (Gricman et al., 2015). The importance of this
position was  observed in case of CYP102A1 as the substitutions of
F87 caused improved selectivity towards propylbenzene and ter-
pene substrates, among others (Gricman et al., 2015; Li et al., 2001;
Seifert et al., 2009). In addition, the substitution of S122 to thre-
onine in CYP1A1 (corresponding position to I85 in CYP109E1 and
F87 in CYP102A1) improved the 7-methoxy- and 7-ethoxyresoruﬁn
O-dealkylase activity (Liu et al., 2004).
Furthermore, our results showed that the substitution of V169
or I241 to alanine residues signiﬁcantly diminished the conversion
of the 24S(OH)VD3 intermediate into 24S,25(OH)2VD3, as com-
pared to reactions with the wild type enzyme. The functional
importance of V169 and I241 was also previously determined for
testosterone conversion by CYP109E1 (Józ´wik et al., 2016). It was
shown that by substituting either residue to an alanine the activity
of CYP109E1 towards testosterone is completely abolished. There-
fore, we suggest that V169 and I241 of CYP109E1 are substrate
speciﬁcity-determining residues.
5. Conclusions
This study describes the identiﬁcation of a new VD3 hydroxy-
lase from B. megaterium, CYP109E1, with 25- and 24-hydroxylation
activity. The established B. megaterium-based whole-cell system for
the conversion of VD3 has a promising potential for the biotechno-
logical production of the valuable metabolite 25(OH)VD3.
In addition, further investigations on CYP109E1 were performed
in order to increase the production of 25(OH)VD3. Based on docking
studies, site-directed mutagenesis was performed at selected posi-
tions in the active site of the enzyme. We  were able to demonstrate
the importance of selected active site residues for VD3 conver-
sion. A change of the regio-selectivity and substrate speciﬁcity was
observed for most of the mutants. A considerable increase of the
production of the valuable metabolite 25(OH)VD3 was achieved
with the I85A mutant. In addition, two novel metabolites of VD3,
24S(OH)VD3 and 24S,25(OH)2VD3, have been identiﬁed, whose
potential for further drug development needs to be investigated.
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Cytochrome P450 enzymes are increasingly investigated due to their potential
application as biocatalysts with high regio- and/or stereo-selectivity and under
mild conditions. Vitamin D3 (VD3) metabolites are of pharmaceutical impor-
tance and are applied for the treatment of VD3 deficiency and other disorders.
However, the chemical synthesis of VD3 derivatives shows low specificity and
low yields. In this study, cytochrome P450 CYP109A2 from Bacillus mega-
terium DSM319 was expressed, purified, and shown to oxidize VD3 with high
regio-selectivity. The in vitro conversion, using cytochrome P450 reductase
(BmCPR) and ferredoxin (Fdx2) from the same strain, showed typical
Michaelis–Menten reaction kinetics. A whole-cell system in B. megaterium
overexpressing CYP109A2 reached 76  5% conversion after 24 h and
allowed to identify the main product by NMR analysis as 25-hydroxylated
VD3. Product yield amounted to 54.9 mgL1day1, rendering the established
whole-cell system as a highly promising biocatalytic route for the production
of this valuable metabolite. The crystal structure of substrate-free CYP109A2
was determined at 2.7 A resolution, displaying an open conformation. Struc-
tural analysis predicts that CYP109A2 uses a highly similar set of residues for
VD3 binding as the related VD3 hydroxylases CYP109E1 from B. megaterium
and CYP107BR1 (Vdh) from Pseudonocardia autotrophica.However, the folds
and sequences of the BC loops in these three P450s are highly divergent, lead-
ing to differences in the shape and apolar/polar surface distribution of their
active site pockets, which may account for the observed differences in substrate
specificity and the regio-selectivity of VD3 hydroxylation.
Database
The atomic coordinates and structure factors have been deposited in the Protein Data Bank
with accession code 5OFQ (substrate-free CYP109A2).
Enzymes
Cytochrome P450 monooxygenase CYP109A2, EC 1.14.14.1, UniProt ID: D5DF88, Ferre-
doxin, UniProt ID: D5DFQ0, cytochrome P450 reductase, EC 1.8.1.2, UniProt ID: D5DGX1.
Abbreviations
25(OH)VD3, 25-hydroxyvitamin D3; BmCPR, B. megaterium cytochrome P450 reductase; DLS, dynamic light scattering; P450, cytochrome
P450; PDB, Protein Data Bank; TB, Terrific Broth; VD3, vitamin D3; d-ALA, d-aminolevulinic acid.
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Introduction
Vitamin D3 (VD3) is a secosteroid that is produced in
the human skin from the precursor compound 7-dehy-
drocholesterol upon exposure to UV light irradiation,
resulting in the opening of the precursor B-ring.
Afterward, VD3 is metabolized successively in the liver
and kidneys to form two derivatives that are highly
important for human health, the 25-hydroxyvitamin
D3 [25(OH)VD3] and 1a,25-dihydroxyvitamin D3
[1a,25(OH)2VD3, Fig. 1]. While the latter derivative is
the biologically active form of VD3, the former one is
the most abundant circulating metabolite of VD3 in
the blood and is, therefore, considered to be an opti-
mal indicator of the nutritional status concerning
VD3 in patients [1,2]. Maintaining an optimal level of
25(OH)VD3 is crucial for reducing the risk of several
chronic diseases or cancer conditions [3]. Moreover,
the 25(OH)VD3 metabolite is acknowledged for better
absorption properties as compared with VD3 in cer-
tain supplement-based treatments [4,5]. Unfortunately,
chemical synthesis of VD3 derivatives is a challenging,
multistep procedure resulting in low product yields,
limiting their usefulness as therapeutic dietary supple-
ments [6]. Biotechnological approaches involving
enzymes capable of specifically oxidizing VD3 offer an
attractive alternative to circumvent such limitations.
In humans, the two consecutive VD3 hydroxylation
steps, at carbons C-25 and C-1, are catalyzed by pro-
teins belonging to the cytochrome P450 superfamily
(P450s or CYPs) [7]. The P450s are heme-containing
enzymes that catalyze the monooxygenation of a large
variety of organic substrates like steroids, fatty acids,
and are generally known to be involved in the oxida-
tive metabolism of xenobiotics and drugs. Considering
the broad range of P450 substrates, the enzymes are of
benefit to synthesis of pharmaceutically and biotechno-
logically valuable compounds, in particular when high
regio- and stereo-selectivity of hydroxylation is
required. Microbial P450s are favored, as they are sol-
uble and more stable than their eukaryotic counter-
parts [8–10]. Thus far, only a few bacterial P450
enzymes have been reported that hydroxylate VD3 to
produce the desired 25(OH)VD3 metabolite, like
CYP105A1 from Streptomyces griseolus [11] or
CYP107BR1 (Vdh) from Pseudonocardia autotrophica
[12]. Most recently, our investigations led to the identi-
fication and characterization of another bacterial VD3-
hydroxylase, cytochrome P450 CYP109E1 from Bacil-
lus megaterium DSM319 [13]. The improvement of
activity and/or regio-selectivity of the three above-
mentioned enzymes by protein engineering was sup-
ported by the knowledge of their structure–function
relationships, due to determination of their crystal
structures in both the open, substrate-free and closed,
substrate-bound states [14–18].
Here, we describe the identification and analysis of a
new cytochrome P450 enzyme from B. megaterium
DSM319, classified as CYP109A2, which shares 45%
amino acid sequence identity with CYP109E1. Similar
to CYP109E1, CYP109A2 exhibits 25-hydroxylation
activity toward VD3, however, with significantly higher
regio-selectivity. A whole-cell B. megaterium-based VD3
oxidation system was established for CYP109A2 and
resulted in higher yields of 25(OH)VD3 as compared
with the previously reported most productive variant of
CYP109E1, i.e., mutant I85A [13]. The three-dimen-
sional structure of CYP109A2 was obtained by X-ray
crystallography and compared with the structures of
other bacterial P450s that convert VD3, suggesting
putative structural features associated with differences
in substrate specificity and regio-selectivity.
Fig. 1. The activation pathway of VD3 in
mammals. First, VD3 undergoes a C-25
hydroxylation resulting in the formation of
25(OH)VD3 (in the liver) followed by the
second hydroxylation at C-1 atom producing
1a,25(OH)2VD3 (in the kidneys).
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Results and Discussion
Identification, sequence analysis, and initial
characterization of CYP109A2
Bioinformatic mining of the B. megaterium DSM319
genome previously led to identification of four genes
putatively encoding for cytochrome P450 enzymes
(CYP102A1, CYP106A1, CYP109E1, and CYP109A2)
[18,19]. Here, we focus on CYP109A2, the remaining
P450 that has not been studied in detail yet. Its open-
reading frame (KEGG: BMD_2035) encodes for a 403
amino acid long protein containing three characteristic
sequence motifs, which support its annotation as a P450
enzyme: (a) heme-binding domain signature proceeding
the L helix (FxxGx(H/R)xCxG), (b) the acid-alcohol
pair in the I helix (Glu244, Thr245), and (c) ExxR motif
in the K helix (Fig. 2). Interestingly, CYP109A2 shares
45% sequence identity with CYP109E1 from the same
organism (the sequence identity with CYP106A1 and
CYP102A1 is 36% and 24%, respectively). Compara-
tive sequence analysis including proteins from different
bacterial sources further shows that CYP109A2 shows
significant sequence homology to VD3 hydroxylating
P450s from the CYP107 and CYP105 family [37% iden-
tity to CYP107BR1 (Vdh) from P. autotrophica, 36% to
CYP107CB2 from Bacillus lehensis G1, 32% identity to
CYP105A1 from S. griseolus, and 30% to CYP105A2
from P. autotrophica]. Residues in CYP109A2 with the
highest degree of conservation have a role in heme bind-
ing or belong to substrate recognition site 4 (SRS4) (cen-
tral part of I helix), whose residues have common roles
in P450s associated with substrate binding, oxygen acti-
vation, and proton delivery during catalysis [20]. Other
regions associated with substrate binding (SRS2, SRS5,
and SRS6) are less well conserved, although relatively
higher conservation levels may be observed in SRS5 or
SRS6 upon pairwise comparison of P450s belonging to
the same CYP family, such as CYP109A2 and
CYP109E1. The lowest degree of conservation is dis-
played by the amino acids belonging to SRS1 (the BC
loop region) and SRS3 (the G helix) (Fig. 2).
Since a significant sequence similarity between bacte-
rial P450s belonging to the same CYP family may cor-
relate to similarities in substrate scope [21], we set out
to establish whether VD3, being a substrate for
CYP109E1, is also converted by CYP109A2. To pro-
duce sufficient amounts of pure and functional
CYP109A2 enzyme for the intended functional analy-
sis, the cyp109a2 gene was cloned into the pET17b
vector and expressed in Escherichia coli C43 (DE3)
cells with high yield (4210 nmolL1). The protein was
purified by affinity chromatography and displayed
characteristic P450 spectroscopic behavior, considering
both the UV-visible spectrum of its oxidized
ligand-free and reduced CO-bound forms (Fig. 3).
Spectroscopic analysis, thus, confirmed that the puri-
fied protein contained the correctly incorporated heme
group and may be functional as a P450 enzyme.
CYP109A2 catalyzes regio-selective oxidation of
vitamin D3 in vitro
Cytochromes P450 are external monooxygenases and
thus require electrons for their catalytic activity from
different (autologous or heterologous) redox partners
[22]. Selection of suitable redox partners to support
CYP109A2 activity was based on previous observations
that B. megaterium cytochrome P450 reductase
(BmCPR) and a ferredoxin (Fdx2) were able to support
CYP106A1 with much higher efficiency than the com-
monly used AdR-Adx4–108 (adrenodoxin reductase –
adrenodoxin) redox partners [23]. Indeed, reconstitution
of CYP109A2 activity was accomplished using both
redox partner systems, but the CYP109A2-catalyzed
in vitro reactions (200 lM, 1 h) yielded a significantly
higher VD3 conversion ratio when using the BmCPR-
Fdx2 redox pair (36  4%) (Fig. 4A) as compared with
the AdR-Adx4–108 pair (20  5%, data not shown).
Usage of the different redox pairs (BmCPR-Fdx2 or
AdR-Adx4–108) to reconstitute CYP109A2 activity
toward VD3 resulted in identical product patterns,
showing one main product P1 (~ 64% of total products)
and one minor product P2 (~ 36% of total products)
(Fig. 4A). Determination of the steady-state kinetics of
VD3 conversion by CYP109A2 showed a typical Miche-
lis-Menten behavior with kcat and KM values of 3.42 
0.15 min1 and 49.0  5.8 lM, respectively (Fig. 5).
These results demonstrate that the CYP109A2 in vitro
activity toward VD3 is lower than that of other previ-
ously characterized bacterial VD3 hydroxylases [24]. In
addition, CYP109A2 displays a lower substrate conver-
sion ratio in comparison to its most closely related
homolog CYP109E1, which was shown to convert
~ 90% of VD3 under the same conditions (when sup-
ported by the AdR–Adx4–108 pair) [13]. The affinity for
VD3 is also lower in CYP109A2 as compared with wild-
type CYP105A1 or Vdh, which showed KM values of
0.54  0.09 lM and 13.5  3.7 lM, respectively [12,25].
However, the regio-selectivity of CYP109A2, as evi-
dent from its product pattern of VD3 conversion, is
superior to that of the other bacterial VD3 hydroxy-
lases. CYP109A2 converts VD3 into two products
only, whereas previously it was shown that CYP109E1
converts the same substrate to seven products [13].
CYP105A1 and Vdh convert VD3 to three products
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[12,25], while for the VD3 25-hydroxylase CYP105A2
from P. autotrophica, the exact product profile is not
yet determined [24]. Interestingly, upon comparison of
the CYP109A2 product retention times with the
available authentic standards and HPLC data previ-
ously obtained for CYP109E1, it was hypothesized
and later shown (see below) that product P1 is 25-
hydroxyvitamin D3. Therefore, to the best of our
Fig. 2. Multiple sequence alignment of CYP109A2 and other bacterial P450s showing 25-hydroxylation activity with VD3 or VD3 derivatives.
Secondary structural elements are shown as in the crystal structure of CYP109A2. Conserved and similar residues are highlighted in red
and yellow, respectively. Helices are labeled A–L. Residues in the six substrate recognition sites (SRS) are enclosed in black boxes. The
characteristic P450 sequence motifs are in blue boxes: the heme-binding domain signature just before the L helix, central part of I helix with
the highly conserved ‘acid-alcohol pair’ of residues, and the ‘ExxR’ motif in the K helix.
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knowledge, the newly identified enzyme, CYP109A2
from B. megaterium, is the most regio-selective bacte-
rial VD3 hydroxylase characterized so far.
Whole-cell-based bioconversion of vitamin D3 by
CYP109A2
Our recent study of CYP109E1 has demonstrated that
the B. megaterium-based whole-cell system may be an
efficient and sustainable route to large-scale produc-
tion of VD3 metabolites like 25(OH)VD3 [13].
B. megaterium is a Gram-positive, nonpathogenic bac-
terium and a well-studied biotechnologically applicable
production host. Its use in the pharmaceutical and
food industries is preferred due to the ability of this
bacterium to grow on a variety of carbon sources and
simple media as well as due to its high protein
production capacity and plasmid stability [26,27].
Importantly, as shown by research results considering
various P450 enzymes, the B. megaterium offers certain
advantages, of being not only a source of new, unchar-
acterized P450s but also a very good host for P450s
and/or their homologous or heterologous redox part-
ners [19,28–30]. Use of the whole-cell expressed P450
(s) in a biotransformation process allows for regenera-
tion of the expensive NADPH cofactor that is neces-
sary for P450 activity.
The B. megaterium MS941 cells were transformed
with expression plasmid pSMF2.1.CYP109A2, and
using such a system 76  5% of 200 lM VD3 was suc-
cessfully converted within 24 h into one main product
P1 (90%) and one minor product P2 (10%) (Fig. 4B).
In comparison to the profile observed in vitro, the
Fig. 3. Spectroscopic properties of CYP109A2. (A) The UV-visible
absorbance spectrum of the reduced CO-bound form of CYP109A2
showing the characteristic Soret peak at 450 nm. (B) The UV-
visible absorbance spectrum of ligand-free CYP109A2 displaying
typical peaks; c (at 417 nm), a (568 nm), and b (536 nm).
Fig. 4. HPLC analysis of CYP109A2-dependent VD3 conversion. (A)
In vitro conversion. (B) Whole-cell conversion in Bacillus megaterium.
The products are labeled P1-P2. The authentic standard of VD3 (gray)
was detected with the same HPLCmethod.
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product ratio obtained in vivo is slightly changed, favor-
ing generation of the main product P1 over product P2.
The changes in the product profile are most probably
caused by the fact that no heterologous redox partners
were expressed along with CYP109A2, leaving only the
endogenous B. megaterium redox proteins (which
remain to be identified) to support its activity. In fact,
it was recently observed that varying the redox partners
for reconstitution of P450-based reactions can influence
the observed product ratios [31,32].
Product isolation and identification by NMR
analysis
As for the in vitro conversion of VD3 by CYP109A2,
the main hydroxylated product obtained by the in vivo
conversion showed an identical retention time in HPLC
analysis as the authentic standard of 25-hydroxyvitamin
D3. To allow full characterization of the product(s) by
NMR spectroscopy, the in vivo reactions were up-scaled
to 400 mL of total culture volume (200 lM VD3), and
thus 16 mg of the product of interest (P1) was obtained.
Unfortunately, the yields of product P2 were not suffi-
cient to allow for the direct product identification by
NMR. For the isolated product P1, the 1H NMR and
13C NMR spectra were recorded. It was observed that
in comparison to standard VD3, product P1 showed res-
onances for an additional tertiary hydroxyl group (at C-
25) in the 13C NMR spectrum (dC 71.15), whereas the
resonances of the methyl groups C-26 and C-27 both
appeared as singlets (dH 1.19 s, 6H) in the
1H NMR
spectrum. This clearly indicated that CYP109A2
catalyzes conversion of VD3 to 25(OH)VD3 as the main
product (Fig. 6). The NMR data are in accordance with
reported literature (Table S1) [33,34].
Efficient biocatalytic production of 25-
hydroxyvitamin D3 by CYP109A2
Based on the results of the in vivo conversion of VD3
performed by the CYP109A2-based whole-cell system,
the yield of 25(OH)VD3 was calculated to be
54.9 mgL1day1. Hence, it becomes apparent that
the production yield of the CYP109A2-based whole-
cell system is significantly higher as compared with
other bacterial in vivo CYP-based systems known to
produce the same product. For example, the previously
studied CYP109E1 expressed in B. megaterium under
the same conditions and reaction time produced
24.5 mgL1day1 of 25(OH)VD3, whereas with its
best mutant I85A, the achieved yield was
45 mgL1day1 [13]. The yield achieved with the
CYP109A2-based system is also higher than the yield
reported for the most productive mutant of CYP105A1
(R73A/R84A), which produced 7.8 mg 25(OH)
VD3L1day1 [14]. Only Vdh expressed in Amycolata
autotrophica (now referred to as P. autotrophica) was
reported to give a higher yield than CYP109A2 being
137 mgL1 [35]. However, this value was obtained
after 72 h, whereas in case of CYP109A2 described
here, 54.9 mgL1 was obtained already after 24 h.
Thus, the B. megaterium CYP109A2-based whole-cell
system offers a very promising biotechnological alter-
native to the production of 25-hydroxyvitamin D3 in
comparison to other characterized P450 biocatalysts.
Crystal structure of substrate-free CYP109A2
In order to determine the geometry of its active site
pocket and predict the residues responsible for VD3
Fig. 5. Determination of the kinetic parameters of VD3 conversion
catalyzed by CYP109A2. Mean values and standard deviations
(error bars) were calculated from the results of three independent
experiments. The data were fitted to the Michaelis–Menten
equation.
Fig. 6. Scheme of the CYP109A2-catalyzed conversion of VD3.
Hydroxylation site is indicated in red.
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binding, the CYP109A2 enzyme was studied by X-ray
crystallography. For crystallization, a C-terminally
His-tagged protein was purified using the previously
described three-step purification procedure, resulting in
protein sample of > 98% purity and low polydispersity
(12.2%) as confirmed by SDS/PAGE analysis and
dynamic light scattering (DLS) measurements (data
not shown). The substrate-free CYP109A2 crystallized
in an orthorhombic space group (P212121), with four
monomers in the asymmetric unit and a solvent con-
tent of 50%. The crystal structure was solved at 2.7 A
resolution by the molecular replacement method, using
the previously determined structure of CYP109E1 (se-
quence similarity 45%, Protein Data Bank [PDB] entry
5L90, [18]) as a search model (see Table 1 for data col-
lection and refinement statistics). All four CYP109A2
molecules have well-defined electron density, except
for the 15 or 16 N-terminal residues and the C-term-
inal His6-tags, for which no electron density was
observed. The central parts of the BC loop, FG loop,
and N-terminal end of the G helix show relatively high
B-factors, related to high mobility of those regions, as
generally observed in P450 crystal structures. The four
CYP109A2 molecules found in the asymmetric unit
have almost identical conformations [the root mean
square deviation (r.m.s.d) of Ca-backbone atoms
ranges between 0.36 and 0.43 A]. Therefore, only one
of the protein molecules will be described further. The
structure of CYP109A2 (residues 16–401) exhibits the
typical organization of a P450 domain, containing 15
helices (labeled A–L, A0, B0, and K0) and 10 b-strands
(arranged in three b-sheets; in the same structural
arrangement as observed in the CYP109E1 crystal
structure, Fig. 7A). The centrally located heme group
is sandwiched between the I and L helices, similarly as
in other P450s. The bound heme is covalently attached
to the protein by an iron-sulfur bond with Cys351 and
is further stabilized by several residues providing van
der Waals and hydrophobic interactions, while its pro-
pionate side chains interact with the side chains of
His91, Arg95, Arg293, and His349. At the distal side
of the heme, no clear electron density was observed
for a heme-bound water molecule, in contrast to many
other P450 crystal structures determined in the sub-
strate-free state. A small blob of electron density is
located at approximately 5 A distance from the heme-
iron, which may correspond to a glycerol molecule
from the cryobuffer, but the quality of the electron
density did not allow unambiguous ligand identifica-
tion. In addition, five PEG 400 molecules and three
sulfate ions (SO24 ), originating from the crystallization
solution, are present in the structure.
Structural comparison of CYP109A2 overall fold
and active site architecture with related vitamin
D3 hydroxylases
CYP109A2 crystallized in an ‘open’ conformation,
which is confirmed by structural alignments against
other P450 structures deposited in the PDB, giving the
best match to those displaying open active site geome-
try (Table S2). The highest structural similarity is
observed with the ‘open’ crystal structure of
CYP109E1 containing four bound corticosterone
molecules in the active site pocket (PDB entry 5L91,
r.m.s.d. of 1.27 A for 368 Ca atoms). In addition, a
significant structural similarity is observed with the
structures of Vdh from P. autotrophica, considering
Table 1. Crystallographic data collection and refinement statistics
of CYP109A2.
CYP109A2
PDB code 5OFQ
Model statistics
Monomers in the AU 4
Solvent content (%) 50
Ligands 5 9 PEG 400, 3 9 sulfate ion
Data collection
Beamline (ESRF) ID23-2
Wavelength (A) 0.873
Resolution range (A) 52–2.70 (2.78–2.70)a
Space group P212121
Unit-cell parameters
a, b, c (A) 77.12 155.53 158.15
a, b, c (°) 90, 90, 90
Observed reflections 287 529 (25 387)
Unique reflections 51 368 (4458)
Multiplicity 5.6 (5.7)
Completeness (%) 97.3 (98.5)
<I/r(I)> 12.4 (1.7)
Rmerge (%) 0.10 (0.94)
Rp.i.m. 0.07 (0.63)
CC (1/2) (%) 99.6 (52.3)
Refinement
Rwork (%) 22.4
Rfree (%) 27.5
R.m.s.d, bond lengths (A) 0.018
R.m.s.d, bond angles (°) 1.418
Average B-factors (A)2
Overall 50.5
Protein 50.4
Heme 50.0
Ramachandran plot statistics
Most favored (%) 95.6
Allowed regions (%) 4.4
Disallowed regions (%) 0
Molprobity overall score 1.49
aValues in parentheses are for the highest resolution shell.
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both its wild-type and its mutant forms (L348M and
F106V) [36] (e.g. wild-type Vdh, PDB entry 3A4G,
r.m.s.d. of 1.44 A for 349 Ca atoms). Visual analysis
of the CYP109A2, CYP109E1, and Vdh structures
shows that they contain similar, wide-open, funnel-
shaped, and solvent-exposed ‘distal’ heme pockets. The
main difference concerns the BC loop/SRS1 region
(loop connecting the B and C helices, residues 71–87
in CYP109A2), whose length, fold, and sequence vary
significantly in the structures of the three different
enzymes (Figs 2 and 7B). CYP109A2 contains the
shortest BC loop, whereas the longest loop is present
in Vdh (Fig. 2). While the BC loop in CYP109A2
folds toward the active site pocket, the loops in
CYP109E1 and especially Vdh are folded more out-
ward (Figs 7B and 8A). As a result, the BC loop in
CYP109A2 restricts access of substrate to the heme-
iron to a larger extent than the BC loops in
CYP109E1 and Vdh. The structural differences in the
BC loop region further result in a striking difference in
the distribution of hydrophobic and polar regions in
the active sites of the three P450s (Fig. 8B–D). In the
region closest to the heme, the active site pockets in
CYP109A2, CYP109E1, and Vdh display a similar,
mainly apolar surface due to the presence of conserved
hydrophobic residues, i.e., Leu84, Met85 (SRS1);
Leu237, Val240, Ala241 (SRS4); Ile288, Ile291 (SRS5);
and Phe389, Val390 (SRS6) in CYP109A2. A bit fur-
ther away from the heme, however, the surfaces show
some significant differences. Residues Arg74, Glu78,
Arg79, and Glu81 of the BC loop in CYP109A2 form a
highly polar surface restricting one side of the active site
pocket (Fig. 8B). In the active site pocket of
CYP109E1, the BC loop also forms a polar surface, but
it is much less pronounced as in CYP109A2 (Fig. 8C),
while in Vdh, it is nearly absent (Fig. 8D). The
observed differences in BC loop geometry, in the extent
of restricted access to the heme-iron and in the apolar/
polar surface distribution around the active site pocket,
will likely influence the substrate-binding modes in the
three different enzymes. In the absence of a closed,
VD3-bound crystal structure of CYP109A2, it remains
unknown whether these differences are directly related
to the differences in regio-selectivity for VD3 hydroxyla-
tion. Arguably, a significantly more polar BC loop
region and a more constricted active site pocket in
CYP109A2, in comparison to CYP109E1 or Vdh,
allows for lower occurrence of differently stabilized
VD3-binding modes, therefore resulting in an increased
regio-selectivity of substrate hydroxylation in compar-
ison to CYP109E1 or Vdh, as observed experimentally.
Indeed, the BC loop, a highly variable and flexible
region in P450s, has been previously associated with dif-
ferences in substrate specificity [37].
Prediction of vitamin D3-binding residues in
CYP109A2
Unfortunately, our experiments to crystalize a structure
of CYP109A2 in its closed conformation were not suc-
cessful, despite extensive efforts to obtain a structure of
substrate-bound and/or product-bound CYP109A2.
Fig. 7. Crystal structure of substrate-free CYP109A2. (A) Ribbon
representation with secondary structure elements labeled following
the common P450 nomenclature (rainbow coloring from blue N0
terminus to red C0 terminus). Helices are labeled A–L following the
common P450 nomenclature of secondary structure elements.
Heme is shown as red stick model. (B) Superposition of the overall
open conformations of CYP109A2, CYP109E1 from
Bacillus megaterium DSM319 and Vdh from Pseudonocardia
autotrophica. Cartoon representation of the aligned structures of
CYP109A2 (green), CYP109E1 (5L90, blue), and Vdh (3A4G, pink) is
shown.
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The residues known or predicted to bind and stabilize
VD3 in the active sites of CYP109E1 or Vdh were, there-
fore, compared to their structural equivalents in
CYP109A2 (Table 2). Based on this comparison, the
following 13 residues of CYP109A2 are predicted to
interact with VD3: Arg74, Leu84, Met85 from SRS1;
Leu167, Val168 from SRS2; Arg186, Asn187, Val190
from SRS3; Leu237, Val240, Thr245 from SRS4; Ile291
from SRS5 and Phe389 from SRS6 (Fig. 9). Of these
residues, six are identical to those in CYP109E1 or Vdh,
while the other residues are relatively similar. This sig-
nificant degree of conservation further supports the
notion that the overall binding mode of VD3 leading to
25-hydroxylation is similar in these enzymes. Whether
the predicted residues in CYP109A2 indeed have impor-
tant roles in substrate binding and conversion has to
await further analysis by site-directed mutagenesis.
In summary, we have shown that cytochrome P450
monooxygenase CYP109A2 from B. megaterium is able
to catalyze hydroxylation of VD3 to its 25-hydroxy-
lated derivative, with high regio-selectivity. The activity
was reconstituted in the whole-cell-based system, allow-
ing to obtain high yields of the desired 25-hydroxylated
product and therefore renders the system as most effi-
cient and regio-selective in comparison to other related
bacterial P450s previously shown to oxidize VD3.
These characteristics highlight the significance of
CYP109A2 as a promising, potential industrially appli-
cable biocatalyst. The crystal structure of CYP109A2
allowed for a detailed analysis of the active site geome-
try and prediction of VD3 interacting residues. Our
study forms the basis to guide future efforts to explore
the substrate scope and selectivity of CYP109A2.
Experimental procedures
Materials
VD3, 25(OH)VD3, (2-hydroxypropyl)-b-cyclodextrin and
saponin (from quillaja bark) were purchased from Sigma-
Aldrich Chemie GmbH (Steinheim, Germany). IPTG and d-
aminolevulinic acid (d-ALA) were purchased from Carbolu-
tion Chemicals GmbH (Saarbruecken, Germany). Bacterial
media were purchased from Becton Dickinson (Heidelberg,
Germany). All other chemicals were from standard sources
and of highest purity available. The E. coli TOP10 strain used
for cloning purposes was bought from Invitrogen (San Diego,
CA, USA), whereas the E. coli C43 (DE3) strain and pET17b
vector used for heterologous expression were purchased from
Novagen (Merck Bioscience, Bad Soden, Germany). The
pSMF2.1 vector was used for protein expression in B. mega-
teriumMS94 [38].
Fig. 8. Comparison of the substrate-binding pockets in CYP109A2, CYP109E1 from Bacillus megaterium DSM319 and Vdh from
Pseudonocardia autotrophica, all presenting an open conformation. (A) Three structures are superimposed and their molecular surfaces are
shown in gray. The steric restriction of the active site pocket imposed by the BC loop region is significantly larger in the CYP109A2
structure (surface in green) than in CYP109E1 (5L90, in blue) and Vdh (3A4G, in magenta). (B–D) Surface representation of the ‘distal’ heme
substrate-binding pockets in CYP109A2 (B), CYP109E1 (C), and Vdh (D). Apolar residues are colored in orange and polar residues in blue.
The different BC loop regions in the three P450s (lower parts of the images) are outlined with a green-dashed line.
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Cloning
The cyp109a2 gene (GenBank GeneID 9117426) was ampli-
fied by PCR using genomic DNA of B. megaterium MS941
as template (mutant derived from DSM319 strain) [39,40].
To allow expression of CYP109A2 carrying a C-terminal
His6-tag, the cyp109a2 gene was extended with a sequence
at the 30-end coding for the desired tag and cloned into the
expression vector pET17b with the NdeI/KpnI restriction
sites yielding pET17b.CYP109A2. The primer pair used
was 50-ATATCATATGAATCCAAAAGCAGT-GAAAAG
AGAAAATCG-30 and 50-TTAGGTACCTCAATGGTGG
TGGTGATGATG-GGCGTTATTAAAAGCAATTTC-30.
The cyp109a2 gene was also cloned into the pSMF2.1 vec-
tor using PacI/SpeI restriction sites and including an opti-
mized ribosomal-binding site for B. megaterium, yielding
pSMF2.1.CYP109A2. The primer pairs used were 50-CG
CTTAATTAAAAATCAAGGAGGTGAATGTACAATG
AATCCAAAAGCAGTGAAAAGAG-30 and 50-TTATCA
ACTAGTTCAGGCGTTATTAAAAGCAATTTCATA-TT
TTTTTACC-30.
Heterologous gene expression and purification
The E. coli C43 (DE3) cells serving as expression host were
transformed with the pET17b.CYP109A2 construct and
cultured overnight in LB medium containing 100 lgmL1
ampicillin, at 37 °C and 140 r.p.m. The overnight culture
was used to inoculate a 250 mL main culture [Terrific
Broth (TB) medium] containing 100 lgmL1 ampicillin.
The main culture was grown at 37 °C and 140 r.p.m. until
the optical density at 600 nm reached 0.6. Gene expression
was induced by addition of 1 mM IPTG and 0.5 mM
d-ALA (heme precursor). The culture was further grown at
30 °C (120 r.p.m.) for 24 h. The E. coli cells were harvested
by centrifugation at 4500 g for 30 min, and cell pellets were
stored at –20 °C until purification. For biochemical charac-
terization, the protein was purified using a simplified proce-
dure (one-step immobilized metal ion affinity
chromatography). For crystallization, a three-step purifica-
tion protocol was followed, as described previously (ion
exchange chromatography, gel filtration, mixed-mode ion
exchange chromatography) [18]. Purification of the redox
partner protein pairs (BmCPR-Fdx2 and AdR-Adx4–108)
was performed according to the previously reported proce-
dures [19,23].
Protein quality analysis
Spectroscopic properties of the purified P450 were analyzed
using a double-beam spectrophotometer (UV-2101PC; Shi-
madzu Corporation, Kyoto, Japan). All UV-visible absor-
bance spectra were recorded from 200 to 700 nm.
Concentration of CYP109A2 was estimated based on CO-
difference spectroscopy (using an extinction coefficient of
Fig. 9. Predicted VD3-binding residues in CYP109A2, identified
based on structural comparison with CYP109E1 and Vdh (Table 2).
The residues are shown as sticks and colored according to the
corresponding substrate recognition site (SRS1 orange, SRS2
green, SRS3 blue, SRS4 yellow, SRS5 pink, and SRS6 cyan).
Residues overlapping in both predictions are labeled in bold. The
heme group is shown as red colored sticks.
Table 2. Identification of residues with predicted VD3-binding roles
in CYP109A2, based on structural comparison to CYP109E1 and
Vdh. (A) Residues of CYP109E1 previously predicted to interact
with the VD3 molecule [13] and their structurally equivalent
residues in CYP109A2. (B) VD3-binding residues in the crystal
structure of VD3-bound Vdh (PDB id: 3A50) [16] and their
structurally equivalent residues in CYP109A2. Residues of
CYP109A2 appearing in both panels are highlighted in blue. The
residues of CYP109E1 studied previously by site-directed
mutagenesis [13,18] are highlighted in gray. Conserved CYP109A2
residues are shown in bold.
A
Predicted
VD3-binding
residues
CYP109E1 CYP109A2 B
VD3-
binding
residues
Vdh (3A50) CYP109A2
SRS1 Arg69 Arg74 SRS1 Thr84 –
Pro71 – Met86 –
Thr78 – Ile88 Leu84
Leu80 – Leu89 Met85
Ile85 Leu84 SRS2 Leu171 Leu167
Asn86 Met85 SRS3 Lys180 Arg186
SRS2 Ile168 Leu167 Asn181 Asn187
Val169 Val168 Met184 Val190
SRS3 Asn191 Val190 SRS4 Leu232 Leu237
SRS4 Leu238 Leu237 Ile235 Val240
Ile241 Val240 Thr240 Thr245
Thr246 Thr245 SRS5 Pro287 Ile291
SRS6 Leu387 Phe389
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91 mm1cm1), according to the method of Omura and
Sato [41]. Protein purity and heterogeneity were analyzed
by SDS/PAGE and DLS, respectively. The DLS measure-
ment was performed using a DynaPro NanoStar instrument
thermostated at 293 K (Wyatt Instruments, Santa Barbara,
CA, USA).
In vitro conversion and kinetic analysis
Enzymatic activity of CYP109A2 was reconstituted in an
in vitro system containing 1 lM CYP109A2, 3 lM ferredoxin
reductase (BmCPR or AdR), 20 lM ferredoxin (Fdx2 or
Adx8–104), 1 mM MgCl2, and a cofactor regenerating system
with glucose-6-phosphate (5 mM) and glucose-6-phosphate
dehydrogenase (1 U), all in 50 mM potassium phosphate
buffer containing 20% glycerol (pH 7.4) and at 250 lL final
volume. VD3 was dissolved in (2-hydroxypropyl)-b-cyclodex-
trin (2.25%) and added at 200 lM final concentration. The
reaction was started by addition of 0.5 mM NADPH at
30 °C. After 1 h, the reaction was stopped and extracted
twice with 500 lL of ethyl acetate. The organic phases were
combined, evaporated to dryness, and prepared for analysis
by HPLC. For determination of kinetic parameters of VD3
conversion by CYP109A2, three independent in vitro reac-
tions were performed (each continuing for 20 min). VD3 con-
centrations ranged from 0 to 400 lM. The kcat and KM values
were calculated by plotting the product formation rate against
increasing substrate concentration. The data were fit to the
Michaelis–Menten equation using ORIGIN software from Ori-
ginLab Corporation (Northampton, MA, USA).
High-performance liquid chromatography
The HPLC analysis was carried out on a Jasco system (Pu-
980 HPLC pump, AS-950 sampler, UV-975 UV-visible
detector, LG-980-02 gradient unit; Jasco, Gross-Umstadt,
Germany) equipped with a reversed-phase Nucleodur 100-5
C18 column (125 9 4 mm; Macherey-Nagel, D€uren, Ger-
many). The column temperature was adjusted to 40 °C.
The samples were dissolved in 200 lL of acetonitrile. A lin-
ear gradient of 60–100% aqueous acetonitrile was applied
for 15 min (1 mLmin1 flow rate), followed by 100% ace-
tonitrile for 15 min. The UV detection of the substrate and
products was accomplished at 265 nm. Assuming that the
absorption properties of the products did not differ from
the substrate, the product formation was calculated as the
relative peak area (area %) of the HPLC chromatograms,
dividing each respective product peak area by the sum of
products and substrate areas.
Whole-cell conversion in Bacillus megaterium
MS941
The whole-cell conversions were performed in B. mega-
terium MS941 cells transformed with the
pSMF2.1.CYP109A2 construct using the polyethylene gly-
col-mediated protoplast transformation method [42]. Initial
seed culture was prepared in LB medium (10 lgmL1
tetracycline). The main culture (50 mL TB medium,
10 lgmL1 tetracycline) was inoculated with 500 lL of the
seed culture (dilution 1 : 100) in 300 mL baffled flasks and
incubated under shaking at 37 °C (140 r.p.m.). The culture
was grown to OD578 of 0.4, and at that point, the recombi-
nant gene expression was induced with xylose (5 mgmL1).
The culture was further grown at 30 °C for 24 h
(140 r.p.m.). To initialize the whole-cell conversion experi-
ments, after 24 h of protein expression, the substrate
[200 lM VD3 dissolved in 45% (2-hydroxypropyl)-b-cyclo-
dextrin)] and a membrane-solubilizing agent (4% Quillaja
Saponin) were added to the cultures. Afterward, the con-
versions were allowed to proceed at 30 °C and 120 r.p.m.
for 24 h. Finally, 500 lL samples of the cultures were
taken, extracted, and prepared for HPLC analysis.
Product isolation and NMR characterization
In order to obtain sufficient amounts of the reaction pro-
duct, the whole-cell based cultivation and conversion exper-
iments were scaled up to 400 mL (2 9 200 mL) and
performed as described above. The main reaction product
(P1) was isolated and purified by reversed-phase HPLC
using a preparative column VP Nucleodur 100-5 C18
(8.0 9 250 mm; Macherey-Nagel). The NMR spectra were
recorded in CDCl3 with a Bruker Avance 500 NMR spec-
trometer at 298 K (Bruker AXS Advanced X-ray Solutions
GmbH, Karlsruhe, Germany). The chemical shifts were rel-
ative to CHCl3 at d 7.26 (
1H NMR) and CDCl3 at d 77.00
(13C NMR) using the standard d notation in parts per mil-
lion. The 1D NMR (1H and 13C NMR) and the 2D NMR
spectra (gs-HH-COSY and gs-HSQCED) were recorded
using the BRUKER pulse program library.
Crystallization, data collection, and structure
determination
Aliquots with purified CYP109A2 were thawed, buffer
exchanged to 20 mM Tris/HCl, pH 8.0, 0.1 mM dithioery-
thritol and concentrated to 40 mgmL1 by ultrafiltration
using a 30-kDa cutoff membrane. Crystallization condition
screening was done in 96-well plate format. Sitting-drop
vapor-diffusion experiments were set up by a Mosquito
crystallization robot (TTP LabTech, Melbourn, UK), using
commercially available high-throughput crystallization
screens. Multiple hits were obtained overnight, and the
most promising condition [2.0 M ammonium sulfate, 0.1 M
HEPES, pH 7.5, and 2% (v/v) PEG 400] was chosen for
further optimization. Crystal optimization was performed
manually at 293 K by the sitting-drop vapor diffusion
method in 24-well plates using reservoir solution volumes
of 300 lL. Protein drops were prepared by mixing 1 lL of
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protein and 1 lL of reservoir solution. A single, red plate-
like crystal of CYP109A2 appeared after 3 days using a
reservoir solution containing 1.9 M ammonium sulfate,
0.1 M HEPES, pH 7.5, and 2% (v/v) PEG 400 and needed
about a week to grow to its final dimensions
(0.12 9 0.04 9 0.03 mm3).
For data collection, the crystal was shortly swiped
through a cryobuffer droplet [mother liquor supplemented
with 30% (v/v) glycerol] and flash-cooled to 100 K in a
cold nitrogen gas cryostream. X-ray diffraction data were
collected at the ID23-2 beam line of the European Syn-
chrotron Radiation Facility (ESRF) in Grenoble, France.
Reflections were indexed and integrated using XDS [43],
while scaling and merging of the data was done with AIM-
LESS from the CCP4 software suite [44]. The structure of
CYP109A2 was determined by molecular replacement using
PHASER from the PHENIX software package [45], applying the
structure of substrate-free CYP109E1 (PDB entry 5L90,
[18]) as a search model. The structure was completed with
several cycles of model refinement using PHENIX.REFINE [46]
alternated with manual model re-building using COOT [47].
At the final stages of refinement and model building, water
molecules were added to the model based on positive differ-
ence electron density peaks and strict interaction criteria.
The final model was validated with MOLPROBITY [48]. The
model coordinates and structure factors are deposited in
the PDB with accession code 5OFQ.
Sequence and structure analysis
Protein sequences were compared using the Basic Local
Alignment Search Tool (BLAST, NCBI). Substrate recogni-
tion sites (SRS) in CYP109A2 were identified by alignment
with P450cam (WP_032492633) and followed a description
defined by Gotoh [49]: SRS1: 71–87 (BC loop), SRS2: 163–
169 (C0-terminal part of F helix), SRS3: 185–192 (N0-terminal
part of G helix), SRS4: 229–247 (central part of I helix),
SRS5: 284–293 (K-b5 connection), and SRS6: 384–392 (b9-
b10 turn). Pairwise structural alignments were done using
PDBEFOLD [50]. Multiple sequence alignment was done with
CLUSTAL OMEGA [51], and the output figure was prepared
with ESPRIPT3 [52]. The GenBank accession codes for ana-
lyzed sequences are as follows: CYP109A2 from B. mega-
terium DSM319 (WP_013082916), CYP109E1 from
B. megaterium DSM319 (WP_013084555), CYP105A1 from
S. griseolus (BAG50411), CYP105A2 from P. autotrophica
(BAA05541), Vdh (CYP107BR1) from P. autotrophica
(C4B644), CYP107CB2 from B. lehensis G1 (AIC83164).
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Table S1. NMR data for the main product of CYP109A2-catalyzed VD3 conversion, namely 
the 25-hydroxylated vitamin D3.  
 
 
25-hydroxyvitamin D3 (Product P1) 
1
H NMR (CDCl3, 500 MHz): δ 0.52 (s, 3xH-18), 0.92 (d, J=6.5 Hz, 3xH-21), 1.02 (m, 
H-22a), 1.06 (m, H-22b), 1.19 (s, 6H, 3xH-26 and 3xH-27), 1.20 (m, H-23a), 1.24 (m, H-
16a), 1.28 (m, H-17), 1.29 (m, H-12a), 1.36 (m, H-24a), 1.39 (m, H-23b), 1.45 (m, 2H, 
H-11a and H-24b), 1.51 (m, H-20), 1.52 (m, 2H, H-11b and H-15a), 1.60 (m, H-2a), 1.63 
(m, H-15b), 1.69 (m, H-9a), 1.86 (m, H-16b), 1.94 (m, H-14), 1.96 (m, H-2b), 1.98 (m, 
H-12b), 2.16 (dd, J=13.5, 8.5 and 5.0 Hz, H-1a), 2.26 (dd, J=13.0 and 7.5 Hz, H-4a), 2.38 
(ddd, J=13.5, 7.5 and 4.6 Hz, H-1b), 2.55 (dd, J=13.0 and 4.0 Hz, H-4b), 2.82 (m, H-9b), 
3.92 (m, H-3), 4.80 (d, J= 2.5 Hz, H-19a), 5.03 (m, H-19b), 6.01 (d, 11.3 Hz, H-7), 6.21 
(d, 11.3 Hz, H-6).  
13
C NMR (CDCl3, 125 MHz): δ 11.99 (CH3, C-18), 18.81 (CH3, C-21), 20.82 (CH2, C-
23), 22.24 (CH2, C-11), 23.56 (CH2, C-15), 27.67 (CH2, C-16), 29.07 (CH2, C-9), 29.29 
(CH3, C-26), 29.34 (CH3, C-27), 31.92 (CH2, C-1), 35.16 (CH2, C-2), 36.10 (CH2, C-22), 
36.40 (CH, C-20), 40.53 (CH2, C-12), 44.39 (CH2, C-24), 45.85 (C, C-13), 45.92 (CH2, 
C-4), 56.33 (CH, C-14), 56.53 (CH, C-17), 69.21 (CH, C-3), 71.15 (C, C-25), 112.40 
(CH2, C-19), 117.51  (CH, C-7), 122.45 (CH, C-6), 135.00 (C, C-5), 142.89 (C, C-8), 
145.09 (C, C-10). 
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Table S2. Highest ranked structural homologues of CYP109A2 found in the PDB. The search 
was performed with PDBeFold [49].      
 
CYP109A2 (open, substrate-free, chain C) 
  
PDB code and 
chain id 
Q score 
RMSD 
Cα [Å] 
Nalign 
% 
Sequence 
P450 and organism 
1 5L91:B 0.77 1.27 368 45 CYP109E1 B. megaterium DSM319 
2 4RM4:A 0.67 1.44 339 47 CYP109B1 B. subtilis 
3 5GNM:B 0.66 1.42 354 34 Vdh (CYP107BR1)-L348M P. autotrophica  
4 5GNL:A 0.66 1.43 351 35 Vdh (CYP107BR1)-F106V P. autotrophica 
5 4YZR:A 0.65 1.58 354 37 PksS B. subtilis 
6 3A4G:A 0.65 1.44 349 35 Vdh (CYP107BR1) P. autotrophica  
7 2BVJ:B 0.64 1.36 340 37 PikC (CYP107L1) S. venezuelae 
8 2WIO:A 0.63 1.41 342 35 EryK (CYP113A1) S. erythrea  
9 3EJE:D 0.62 1.85 357 35 BioI (CYP107H1) B. subtilis 
10 5IKI:A 0.62 1.81 352 38 CYP106A2 B. megaterium 
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Cytochrome P450 monooxygenases (P450s) are attractive enzymes for the
pharmaceutical industry, in particular, for applications in steroidal drug syn-
thesis. Here, we report a comprehensive functional and structural characteri-
zation of CYP109E1, a novel steroid-converting cytochrome P450 enzyme
identified from the genome of Bacillus megaterium DSM319. In vitro and
whole-cell in vivo turnover experiments, combined with binding assays,
revealed that CYP109E1 is able to hydroxylate testosterone at position 16b.
Related steroids with bulky substituents at carbon C17, like corticosterone,
bind to the enzyme without being converted. High-resolution X-ray struc-
tures were solved of a steroid-free form of CYP109E1 and of complexes with
testosterone and corticosterone. The structural analysis revealed a highly
dynamic active site at the distal side of the heme, which is wide open in the
absence of steroids, can bind four ordered corticosterone molecules simulta-
neously, and undergoes substantial narrowing upon binding of single steroid
molecules. In the crystal structures, the single bound steroids adopt unpro-
ductive binding modes coordinating the heme-iron with their C3-keto oxy-
gen. Molecular dynamics (MD) simulations suggest that the steroids may
also bind in ~180° reversed orientations with the C16 carbon and C17-substi-
tuents pointing toward the heme, leading to productive binding of testos-
terone explaining the observed regio- and stereoselectivity. The X-ray
structures and MD simulations further identify several residues with impor-
tant roles in steroid binding and conversion, which could be confirmed by
site-directed mutagenesis. Taken together, our results provide unique insights
into the CYP109E1 activity, substrate specificity, and regio/stereoselectivity.
Database
The atomic coordinates and structure factors have been deposited in the Protein Data Bank
with accession codes 5L90 (steroid-free CYP109E1), 5L91 (CYP109E1-COR4), 5L94
(CYP109E1-TES), and 5L92 (CYP109E1-COR).
Enzymes
Cytochrome P450 monooxygenase CYP109E1, EC 1.14.14.1, UniProt ID: D5DKI8, Adreno-
doxin reductase EC 1.18.1.6.
Abbreviations
COR, corticosterone; P450, cytochrome P450 monooxygenase; SRS, substrate recognition site; TES, testosterone.
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Introduction
Cytochrome P450 monooxygenases (P450s) constitute
a large superfamily of enzymes, found in all domains
of life, which catalyze oxygen-mediated hydroxylation
of a wide variety of aromatic and aliphatic com-
pounds. In nature, these enzymes play essential roles
in metabolic processes like steroid biosynthesis, fatty
acid metabolism, or biotransformation of drugs and
other xenobiotics. In the laboratory and biotechno-
logical industry, they are considered as high potential
biocatalysts, owing to their ability to selectively oxi-
dize unreactive C-H bonds at mild conditions [1].
Their application toward cost-effective and environ-
mentally friendly production of steroid derivatives is
of particular interest, considering the wide use of such
compounds as therapeutic agents [2,3]. Currently
more than 300 steroid drugs are authorized, making
them the most marketed group of products in the
pharmaceutical industry [4]. The ability of P450s to
perform regioselective and stereoselective hydroxyla-
tion of steroids has led to an ongoing search and
characterization of new enzymes, in particular from
prokaryotic sources, as these are more amenable to
industrial application than their eukaryotic counter-
parts [5].
To efficiently handle P450s and to design improved
variants for synthetic applications, it is crucial to
understand the structure-function relationships govern-
ing their substrate specificity and regio- and stereose-
lectivity [6,7]. Although a wealth of functional and
structural data are available for these enzymes, it has
proven difficult to pinpoint the molecular determi-
nants of their different specificities. Crystal structures
of P450 enzymes from mammalian and bacterial
sources have revealed a high conformational variabil-
ity, despite their common overall fold [8–10]. In par-
ticular, a few characteristic, highly flexible regions
around the P450 distal heme pocket (the BC loop, F
and G helices together with the FG loop) are associ-
ated with substrate access, substrate binding and pro-
duct release. Understanding substrate binding and
conversion by P450s requires the analysis of crystallo-
graphic ‘snapshots’ of their open (substrate-free) and
closed (substrate-bound) states, which frequently are
not available for individual P450s. Combining findings
from X-ray crystallography, computational docking,
and MD simulations has significantly increased the
understanding of mammalian and bacterial P450s
[11,12]. Nevertheless, for new, soluble, prokary-
otic P450s, structural characterization is indispensable
for adapting them to specific biotechnological
applications.
To date, only a few bacterial steroid-specific P450s
have been functionally and structurally characterized.
Recently published examples include CYP106A2 from
Bacillus megaterium ATCC 13368 [13], CYP154C5
from Nocardia farcinica [14], CYP154C3 from Strepto-
myces griseus [15], and CYP109B1 from Bacillus
subtilis [16]. Of these, CYP154C5 is of particular inter-
est, as it exhibits an exceptionally high regio- and
stereoselectivity to various pregnanes and androstanes,
including pregnenolone, progesterone, testosterone,
and androstenedione, yielding only 16a-hydroxylated
steroids. Crystal structures of steroid-bound
CYP154C5 reveal a narrow, nearly closed active site,
mostly hydrophobic with two opposing polar regions,
perfectly matching the size and polarity distribution of
the steroids. The apolar/polar shape complementarity
leads to a highly ordered binding mode of the steroids,
with the a-face of their C16 carbon at a suitable
distance from the heme-iron for allowing a radical
attack by the reactive iron-oxo species (compound I)
of the catalytic cycle, thus explaining the high regio-
and stereoselectivity of the enzyme. Of the other two
enzymes, CYP109B1 is of interest as it represents the
first member of the CYP109 family of which a crys-
tal structure has been determined. It was crystallized
in an ‘open’ conformation with no ligands bound in
the active site. Sequence alignment with different
CYP109 family members, and members of related
P450 families, suggested that variations in the so
called BC loop, one of the common P450 regions
involved in substrate binding, may primarily account
for the diverse substrate specificities among these
enzymes.
Recently, the genomes of Bacillus megaterium
DSM319 [17] and ATCC 13368 were sequenced, allow-
ing exploration of their cytochrome P450 complement.
Its analysis has resulted in the identification and char-
acterization of several novel steroid-converting P450s
[18–21]. Here, we report the functional and structural
properties of CYP109E1 from B. megaterium
DSM319. Using in vitro and in vivo turnover experi-
ments, we demonstrate that the enzyme converts
testosterone to 16b-hydroxytestosterone with a high
stereo- and regioselectivity. Crystal structures of
CYP109E1 were determined both in steroid-free and
steroid-bound states allowing a detailed analysis of the
interactions and conformational changes associated
with steroid binding. In addition, we employed MD
simulations to test putative productive steroid-binding
modes in the active site pocket of CYP109E1, leading
to a better understanding of the structural determi-
nants of the enzyme’s activity.
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Results
Identification and bioinformatic analysis of
CYP109E1
The cyp109e1 gene was identified in the genome of
B. megaterium DSM319 by the same bioinformatic
search strategy used previously for identifying
cyp106a1 [20]. A multiple amino acid sequence align-
ment of CYP109E1 (UniProtKB entry d5dki8) with its
closest homologs is presented in Fig. 1. Classification
of the enzyme into the CYP109 family was based on
the conventional P450 nomenclature system [22].
Indeed, CYP109E1 shares close similarity with other
characterized CYP109 family members, that is,
CYP109B1 from B. subtilis strain 168 (47% sequence
identity), CYP109A1 from B. subtilis strain W23 (43%
sequence identity), and the three fatty acid-oxidizing
proteins CYP109C1, CYP109C2, and CYP109D1 from
Sorangium cellulosum strain So ce56 (39%, 41%, and
33% sequence identity, respectively) [16,23,24]. How-
ever, the phylogenetic tree (Fig. 2) indicates that
CYP109E1 shares the closest similarity with
CYP106A1 from the same organism (42% amino acid
sequence identity). This close relationship, which has
been noted also for other CYP109 and CYP106 family
members from Bacillus species [25], may indicate that
these enzymes convert similar substrates.
Expression, purification, and spectroscopic
characterization of CYP109E1
CYP109E1 was expressed in E. coli as a soluble pro-
tein, containing the gene-encoded residues 1–404,
fused to a C-terminal polyhistidine tag. Purification
was accomplished by employing a three-step purifica-
tion strategy, including anion-exchange, size-exclu-
sion, and mixed mode ion-exchange chromatography.
Immobilized metal ion affinity chromatography was
on purpose excluded from the purification protocol
to eliminate the risk of imidazole affecting the func-
tional assays and crystallization experiments. Typi-
cally, 25 mg of pure protein was obtained from
0.5 L of expression culture, with an estimated purity
of > 95% as judged by SDS/PAGE. Analysis of
UV-visible absorption and reduced CO-difference
spectra of reduced CYP109E1 revealed all character-
istic P450 peaks, confirming the structural integrity
of the protein with correct incorporation of the
heme cofactor. The purified protein thus obtained
was used for subsequent functional and structural
characterization.
Substrate screening, conversion, and product
identification
Considering the close phylogenetic distance between
CYP109E1 and CYP106A1, it was proposed that ster-
oids being substrates of CYP106A1 could also be suit-
able ligands for CYP109E1. The potential of
CYP109E1 as a steroid hydroxylase was, therefore,
tested in ligand-binding experiments using a library of
13 steroids (Table 1, see Table S2 for chemical struc-
tures). Six steroids induced a type I spectral shift upon
titration to CYP109E1: androstenedione (1), corticos-
terone (4), deoxycorticosterone (5), dexamethasone (7),
testosterone (11), and testosterone acetate (12), indicat-
ing displacement of the axial heme water and thus
marking them as potential CYP109E1 substrates.
However, several studies have shown that, on one
hand, not all compounds inducing type I shift are
substrates of P450s [19,26,27] while, on the other
hand, substrates do not always induce a type I spectral
shift [18]. Consequently, all 13 steroids were further
subjected to an in vitro CYP109E1-dependent enzy-
matic conversion assay, using bovine adrenodoxin and
adrenodoxin reductase (Adx4–108 and AdR) as surro-
gate redox partners for the reconstitution of P450
activity. Most steroids were not converted by
CYP109E1 (including all steroids which did not induce
a type I spectral shift) or showed only very low to neg-
ligible conversion rates (< 10%). Only testosterone
(11) showed substantial turnover by CYP109E1, and
analysis of the reaction mixture by HPLC revealed one
main (69%) and one minor (14%) product (Fig. 3), with
a catalytic activity of 4.35 and 0.93 nmol pro-
duct(nmol P450)1min1, respectively. Structure
determination of these products by NMR spectroscopy
required a substantial increase in their amounts, which
could not easily be accomplished with the in vitro
activity assay. This was the incentive for developing a
B. megaterium whole-cell system overexpressing
Fig. 1. Multiple sequence alignment of CYP109E1 with P450s identified in B. megaterium DSM319 and other known CYP109 family
members. Secondary structural elements are shown as in the substrate-free CYP109E1 crystal structure (helices labeled A–L). Conserved
and similar residues are highlighted in red and yellow, respectively. Highly conserved, functionally relevant regions (central part of I helix,
EXXR motif and heme-binding domain signature) are shown with violet frames. For all sequences shown, the UniProtKB accession numbers
are the same as used in the phylogenetic tree (Figure 2) (for CYP102A1 only residues 1–472 of the heme domain are shown).
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CYP109E1, thus allowing the conversion of substrates
under more optimal in vivo conditions and without the
need of surrogate P450 redox partners. Testosterone
turnover by CYP109E1 was successfully reproduced in
the B. megaterium whole-cell system, enabling conver-
sion of 26 mg of testosterone (300 lM) within 6 h to
19 mg and 5 mg of the main and minor product,
respectively. Structure elucidation by NMR identified
the main product as 16b-hydroxytestosterone and the
side product as androstenedione (Table S3). The for-
mation of androstenedione as a side product may be
the result of a weak hydroxylation activity toward the
C17 atom of testosterone, yielding a 17,17-gem-diol
intermediate that subsequently dehydrates to the corre-
sponding oxocarbon.
To investigate whether the differences in the conver-
sion of compounds inducing a type I spectral shift are
due to major differences in binding to CYP109E1, we
compared the affinities of testosterone (converted sub-
strate) and corticosterone (bound, but not converted).
Quantitative analysis of the spectral shift titration data
revealed that both compounds displayed very similar
binding affinities to CYP109E1 with a dissociation
constant (KD) of 105  10 lM and 91  8 lM, respec-
tively (Fig. 4). Thus, the highly selective activity of
CYP109E1 toward testosterone, versus no conversion
of corticosterone, is not correlated with a difference in
steroid-binding affinity. In summary, the functional
experiments revealed that CYP109E1 displays a rather
narrow steroid-binding specificity, with relatively
weak-binding affinities, and is able to hydroxylate
testosterone to 16b-hydroxytestosterone with very high
regio- and stereoselectivity.
Overall structure of steroid-free CYP109E1
To evaluate the structural basis for the selectivity of
steroid binding and conversion, crystallization of
CYP109E1 in the presence and absence of a sub-
strate was performed. Purified CYP109E1 was suc-
cessfully crystallized in the absence of steroids, and
its crystal structure was solved and refined to a 2.55
A resolution (see Table 2 for the relevant data col-
lection and refinement statistics). The CYP109E1
crystals contain two protein molecules in the asym-
metric unit. Both polypeptide chains, and their asso-
ciated heme cofactors, are well defined in the
electron density, except for residues 1–20 and the C-
terminal His6-tags. Since the two crystallographically
independent CYP109E1 molecules have nearly identi-
cal conformations [the root mean square deviation
(RMSD) of Ca-backbone atoms is 0.34 A for 374
aligned residues], we will restrict the description to
only one of them. CYP109E1 adopts the characteris-
tic triangular ‘P450-fold’ and contains 13 a-helices,
two 310 helices, and 10 b-strands (arranged in a five-
stranded sheet, three-stranded sheet, and a b-finger,
Fig. 5A). The overall fold of the P450 enzyme is well
conserved: the closest structural homolog of
CYP109E1 is substrate-free CYP109B1 from B. sub-
tilis (PDB entry 4rm4, RMSD of Ca-backbone atoms
of 1.19 A for 347 common residues). A unique fea-
ture of the CYP109E1 structure is presented by its
G helix (following nomenclature of secondary
Fig. 2. Phylogenetic tree of the CYP109 family members and
related P450s from B. megaterium DSM319. P450s from
B. megaterium DSM319 are indicated with a closed circle (•).
CYP109C1, CYP109C2, and CYP109D1 are from
Sorangium cellulosum So ce56; CYP109A1 and CYP109B1 are from
B. subtilis W23 and 168, respectively. The UniProtKB accession
numbers are given next to the associated CYP names. The tree is
drawn to scale, with branch lengths in the same units as those of
the evolutionary distances used to infer the phylogenetic tree.
Table 1. Steroid binding and in vitro conversion activity of
CYP109E1 toward selected steroids. Chemical structures of the
steroids are shown in supplementary Table S2. The + and 
indicate positive and negative outcomes of what is stated in the
column headers.
Compound Type I shift In vitro conversion
Androstenedione (1) + + (< 10%)
Cortisol (2)  
Cortisone (3)  
Corticosterone (4) +  (< 2%)
Deoxycorticosterone (5) + + (< 7%)
11-deoxycortisol (6)  
Dexamethasone (7) + 
Prednisolone (8)  
Prednisone (9)  
Progesterone (10)  
Testosterone (11) + +
Testosterone acetate (12) + + (< 10%)
19-nortestosterone (13)  
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structural elements established by Poulos et al. [28]),
which is significantly longer than in other bacterial
P450 structures. A structural comparison with other
P450s further reveals that steroid-free CYP109E1
adopts an open conformation with a spacious active
site pocket at the distal side of the heme, which is
freely accessible to solvent (Fig. 5B). The heme
cofactor is bound between the I and L helices, with
the thiolate group of Cys352 serving as the fifth
ligand of the heme-iron. No electron density was
observed for a water molecule coordinating the
heme-iron as a sixth ligand. Instead, a small blob of
electron density was visible at about 4 A distance
from the heme, but the density was of insufficient
quality to allow identification of the bound ligand.
The noncovalent interactions between CYP109E1 and
its heme are highly similar as in other class I P450s.
Stabilization is provided by van der Waals interac-
tions between the heme core and several apolar pro-
tein side chains, and by ion pairs formed between
Fig. 3. In vitro conversion of testosterone
by purified CYP109E1. (A) Schematic
representation of the reaction and (B) HPLC
chromatogram.
Fig. 4. Type I spectral shifts induced by steroid binding to CYP109E1 and the derived binding curves. (A) Binding curve of testosterone.
(B) Binding curve of corticosterone. The spectral shifts upon titration of the steroids are shown as insets. The enzyme solution (10 lM,
50 mM potassium phosphate buffer, pH 7.4) was titrated with increasing amounts of substrates dissolved in DMSO. The peak-to-through
absorbance differences were plotted against the increasing concentrations of the substrate. Plotted data points are the mean values from
three independent measurements. Error bars represent the standard deviations. The curves were fitted by hyperbolic regression.
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the heme propionates and the side chains of highly
conserved residues His92, Arg96, Arg294, and
His350.
Active site pocket of steroid-free CYP109E1
The geometry of the active site pocket in the open
form of CYP109E1 was analyzed in more detail. As
shown in Fig. 5B, it resembles a funnel, wide open at
the entrance but becoming more constricted as it leads
toward the heme. The structural regions surrounding
the active site pocket are equivalent to the six sub-
strate recognition sites commonly found in P450s [29]:
the BC loop (substrate recognition site 1 or SRS1),
parts of the F and G helices (SRS2 and SRS3, respec-
tively), the central segment of the I helix (SRS4), the
Table 2. Data collection, refinement, and model statistics of CYP109E1.
Substrate-free CYP109E1 CYP109E1-COR4 CYP109E1-TES CYP109E1-COR
Conformation Open Open Closed & open Closed & open
PDB code 5L90 5L91 5L94 5L92
Model statistics
Monomers in the AU 2 2 2 2
Solvent content (%) 61.7 60.2 49.1 49.1
Ligands n/a Four corticosterone
molecules/monomer
Testosterone (TES)
(in chain A)
Corticosterone (COR),
malonic acid (MLA)
(in chain A)
Data collection
X-ray source (ESRF/
in-house)
ID29 ID23-2 In-house ID23-1
Wavelength (A) 1.04541 0.87261 1.5418 0.97241
Resolution range (A) 60–2.55 (2.65–2.55)a 49–2.20 (2.26–2.20) 56–2.25 (2.32–2.25) 48–2.10 (2.16–2.10)
Space group P 32 2 1 P 32 2 1 P 1 21 1 P 1 21 1
Unit-cell parameters
a, b, c (A) 121.3, 121.3, 144.2 120.4, 120.4, 140.8 60.4, 134.9, 61.9 60.5, 135.7, 61.6
a, b, c, ° 90, 90, 120 90, 90, 120 90, 113.8, 90 90, 114.4, 90
Observed reflections 293 843 (30 950) 355 244 (26 012) 293 196 (26 695) 156 293 (12 345)
Unique reflections 40 454 (4508) 60 153 (4384) 42 810 (3945) 51 292 (12 345)
Multiplicity 7.3 (6.9) 5.9 (5.9) 6.8 (6.8) 3.0 (2.9)
Completeness (%) 99.9 (99.9) 99.7 (100) 99.7 (99.1) 97.4 (98.8)
<I/r(I)> 11.6 (2.6) 15.9 (2.3) 12.2 (2.7) 23.3 (4.1)
Rmerge (%) 9.6 (80.2) 8.7 (66.9) 14.2 (73.9) 2.8 (22.2)
CC (1/2) (%) 99.8 (84.8) 99.8 (80.1) 99.6 (83.7) 99.9 (91.4)
Refinement
Rwork (%) 21.44 18.48 21.90 20.09
Rfree (%) 25.88 23.21 26.28 24.31
R.m.s.deviation, bond lengths (A) 0.017 0.014 0.014 0.014
R.m.s.deviation, bond angles (°) 1.679 1.322 1.252 1.299
Average B-factors (A)2
Overall 73.65 46.81 40.16 42.65
Protein 73.96 46.49 40.45 42.92
Heme 48.29 28.30 27.39 28.22
Testosterone (TES) n/a n/a 35.29 n/a
Corticosterone (COR) n/a n/a n/a 43.43
COR-1 n/a 48.66 n/a n/a
COR-2 n/a 77.89 n/a n/a
COR-3 n/a 86.81 n/a n/a
COR-4 n/a 56.60 n/a n/a
Malonic acid (MLA) n/a n/a n/a 42.14
Ramachandran plot statistics
Most favored (%) 94.9 95.6 96.1 96.6
Allowed regions (%) 4.8 4.3 3.9 3.4
Disallowed regions (%) 0.3 0.1 0.00 0.00
Molprobity overall score 1.62 1.54 1.22 1.14
a Values in parentheses refer to data in the highest resolution shells.
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region connecting helix K and strand b5 (SRS5) and
the b9–b10 turn (SRS6). Close to the heme, the active
site is very hydrophobic and its surface is roughly built
of two rings of residues. The first ring (closest to the
heme) contains residues Ile85 (BC loop); Leu238,
Ala242, and Thr246 (I helix); Pro288, Val289, and
Leu292 (K-b5 loop). Many of these residues are highly
to moderately conserved among P450s, for example,
Thr246, Ala242, or Val289, in agreement with com-
mon roles in catalysis and substrate binding [30]. The
second ring contains residues Arg69, Leu80, and
Asn86 (BC loop); Ile168 and Val169 (F helix); Ile241
and Glu245 (I helix); Phe391 and Val392 (b9–b10
turn). Residues Arg69, Asn86, and Glu245 form two
polar-charged surface patches located at opposite sides
of the active site pocket. Further away from the heme,
near the entrance of the active site pocket, residues are
mostly polar charged. Active site residues in the sec-
ond ring, and residues at the entrance of the active site
pocket in CYP109E1, show substantial divergence with
respect to other P450s, including the testosterone-
hydroxylating enzymes like CYP109B1 from B. subtilis
or CYP154C5 from N. farcinica.
Structures of CYP109E1 with single bound
corticosterone or testosterone
To characterize how steroids interact with CYP109E1,
crystal structures of CYP109E1 with bound corticos-
terone (type I shift, but no substrate) or testosterone
(type I shift, substrate) (CYP109E1-COR and
CYP109E1-TES) were obtained by cocrystallization
and refined at 2.25–2.1 A resolution (see Table 2 for
details). Like the steroid-free crystals, the steroid-
bound cocrystals contain two polypeptide chains per
asymmetric unit (solvent content of 49%), yet they
belong to a different space group and show a different
crystal packing geometry. Only one of the two unique
CYP109E1 protein molecules in each cocrystal has a
bound steroid. The protein molecules lacking a bound
steroid adopt an open conformation similar to that of
steroid-free CYP109E1. No electron density is present
for the BC loop, FG loop, and several residues at the
end of the G helix, indicating that these regions are
significantly disordered. In the protein molecules with
a bound steroid, a remarkable narrowing and partial
closure of the active site pocket is observed, allowing
most substrate-binding regions to closely approach
and interact with the steroids. The F and G helices,
together with the FG loop, show the largest displace-
ment, while the BC loop and b9–b10 turn show
smaller readjustments (Fig. 6A). The central part of
the BC loop (residues 71–75) is highly disordered and
could not be resolved in the electron density map. The
conformational change in the FG helices is accompa-
nied by reorientations of the H helix and HI loop. In
addition, a local widening of the I helix is observed at
residues 242–246, creating a groove which allows close
packing of the steroids near the heme. A similar
groove in the I helix has also been observed in other
Fig. 5. Overall structure and the active site of CYP109E1. (A) Overall structure shown in ribbon representation, with rainbow coloring from
blue N’ terminus to red C’ terminus. The heme cofactor is shown in red and beta strands in gray. Secondary structural elements are labeled
following the common P450 nomenclature. (B) Active site pocket of substrate-free CYP109E1. Coloring apolar–polar, orange-blue.
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substrate-bound bacterial P450 structures, and its sub-
strate-induced conformation is believed to play an
important role in oxygen activation and proton deliv-
ery [31]. Interestingly, four ordered water molecules
are found at the interface of the I and E helix, two of
which are located in the groove of the I helix (Fig. 7).
The four waters form a continuous hydrogen-bonded
network, which includes the main-chain carbonyls of
Ala242 and Gly243, the side-chain hydroxyl groups of
Thr246 and Thr247, and the main-chain amide of
Thr248. Although the network is not directly con-
nected to bulk solvent (the distance with the nearest
water bound at the protein surface is 5.3 A), it corre-
lates well with the so called ‘solvent channel’ found in
many P450s, located between the F, E, and I helices,
which is believed to serve as a water access channel
and/or proton delivery network [32].
Electron density of the bound steroids was of suffi-
cient quality to allow a clear characterization of their
binding modes (Fig. 6B, C). Both steroids show an
unproductive binding mode: the corticosterone and
testosterone molecules are bound in roughly perpendic-
ular orientations relative to the heme plane, with their
C3-keto oxygen atoms coordinating the heme-iron at
the sixth axial position. The b-faces of the steroids are
oriented toward the I helix, while the C17 substituents
are pointing away from the heme toward the entrance
of the active site pocket. The two steroids are mainly
bound by van der Waals and hydrophobic interactions.
Residues in the active site pocket making hydrophobic
interactions with the steroids are Leu80 (BC loop,
SRS1), Ile168, Val169 (F helix, SRS2), Leu238, Ile241,
Ala242, Thr246 (I helix, SRS4), Val289, Ala291,
His293 (K/b5 connecting region, SRS5), and Phe391,
Val392 (b9–b10 turn, SRS6). No direct hydrogen
bonds are observed between the protein and the two
steroid molecules. In the structure with bound corticos-
terone, a malonic acid molecule is present in the active
site forming van der Waals contacts with ring B of the
steroid (Fig. 6C). The malonic acid molecule is further
stabilized by hydrogen bonds with His293 (SRS5) and
one of the heme-propionate groups, and by van der
Waals contacts with residues Arg69, Ile85 (SRS1),
Leu292 (SRS5), and Phe391 (SRS6). Its presence is
most likely a crystallographic artifact, as malonic acid
is the major component of tacsimate, the reagent used
in the crystallization of CYP109E1-COR.
Multiple corticosterone-bound CYP109E1
structure
An additional structure of corticosterone-bound
CYP109E1 was obtained at 2.2 A resolution by soaking
the steroid into pregrown, steroid-free crystals
(CYP109E1-COR4, Table 2). Interestingly, the corticos-
terone-soaked crystals display a water as the sixth axial
ligand of the heme-iron and multiple steroid binding
(four corticosterones, Fig. 8). For clarity, we abbreviate
the ligands as COR-1, COR-2, COR-3, and COR-4.
COR-1 is located closest to the heme-iron, while COR-4
is most distant. The protein molecules in CYP109E1-
COR4 adopt an open state, with only a minor reposition-
ing of the G helix toward the bound steroids. The limited
conformational changes compared to steroid-free
CYP109E1 are not surprising, since crystal packing inter-
actions between the neighboring protein molecules lock
the F and G helices, FG loop, and BC loop in an ‘open’
position (Fig. 8A). It is remarkable, however, that the
open state allows ordered binding of multiple steroids.
The four steroids are bound in different orientations
and show substantial intermolecular van der Waals
contacts between their steroid rings. COR-1 is pointing
with its bulky C17-substituent toward the heme and its
C21-hydroxyl group forms a hydrogen bond with a
water molecule coordinating the heme-iron (Fig. 8B).
Additional interactions of this steroid at the active site
pocket include two direct hydrogen bonds, between
the C3-keto oxygen and the side chain of Lys187
(SRS3) and between the C11-hydroxyl group and the
main-chain carbonyl oxygen of Ile241 (SRS4), two
water-mediated hydrogen bonds, between the C11-
hydroxyl group and the side chain of Glu245 and
between the C21-hydroxyl group and the main-chain
carbonyl group of Ala242 (SRS4), as well as several
hydrophobic contacts with residues Ile85 (SRS1),
Ile168, Val169 (SRS2), Thr246 (SRS4), Val289 (SRS5),
and Val392 (SRS6). The other three corticosterones
also make specific contacts with the protein (interac-
tions described in detail in Table S4).
Modeling of regio- and stereoselectivity of
CYP109E1
In the CYP109E1-TES crystal structure, the shape of
the electron density for the bound steroid suggested
that testosterone may perhaps adopt an alternative,
reversed binding mode, in which the C16 and C17 car-
bons are located close to the Fe atom (~4 A), consis-
tent with the observed activity of CYP109E1. Addition
of such a putative productive binding mode in the
refined CYP109E1-TES structure resulted in a poor fit
to the observed electron density, thus, we assume that
testosterone predominantly adopts the unproductive
binding mode in the protein crystals. Therefore, to
explore the molecular basis of its selective steroid con-
version and regio/stereoselectivity, MD simulations of
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the CYP109E1-oxoferryl species (compound I) in
complex with corticosterone or testosterone were per-
formed. Starting models for the MD simulations were
based on the CYP109E1-TES structure in which the
crystallographically observed testosterone molecule
was replaced by docked steroids (corticosterone or
testosterone) in reversed orientations, with the C16
carbon atom or C17 substituents oriented toward the
heme-iron. Steroid conversion and regio/stereoselectiv-
ity of the CYP109E/steroid complexes were modeled
by assigning each frame of the MD simulation as
being in either a near-attack conformation or in a non-
productive conformation, on the basis of distance
and angle cutoffs, following previously published
procedures [33–35]. The number of near-attack confor-
mations was the highest for MD simulations
with testosterone, where 16% of the simulation frames
revealed near-attack conformations suggesting
formation of 16b-hydroxytestosterone (pro-16b, 99%)
or androstenedione (pro-17a, 1%). No pro-16a near-
Fig. 6. Conformational changes and steroid-binding modes in CYP109E1. (A) Superposition of substrate-free CYP109E1 (gray), CYP109E1-
TES (light blue), and CYP109E1-COR (orange) showing the open–closed conformational changes. COR is shown as cyan stick model. (B)
Amino acid residues involved in testosterone binding (CYP109E1-TES) are shown and TES is shown as violet stick model. Black mesh is the
composite omit 2Fo  Fc electron density map, calculated at 2.25 A resolution and contoured at 1r. (C) Residues binding single
corticosterone and malonic acid in the active site of CYP109E1-COR (green) in comparison to substrate-free structure (gray), with COR
shown in cyan and MLA in light pink. Black mesh is the composite omit 2Fo  Fc electron density map, calculated at 2.1 A resolution and
contoured at 1r. (D) Comparison of testosterone binding modes observed in CYP109E1 (violet stick model) and CYP154C5 from N. farcinica
(in gray, PDB entry 4j6d). Amino acid residues providing stabilizing interactions in CYP154C5 are shown and compared to their structural
homologues in CYP109E1. Distances are given inangstroms next to the black dashed lines.
4137The FEBS Journal 283 (2016) 4128–4148 ª 2016 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
I. K. Jozwik et al. Structure of testosterone-converting CYP109E1
54
attack conformations occurred in the simulations, in
accordance with the observed stereoselectivity of the
enzyme. Interactions of one of the most frequently vis-
ited testosterone-binding poses were analyzed in detail
(Fig. 9). The testosterone molecule is positioned opti-
mally for abstraction of the C16b-hydrogen, and forms
hydrophobic interactions with the same residues as in
the CYP109E1-TES crystal structure, that is, Leu80
(SRS1), Ile168 (SRS2), Ile241 and Thr246 (SRS4),
Val289 (SRS5), Phe391 and Val392 (SRS6). In
addition, the testosterone C3-keto oxygen is in hydro-
gen-bonding distance to Lys187 (SRS3). In the case of
corticosterone, only 0.8% of the MD simulation
frames showed near-attack conformations (suggesting
generation of a 16a-hydroxylated product). The results
are in concordance with the lack of experimentally
observed corticosterone conversion by CYP109E1.
Site-directed mutagenesis
To substantiate the crystallographic and modeling
results, single alanine mutations were prepared of a
few selected residues (Val169, Lys187, Ile241,
Glu245, and Thr246) in the active site pocket of
CYP109E1 and their effect on CYP109E1-catalyzed
conversion of testosterone was analyzed using the
in vitro activity assay (Table 3). Replacement of
Val169 and Ile241 by alanine resulted in almost
complete abolishment of 16b-hydroxytestosterone
production, confirming the importance of these resi-
dues for productive steroid binding. The K187A
mutation also caused a decrease in activity compared
to the wild-type enzyme, but the effect is much smal-
ler than for the V169 and I241 mutations. Thus, the
hydrogen bond of the testosterone C3-keto group
with the side chain of Lys187, as observed in the
MD simulations, is not a crucial interaction for pro-
ductive binding of testosterone. Interestingly, alanine
mutations of Glu245 and Thr246 (the conserved
‘acid-alcohol’ pair) led to opposite effects on
CYP109E1 activity toward testosterone. While the
T246A mutation resulted in a drastic decrease in
16b-hydroxytestosterone production, the E245A
mutation did not significantly affect the CYP109E1
activity. These results support the relevance of the
water channel observed in the single steroid-bound
CYP109E1 structures, and implicates a role for
Thr246, but not Glu245, in proton delivery and oxy-
gen activation within the active site.
Discussion
Only a few bacterial P450s have been characterized
that are able to hydroxylate testosterone at different
positions in the steroid skeleton, with high regio- and
stereoselectivity [36]. Recent examples include
CYP109B1 from B. subtilis and CYP154C5 from
N. farcinica, which produce 15b- and 16a-hydroxy-
lated testosterone, respectively [37,38]. CYP109E1
from B. megaterium is the first example of a wild-type
bacterial P450 showing highly selective 16b-hydroxy-
lase activity toward testosterone. Production of
16b-hydroxytestosterone has previously been observed
with specific P450 BM3 mutants, obtained by protein
engineering, but these mutants do not display the same
high level of regio- and stereoselectivity as CYP109E1
[39–41]. Similarly, various mammalian P450s are able
to hydroxylate testosterone at position 16b, but they
Fig. 7. Putative proton relay network in CYP109E1. Local distortion
in the central part of I helix, upon binding of single testosterone or
corticosterone (CYP109E1-TES is depicted here) allowed for
binding of four ordered water molecules in the back of I helix
(labeled a, b, c, and d). The putative proton delivery pathway from
conserved Thr246 to bulk solvent is shown, involving water
molecules found in the ‘solvent channel’ between the F, E and I
helices. The solvent accessible surface is shown (calculated after
removing all waters, testosterone and the heme from the
structure). For clarity, only a selection of the hydrogen bonds of
the waters with protein atoms are shown. Residue Glu245 does
not participate in the hydrogen bond network.
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lack sufficient regio- and stereoselectivity. Low solubil-
ity and generally low expression levels of mammalian
P450s further hinder their biotechnological use [42]. In
contrast, the successful development of a CYP109E1-
catalyzed whole-cell system for the production of
16b-hydroxylated testosterone, as reported here,
Fig. 8. Multiple corticosterone binding in CYP109E1. (A) Representation of intermolecular packing interactions in the crystal lattice of
CYP109E1-COR4. The mobility of the F and G helices, FG and BC-loop is restricted, thus locking the CYP109E1 molecules in an open state.
(B) Close up on multiple corticosterone binding orientations in CYP109E1 and recognition of COR-1. Hydrogen-bonding interactions of COR-
1 are shown as black dashed lines. Black mesh is the composite omit 2Fo  Fc electron density map, calculated at 2.2 A resolution and
contoured at 1r.
Fig. 9. Main productive testosterone binding mode in CYP109E1. (A) Representation of the most frequently visited testosterone
conformation in the hydrophobic active site of CYP109E1 during molecular dynamics simulations. The C16 atom of testosterone is at an
appropriate distance and angle from the oxoferryl oxygen atom to allow abstraction of its 16b-hydrogen, in accordance with the formation of
the main observed turnover product, 16b-hydroxytestosterone. Testosterone is drawn in light blue-colored sticks and the hypothetical heme
oxoferryl moiety (Fe(IV) = O or compound I) is in orange. The locations of the two C16-hydrogens targeted in predictions by MD simulations
are shown by arrows. Distances are given in angstroms next to the black dashed lines. (B) Surface representation of the same binding
mode as depicted in panel A, coloring apolar–polar, orange-blue.
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demonstrates the potential of this bacterial enzyme for
biotechnological applications.
To further improve CYP109E1 for biotechnological
purposes and to better understand its structure-
function relationships, crystal structures of CYP109E1
with and without steroids were obtained, revealing
interesting features related to steroid binding and pro-
tein conformational dynamics. The structures confirm
the general view that P450s possess a highly dynamic
active site, which exists in a primarily open state in the
absence of bound substrate, but changes toward a
more closed state when the substrate is bound. Unex-
pectedly, and for the first time, crystal structures have
revealed a P450 distal pocket with either four ligand
molecules or only a single ligand molecule bound in a
distinct way. Arguably, the presence of four bound
corticosterone molecules in the open active site pocket
of CYP109E1 is a crystallographic artifact, as it is
influenced by the high concentration of the steroid in
the crystal-binding experiment. Furthermore, crystal-
packing interactions in the CYP109E1-COR4 structure
effectively lock CYP109E1 in an open conformation,
resisting the conversion into the closed structure
expected upon substrate binding. On the other hand,
the crystallographically observed binding of multiple
corticosterone steroids to the open form of CYP109E1
may represent a snapshot of the initial substrate recog-
nition and binding events. Multiple substrate binding
occurs in other P450s, and has been implicated in the
mechanisms of homo- and heterotopic cooperativity
observed in mammalian P450s enzymes [43,44]. There
are no indications, however, for cooperative steroid
binding by CYP109E1, as evident from the hyperbolic
binding curves derived from the P450 spectral shift
titration assays (no sigmoidal fit).
The single steroid-bound structures of CYP109E1 in
the closed conformation, complemented with the MD
simulations and site-directed mutagenesis results, pro-
vide clear insights on how this enzyme accomplishes
selective 16b-hydroxylation of testosterone. The nar-
row shape of the active site pocket in the closed form
of the enzyme, and the almost exclusively hydrophobic
surface of the active site walls near the heme, restrict
the binding modes of the steroids to an orientation in
which their longitudinal axis is roughly perpendicular
to the heme plane. Two main binding modes are possi-
ble for 3-oxo-D4-steroids like testosterone and corticos-
terone, with either the C3-keto oxygen down (toward
heme) and C17-substituent up (away from heme) or
with the C17-substituent down and C3-keto oxygen
up. The first binding mode may have a possible inhibi-
tory effect, by preventing oxygen binding to the heme-
iron. Although it should be noted that coordination of
the keto C3-group is less likely to occur with reduced
iron in the ferrous state. The second binding mode
may lead to 16b-hydroxylation for steroids carrying a
small C17 substituent, like testosterone, as supported
by the MD simulations which show a substantial num-
ber of pro-16b productive conformations. Bulky polar
C17 substituents (as in corticosterone) most probably
cause a steric hindrance, blocking an optimal approach
of the C16 carbon to the heme-iron, and result in
steroids being bound in unproductive conformations
(as supported by our MD simulations with corticos-
terone). For testosterone, a third, minor productive
binding mode positions the a-face of the C17 carbon
close to the heme-iron, (in MD simulations a few pro-
17a near-attack conformations were observed), so that
a second hydroxylation at this position can occur fol-
lowed by removal of a water molecule, explaining the
production of androstenedione as a side product. A
similar oxidation reaction has very recently been
observed with CYP106A1 where an 11-oxidase activity
toward 11-hydroxy steroids was demonstrated [19,45].
The molecular basis for the stereoselectivity of
CYP109E1 toward 16b-hydroxylation of testosterone
is further clarified by a structural comparison with
CYP154C5, which converts testosterone to 16a-
hydroxytestosterone. The shape and volume of the
active site pockets in the testosterone-bound crystal
structures of these two enzymes are significantly differ-
ent, which is primarily due to the highly variable BC
loop. This loop is much longer in CYP154C5 and
functions as a lid that almost completely locks the
active site pocket. A closure to this extent is not
observed in the testosterone-bound CYP109E1 struc-
ture. Although near to the heme, the active site pocket
in testosterone-bound CYP109E1 is more restricted
Table 3. Effect of introduced mutations on production of 16-b-
hydroxytestosterone (16b-OH-TES) by CYP109E1 enzyme variants.
The in vitro reactions were carried out in 50 mM potassium
phosphate buffer with 2% glycerol, pH 7.4, at 30 °C for 30 min.
Bovine Adx4–108 and AdR were used as redox partners and 200 lM
of substrate dissolved in DMSO was added. Shown are the mean
values and standard deviations (SD) of three independent
measurements.
CYP109E1 variant
Catalytic activity for the
formation of 16b-OH-TES,
nmol(nmol P450)1min1
WT 4.35  0.02
K187A 1.43  0.06
V169A 0.07  0.02
I241A 0.01  0.01
E245A 4.69  0.04
T246A 0.12  0.04
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compared to CYP154C5, near its entrance, it is more
open and accessible to solvent. The different shapes of
the active site pockets are coupled to different orienta-
tions of the bound steroids relative to the heme plane:
roughly perpendicular in the CYP109E1-TES struc-
ture, while more-or-less parallel in the CYP154C5-TES
complex. While the perpendicular binding mode of
testosterone is optimal for C-H abstraction from the
b-face of the C16 carbon, the parallel binding orienta-
tion in CYP154C5-TES positions the a-face of the
testosterone C16 carbon close to the heme-iron,
explaining the difference in stereoselectivity of these
enzymes [14]. The parallel binding orientation of
testosterone in CYP154C5 is stabilized by interactions
of the apolar steroid ring system with hydrophobic
residues from two opposite regions (BC loop and I
helix) in the active site pocket. The polar C17 sub-
stituent forms a hydrogen bond with Gln398 (from
SRS6), while the C3 substituent is bound near to
Gln239 in a solvent-accessible pocket. In CYP109E1,
the equivalent residues to Gln239 and Gln398 of
CYP154C5 are Ile237 and Val392, respectively
(Fig. 6D). Lack of polar residues in the active site
pocket near the heme thus prevents a similar binding
orientation of testosterone in CYP109E1 as in
CYP154C5. In addition, the side chains of Leu80 (BC
loop) and Ile241 (I helix) in CYP109E1 pose a steric
hindrance to the incoming steroid molecule, favoring a
perpendicular over a parallel binding orientation.
Thus, the difference in stereoselectivity between
CYP109E1 and CYP154C5 toward C16-hydroxylation
of testosterone is a result of the differences in the
shape and the apolar/polar surface distribution of their
active site pocket, leading to a different binding orien-
tation of the steroid relative to the heme.
In conclusion, we have identified CYP109E1 as a
novel steroid-hydroxylating cytochrome P450 enzyme
from Bacillus megaterium DSM319, with the ability to
selectively convert testosterone to 16b-hydroxytestos-
terone. Our combined structural, biochemical, and
molecular modeling studies provided several insights
into the molecular basis of steroid binding by
CYP109E1 and of its regio- and stereoselectivity
toward testosterone. First, binding of single steroid
molecules like testosterone and corticosterone stabilizes
a change in the active site pocket toward a more
closed and narrow conformation. The steroid-induced
structural changes include the local widening of the
central I helix, which is coupled with the formation of
a water channel believed to function as a water access
channel and/or proton delivery network during cataly-
sis. Secondly, the steroids may bind in two opposite
orientations, with either their C3-keto oxygen or their
C16 carbon and C17 substituent directed toward the
heme. The first orientation leads to nonproductive
binding. The second orientation results in productive
binding for testosterone, and nicely explains the high
selectivity toward 16b-hydroxylation. The larger C17
substituent of corticosterone, and the presence of its
C21-hydroxyl group, prohibit productive binding of
this steroid. Our results will facilitate future protein
engineering experiments to improve this enzyme for
biotechnological applications.
Experimental procedures
Materials
The steroid compounds used in this study were obtained
from Sigma-Aldrich (Steinheim, Germany). All other chem-
icals were of highest grade available.
Bioinformatics analysis
Identification of close homologs and comparison of protein
sequences were performed using the Basic Local Alignment
Search Tool (BLAST, NCBI). Multiple sequence alignment
was done with Clustal Omega [46] and visualized with
ESPript3 [47]. Evolutionary analysis was carried out using
Molecular Evolutionary Genetics Analysis (MEGA) version
6.0 software [48]. The phylogenetic tree was constructed
using the Neighbor-joining method [49] and the evolution-
ary distances were computed using the Poisson correction
method [50].
Cloning of wild-type enzyme
The gene encoding CYP109E1 (GenBank GeneID 9119265)
was amplified by the PCR using genomic DNA of B. mega-
terium MS941, a mutant form of B. megaterium, derived
from the DSM319 strain [51]. The PCR primers were
designed (MWG-Biotech AG, Ebersberg, Germany) to
introduce an NdeI restriction site at the 50 end of the frag-
ment and a KpnI restriction site with a 6-histidine tag at
the 30 end. Following the amplification of the cyp109e1
gene, the PCR product was cloned into the pCR4Bl-TOPO
vector (Invitrogen, San Diego, CA, USA) and the vector
was further digested with the restriction enzymes cutting at
the above-mentioned sites and ligated into the expression
vector pET17b (Merck Bioscience, Bad Soden, Germany),
creating the pET17b_109E1 vector. The cyp109e1 gene was
further amplified by PCR from the previously constructed
pET17b expression vector using PCR primers designed to
include a SpeI restriction site at the 50 end and a KpnI
restriction site at the 30 end of the fragment. The resulting
PCR product was subcloned in the pCR4-TOPO vector
and digested with the corresponding restriction enzymes.
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The fragment was then ligated to the previously linearized
pSMF2.1 vector [52], yielding the pSMF2.1E construct.
Sequences of the designed primers are given in supplemen-
tary Table S1. Sequences of all created vectors were verified
by DNA sequencing, carried out by Eurofins-MWG
(Ebersberg, Germany).
Site-directed mutagenesis
The mutants of CYP109E1 were generated by the Quik-
Change site-directed mutagenesis method using the plasmid
pET17b_109E1 as template and Phusion polymerase for
DNA replication (Thermo Fisher Scientific GmbH, Dreir-
eich, Germany). The reactions were performed in 50 lL,
using a gradient cycler (PTC-200 DNA Engine cycler).
Twenty cycles were carried out as follows: initial denatura-
tion at 95 °C for 30 sec, denaturation at 95 °C for 30 sec,
annealing at 58 °C for 30 sec, and extension at 72 °C for
4 min. The oligonucleotide primers for mutagenesis are
shown in Table S1. Correct generation of the desired muta-
tions was confirmed by DNA sequencing.
Expression and purification
A 30-mL preculture of E. coli C43 (DE3) cells carrying the
pET17b_109E1 vector was grown overnight in LB medium
containing 100 lgmL1 ampicillin at 37 °C (150 rpm).
This culture was used to inoculate a 1.2-L production cul-
ture, divided over four 2-L baffled flasks, in Terrific Broth
(TB) medium containing 100 lgmL1 ampicillin. Cultiva-
tion was continued at 37 °C (150 rpm) until the OD600
reached 0.5, after which 1 mM IPTG and 0.5 mM d-amino-
levulinic acid were added to start protein expression and
support heme synthesis, respectively. After 24 h of incuba-
tion at 30 °C, 100 rpm, the cells were harvested by centrifu-
gation (4500 g for 35 min) and the cell pellet was stored at
20 °C until further use. All purification steps were per-
formed at 4 °C. For crystallization and spectral characteri-
zation of wild-type CYP109E1, a three-step purification
procedure was applied, starting with resuspension of the
cell pellet in 100 mL cold lysis buffer containing 50 mM
Tris/HCl, pH 8.0, 1 mM EDTA, 20 mM NaCl, and 0.1 mM
dithioerythritol, followed by the addition of 50 lgmL1
PMSF. The mixture was sonicated for 15 min (15 sec on,
15 sec off) on ice and, subsequently, the same amount of
PMSF was added. Cell-free extract was obtained by ultra-
centrifugation at 40 000 g for 35 min at 4 °C. The super-
natant containing CYP109E1 was loaded onto a 50-mL
SOURCE 30Q anion-exchange column (GE Healthcare,
Solingen, Germany) equilibrated with three column vol-
umes of 20 mM Tris/HCl, pH 7.4, 0.1 mM dithioerythritol.
The column was washed with the same buffer before elu-
tion of CYP109E1 with a linear gradient of 0–500 mM
NaCl. Fractions with the highest A418/A280 ratio were
combined and concentrated by ultrafiltration using a 30-
kDa cutoff membrane (Amicon Ultra/Millipore). The pro-
tein concentrate was then manually loaded onto a Superdex
75 (200 mL) gel filtration column (GE Healthcare) and
CYP109E1 was eluted with 50 mM potassium phosphate
buffer, pH 7.4, 0.1 mM dithioerythritol. The fractions with
the highest A418/A280 ratio were pooled, diluted 1:5 with
5 mM potassium phosphate buffer, pH 7.4 and 0.05 mM
dithioerythritol, before loading them onto a hydroxyapatite
column (50 mL, Bio-Rad, Hercules, CA, USA). The col-
umn was washed with 10 mM potassium phosphate buffer,
pH 7.4, 0.1 mM dithioerythritol, and CYP109E1 was eluted
with a buffer concentration gradient ranging from 10 to
100 mM. Fractions containing purified CYP109E1 with an
A418/A280 ratio larger than 1.6 were collected, concentrated
by ultrafiltration using a 30-kDa cutoff membrane, and
stored at 80 °C after flash-freezing in liquid nitrogen. For
in vitro conversion experiments, the wild-type protein and
its mutants were purified with an alternative one-step
purification procedure. The cell pellets were resuspended in
50 mM potassium phosphate buffer, pH 7.4, containing
300 mM NaCl and 20% glycerol. Then, PMSF was added to
a final concentration of 1 mM and the suspension was soni-
cated for 15 min (15 sec on, 15 sec off) on ice. Cell-free
extract was obtained by ultracentrifugation at 30 000 rpm
for 30 min, at 4 °C. The supernatant was applied to immo-
bilized metal ion affinity chromatography column (TALON,
Takara Bio Europe, Saint-Germain-en-Laye, France) equili-
brated with 50 mM potassium phosphate buffer, pH 7.4,
containing 300 mM NaCl and 20% glycerol. The column
was washed with 5 column volumes of the same buffer con-
taining 20 mM imidazole, and the tagged protein was eluted
with a buffer containing 150 mM imidazole.
Enzyme analysis
The UV/Vis spectra of the purified protein were recorded
using a double-beam spectrophotometer (UV-2101PC, Shi-
madzu, Japan) from 200 to 700 nm. CYP109E1 concentra-
tions were determined by CO-difference spectroscopy of the
reduced protein, following the method of Omura and Sato
[53] and using an extinction coefficient of 91 mM1cm1.
Protein purity was analyzed by SDS/PAGE.
Difference spectroscopy and determination of
dissociation constants (KD)
Substrate-induced spin-shift states were studied via a dou-
ble-beam spectrophotometer (UV-2101PC, Shimadzu,
Japan), using tandem quartz cuvettes, according to the
method of Schenkman and Jansson [54]. One of the cuvette
chambers contained the purified CYP109E1 protein solu-
tion (10 lM) in 50 mM potassium phosphate buffer, pH 7.4,
while the other chamber was filled with the corresponding
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buffer only. The steroids were dissolved in DMSO (2.5–
20 mM stock solutions) and the enzyme solution was
titrated with increasing amounts of testosterone or corticos-
terone, in the range of 0–200 lM or until saturation was
reached, while the spectrum was recorded between 350 and
500 nm. All titrations were carried out in triplicates. The
data were analyzed by plotting the peak-to-trough differ-
ences (DA: AmaxAmin) against the steroid concentrations.
The subsequent hyperbolic fitting was performed using
ORIGIN software (OriginLab Corporation, Northampton,
MA, USA), and the equilibrium dissociation constants (KD)
were determined with a regression coefficient of R2 = 0.99.
In vitro substrate turnover
The in vitro turnover of tested steroids was performed in a
final volume of 250 lL, using 50 mM potassium phosphate
buffer with 2% glycerol, pH 7.4, at 30 °C for 30 min. The
reconstituted system contained CYP109E1 (1 lM), bovine
Adx4–108 (20 lM), AdR (2 lM), a NADPH-regenerating sys-
tem (1 mM MgCl2, 5 mM glucose-6-phosphate, 1 U glucose-
6-phosphate dehydrogenase) and 200 lM of the correspond-
ing steroid dissolved in DMSO. The reactions were initiated
by the addition of NADPH to a final concentration of
1 mM, then stopped and extracted twice with the addition of
250 lL of ethyl acetate. The samples were centrifuged
(10 000 rpm, 10 min), the organic phases were combined
and evaporated until complete dryness and, after resuspen-
sion, analyzed by HPLC. Since, the absorption properties of
the products did not differ from the respective substrates,
the product formation was calculated from the relative peak
area (area %) of the HPLC chromatograms, dividing each
respective product peak area by the sum of all peak areas.
Whole-cell conversion with Bacillus megaterium
MS941
The in vivo conversions were done with the B. megaterium
strain MS941 [51]. The MS941 cells were transformed with
the pSMF2.1E vector, using the polyethylene glycol-mediated
protoplast transformation method [55]. For cultivation, a
complex medium was used (24 gL1 yeast extract, 12 gL1
soytone, 2.31 gL1 KH2PO4, and 1.25 gL1 KHPO4) sup-
plemented with 10 lgmL1 tetracycline at 30 °C, 180 rpm.
First, a 50-mL overnight culture was prepared, inoculated
from a 80 °C glycerol stock of the transformed MS941 cells.
This culture was then used to inoculate the main culture in a
300-mL baffled shake flask filled with 50 mL complex med-
ium. The main culture was incubated, until the OD578 reached
0.4, when the protein expression was induced by the addition
of xylose at a final concentration of 5 mgmL1. After 24 h,
the cultures were harvested by centrifugation (15 min,
10 000 g, 4 °C) and the pellets resuspended in 50 mL of
50 mM potassium phosphate buffer, pH 7.4. The substrates,
dissolved in DMSO, were added at a final concentration of
200 lM. The 500 lL samples were taken from the cultures at
fixed time points, followed by extraction and HPLC analysis.
To obtain sufficient product quantities for structural analysis
by NMR spectroscopy (mg range), the volume of the main
culture was increased to 750 mL (3 9 250 mL) in 2-L baffled
flasks. After a 24-h expression period, the cultures were har-
vested by centrifugation, resuspended in 375 mL of 50 mM
potassium phosphate buffer, pH 7.4, and the corresponding
substrates were added at a final concentration of 300 lM. Fol-
lowing the conversion, the cultures were extracted twice with
ethyl acetate, the organic phases were combined and evapo-
rated (Rotavapor R-114; B €UCHI Labortechnik AG, Flawil,
Switzerland). The purification and isolation of products was
carried out by preparative HPLC.
HPLC analysis and product isolation
The HPLC analyses were carried out with a Jasco system
(Pu-980 HPLC pump, AS-950 sampler, UV-975 UV/visible
detector, LG-980-02 gradient unit; Jasco, Gross-Umstadt,
Germany), using a reversed-phase ec MN Nucleodur C18
(3 lM, 4.0 9 125 mm) column (Macherey-Nagel, Bethle-
hem, PA, USA) kept at an oven temperature of 40 °C. The
steroids were eluted using a gradient method, starting with
a mobile phase consisting of acetonitrile:H2O in a ratio of
1:9, increasing it to 1:1. The flow rate was 1 mLmin1 and
the UV detection of the substrate and product was accom-
plished at 240 or 254 nm. For product isolation, the dis-
solved extracts were filtered (Acrodisc PTFE syringe filter,
0.45 lm, PALL) and injected to a reversed-phase ec MN
Nucleodur C18 (5 lM, 8.0 9 250 mm) column (Macherey-
Nagel, Bethlehem, PA, USA). The HPLC run was carried
out analogously to the analytical HPLC conditions with an
increased flow rate of 2.5 mLmin1. Fractions were col-
lected with an Advantec CHF122 SB fraction collector,
combined, and evaporated on a rotary evaporator (Rotava-
por R-114 from B €UCHI Labortechnik AG).
NMR spectroscopy
The NMR spectra were recorded in deuterated chloroform
(CDCl3) with a Bruker DRX 500 or a Bruker Avance 500
NMR spectrometer at 300 K. The chemical shifts were rel-
ative to CDCl3 at d 24.7 (
1H NMR) and 77.00 (13C NMR),
using the standard d notation in parts per million. The 1D
NMR (1H and 13C NMR, DEPT135) and the 2D NMR
spectra (gs-HH-COSY, gs-NOESY, gs-HSQCED, and gs-
HMBC) were recorded using the BRUKER pulse program
library. All assignments were based on extensive NMR
spectral evidence.
Crystallization
After thawing, aliquots of purified CYP109E1 were buffer
exchanged to 20 mM Tris/HCl, pH 8.0, 0.1 mM
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dithioerythritol using a PD-10 desalting column (GE
Healthcare) and concentrated to 40 mgmL1. Screening
for crystallization growth conditions was done at 293 K by
the sitting-drop vapor-diffusion method, using 96-well crys-
tallization plates, a Mosquito crystallization robot, (TTP
LabTech, Melbourn, UK) and a few commercially avail-
able screens. Lead crystallization conditions were optimized
manually in 24-well plates at 293 K. Initial crystals grew
with a reservoir solution containing 25% poly(ethylene gly-
col) 3350, 0.1 M Bis-tris, pH 6.5, and 4% tacsimate reagent
(pH 6.0) (Hampton Research, Aliso Viejo, CA, USA).
Diffraction quality crystals were obtained by applying a
streak-seeding protocol. First, protein drops were prepared
by mixing 2 lL of concentrated CYP109E1 (40 mgmL1)
with an equal volume of reservoir solution, containing 20%
poly(ethylene glycol) 3350, 0.1 M Bis-tris, pH 6.5, and 4%
tacsimate reagent pH 6.0. Droplets were equilibrated
against 500 lL of the reservoir solution for 1 h, and then
streak-seeded. Red-colored, cubic-shaped crystals of
CYP109E1 (space group P3221) grew overnight and
reached a final average size of approximately
0.15 9 0.15 9 0.15 mm3 in about 7 days. Corticosterone-
bound CYP109E1 crystals were initially obtained by crystal
soaking experiments. For this, corticosterone was added as
a solid powder directly into crystallization drops containing
native CYP109E1 crystals, followed by equilibration
against the original crystallization solution for 3–4 weeks.
Alternatively, cocrystallization screens were employed with
corticosterone and testosterone (in a 1:5 molar ratio of pro-
tein:steroid, using stocks solutions of the steroids in
DMSO), resulting in large cuboid-shaped crystals (space
group P21) grown from 9% poly(ethylene glycol) 3350 and
8% tacsimate pH 5.0 (Hampton Research). Prior to data
collection, crystals were briefly soaked in a cryoprotectant
solution containing mother liquor, supplemented with 20%
(v/v) glycerol. Cryoprotection of crystals obtained by
cocrystallization was accomplished by raising the poly(ethy-
lene glycol) 3350 concentration to 35%. Subsequently, all
crystals were flash-cooled at 100 K in the cold nitrogen gas
stream of the camera’s cryostat.
Data collection and structure determination
X-ray diffraction data were collected at the ID29, ID23-1,
and ID23-2 beam lines of the European Synchrotron Radi-
ation Facility (ESRF), Grenoble, all equipped with Pilatus
detectors. Additional data were recorded using an in-house
rotating anode X-ray source (Bruker MicroSTAR) and an
image plate detector (mar345TM). Single crystals of
CYP109E1 were used to obtain diffraction datasets in the
2.55–2.1 A resolution range. Reflections were indexed and
integrated using iMosflm [56] or XDS [57], while scaling
and merging of the data was done with AIMLESS from
the CCP4 software suite [58]. The structure of native
CYP109E1 was solved by molecular replacement with
Phaser from the PHENIX suite [59], using the structure of
HmtT from Streptomyces himastatinicus (PDB ID 4ggv,
39% sequence identity) as a search model. Two protein
molecules were located in the asymmetric unit, consistent
with Matthew coefficient calculations indicating a solvent
content of 61%. Automatic model rebuilding using routines
in PHENIX yielded approximately 80% of the polypeptide
model. The model was completed by iterative cycles of
model building with Coot [60] and structure refinement
with Phenix.refine [61]. The structure of substrate-free
CYP109E1 then served as a starting point to solve the
CYP109E1 steroid-bound structures. At the final stages of
refinement, water molecules were added to the structures
based on peaks in the electron density maps and using
strict interaction criteria. The quality of the refined protein
models was validated using MolProbity [62].
Structure analysis
Pairwise comparison of the obtained structures with other
P450 structures and RMSD calculations were done with
the PDBeFold engine [63] Protein–ligand interactions were
analyzed by LigPlot+ [64]. Substrate recognition sites (SRS)
in CYP109E1 were identified based on alignment with
P450cam and the description provided by Gotoh [29]. The
respective residue ranges in CYP109E1 are: SRS1 67–89,
SRS2 165–171, SRS3 187–194, SRS4 230–249, SRS5 286–
295, and SRS6 388–395.
Molecular dynamics simulations
Molecular dynamics simulations were performed using the
CYP109E1-TES crystal structure as a starting model, fol-
lowing the same procedure as previously described [33].
First, testosterone and all water molecules were removed
from the crystal structure, and the heme and its cysteine
ligand were replaced by a model of heme compound I
covalently bound to cysteine. The tested ligand (testos-
terone or corticosterone) was then manually placed back in
the binding pocket using PyMOL (Schr€odinger, Cambridge,
MA, USA). Testosterone was placed in 10 different starting
orientations where the distance between the C16b hydrogen
and the ferryl oxygen atom of heme compound I was less
than 4 A. Corticosterone was placed in starting orientations
similar to the COR-1 steroid orientation in the CYP109E1-
COR4 crystal structure. To ensure extensive conforma-
tional sampling, ten 100-ns MD simulations with different
initial orientations of the steroid were performed for each
CYP109E1-steroid system, and the AMBER03 force field
[65] in GROMACS version 5.0.4 was used [66]. Force fields for
testosterone and corticosterone were generated by use of
the structures derived from the PubChem database [67]
and subsequent energy minimization in YASARA
(www.YASARA.org). The RESP partial charges of the
molecules were calculated using the R.E.D webserver with
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the RESP-A1B charge model [68]. The force field was built
with the ANTECHAMBER module of AMBER 10 [69]
and converted into the GROMACS topology format. The
force field of the cysteine-heme compound I complex was
used as previously described [70]. An octahedral water box
of SPC/E water with periodic boundaries at least 1.2 nm
from the protein was used. Simulations were run at 300 K
and 1 bar. Pressure coupling was performed with a Par-
rinello–Rahman barostat [71]. The Nose–Hoover coupling
scheme was used to maintain the temperature, with cou-
pling constant of 0.5 ps [72]. Initial velocities were ran-
domly assigned. The LINCS algorithm was applied to
constrain all bonds containing hydrogen atoms [73]. Seven-
teen sodium counter ions were added to maintain the neu-
tral charge of the systems. Long-range electrostatic
interactions were treated by using the particle-mesh Ewald
method [74]. Energy minimization was performed using the
steepest descent method with positional restraints on pro-
tein heavy atoms and a maximum allowed force of
1000 kJmol1nm1. A 2-fs time step was used and coordi-
nates were saved every 1000 steps (2 ps). To determine
near-attack conformations the distance between the 16a or
16b hydrogen and the ferryl oxygen of compound I ferryl
oxygen was measured. In case of simulations with testos-
terone, additionally the distance between the 17a hydrogen
and the ferryl oxygen was measured. Angles between the
C16 or C17 carbon, their hydrogens and the ferryl oxygen
were also measured. Based on the previously described cut-
offs [33–35], ligand conformations were considered near to
attack, if at least one of the measured distances was < 3.5
A and the angle was 180  45°. All other conformations
were considered nonproductive. The number of frames in
MD trajectories suggesting pro-16a, pro-16b, pro-17a, and
nonproductive conformations were counted and expressed
as percentages.
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Table S1 Oligonucleotide primers used in this work. The restriction sites for the respective 
restriction enzymes are shown in italics, and the sequence encoding the His6-tag is underlined.  
 
 
Name Description Nucleotide sequence (5 '→ 3') 
205-for-NdeI Forward primer for the 
amplification of CYP109E1 
with NdeI restriction site 
CATATGAAAACAGAAAGAGAAA
ACGG  
205-rev-KpnI Reverse primer for the 
amplification of CYP109E1 
with His6-tag and KpnI 
restriction site 
GGTACCTTAATGGTGATGGTGAT
GGTGTACGTTTTTACGAATCAAT
AATT 
205-SpeI-for Forward primer for the 
amplification of CYP109E1 
with SpeI restriction site 
and RBS 
ACTAGTAAATCAAGGAGGTGAAT
ATACAATGAAAACAGAAAGAGA
AAACGG  
205-KpnI-rev 
 
Reverse primer for the 
amplification of CYP109E1 
with His6-tag and KpnI 
restriction site 
GGTACCTTATACGTTTTTACGAAT
CAATAATT 
205-RT-for 
 
RT-Forward primer for the 
amplification of CYP109E1 
AAACGGAATTGTCCGTCAAG 
205-RT-rev 
 
RT-Reverse primer for the 
amplification of CYP109E1 
CACTTCTTTGACCCCGTCAT 
 
Mutation Oligonucleotides 
K187A-109E1-for CTCCAGCAAGAGGCAATGAAAGCAAATGATGAGC 
 
K187A-109E1-rev GCTCATCATTTGCTTTCATTGCCTCTTGCTGGAG 
 
V169A-109E1-for
  
GATATTATCGCAGCCGGTCCTTCTAATAACGAACGT 
V196A-109E1-rev ACGTTCGTTATTAGAAGGACCGGCTGCGATAATATC 
I241A-109E1-for CTATTTTGCTACTGGCTGCTGGAAACGAAACAACCAC 
 
I241A-109E1-rev GTGGTTGTTTCGTTTCCAGCAGCCAGTAGCAAAATAG 
E245A-109E1-for CTGATTGCTGGAAACGCAACAACCACAAATTTAATTTC 
E245A-109E1-rev GAAATTAAATTTGTGGTTGTTGCGTTTCCAGCAATCAG 
T246A-109E1-for
  
CTGATTGCTGGAAACGAAGCAACCACAAATTTAATTTC 
T246A-109E1-rev
  
GAAATTAAATTTGTGGTTGCTTCGTTTCCAGCAATCAG 
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Table S2 Chemical structures of compounds used for CYP109E1 substrate screening. 
 
 
 
  
Short C17 substituent at steroid D ring Large C17 substituent at steroid D ring 
testosterone (11) 
androstenedione (1) 
 
19- nortestosterone (13) 
 
 
 
 
 
 
 corticosterone (4) 
  deoxycorticosterone (5) 
cortisol (2) 
cortisone (3) 
11-deoxycortisol (6)
dexamethasone (7) 
 prednisolone (8)
prednisone (9) 
progesterone (10) 
 testosterone acetate (12) 
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Table S3 Structural NMR data of 16β-hydroxytestosterone and androstendione in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16β-Hydroxytestosterone Androstendione 
 δC δH (J in Hz) δC δH (J in Hz) 
1 35.63 2.00 ddd (13.5, 5.0, 3.5) 
1.66 ddd (14.0, 13.5, 5.0) 
35.69 2.02 ddd (13.5, 5.0, 3.2) 
1.70 m 
2 33.88 2.38 m 
2.31 m 
33.89 2.40 m 
2.35 m 
3 199.68 ------------------------ 199.29 ------------------------ 
4 123.84 5.70 s 124.15 5.73 brs 
5 171.20 ------------------------ 170.27 ------------------------ 
6 32.69 2.37 m 
2.25 m 
32.55 2.42 m 
2.31 m 
7 31.66 1.84 m 
0.98 m 
30.74 1.96 m 
1.11 m 
8 34.99 1.62 m 35.15 1.72 m 
9 54.01 0.92 m 53.82 0.97 ddd (12.5, 10.5, 4.0) 
10 38.66 ------------------------ 38.63 ------------------------ 
11 20.32 1.57 m 
1.43 m 
20.31 1.68 m 
1.44 m 
12 37.01 1.87 m 
1.08 ddd (13.0, 13.0, 4.5) 
35.73 2.45 ddd (19.5, 9.0, 1.0) 
2.09 ddd (19.5, 9.0, 9.0) 
13 42.33 ------------------------ 47.49 ------------------------ 
14 46.96 0.78 ddd (13.5, 11.0, 6.7) 50.84 1.28 m 
15 34.91 2.20 m 
1.28  ddd (13.5, 13.5, 5.0) 
21.74 1.96 m 
1.56 m 
16 69.83 4.14 ddd (7.7, 7.7, 5.0) 31.27 1.85 ddd (13.0, 4.0, 2.5) 
1.27 m 
17 80.55 3.35 d (7.7) 220.30 ------------------------ 
18 11.83 0.83 s (3H) 13.69 0.90 s (3H) 
19 17.37 1.17 s (3H) 17.37 1.20 s (3H) 
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Table S4 Binding interactions of COR-2, COR-3 and COR-4 in CYP109E1-COR4 crystal 
structure. Hydrogen bonding and hydrophobic interactions are described as identified by 
LigPlot+.  
 
 
Ligand  Hydrogen bonding Hydrophobic interactions 
COR-2 Corticosterone C21-hydroxyl with Gln75 (SRS1) Arg69 (SRS1) 
  Corticosterone C11-hydroxyl with Thr78 (SRS1) (water-mediated bond)   Pro71 (SRS1) 
    Gln75 (SRS1) 
    Leu80 (SRS1) 
    Gly81 (SRS1) 
    Ile85 (SRS1)  
    Asn86 (SRS1) 
    Ile241 (SRS4) 
    COR-1 
    COR-4 
COR-3 Corticosterone C3-keto oxygen with heme propionate (water-mediated bond) Val46 
  Corticosterone C3-keto oxygen with amide nitrogen of His293 (SRS5) Leu292 (SRS5) 
  Corticosterone C21-hydroxyl group with backbone carbonyl of Arg44 His312  
    Phe391 (SRS6) 
COR-4 Corticosterone C21-hydroxyl and C20-keto oxygen with side chain of Arg76 (SRS1) Thr78 (SRS1) 
    Lys187 (SRS3) 
    Met188 (SRS3) 
    Asn191 (SRS3) 
    Ile241 (SRS4) 
    COR-1 
    COR-2 
    COR-3 
 
71
Scientific articles 
 
 
 
2.4 (Putkaradze et al., 2017) 
 
CYP109E1 is a novel versatile statin and terpene oxidase from  Bacillus 
megaterium.  
Putkaradze N, Litzenburger M, Ammar Abdulmughni, Mohammed Milhim, Elisa Brill, 
Frank Hannemann and Rita Bernhardt. 
 
 
Applied Microbiology Biotechnology, 2017 Dec; 101: 8379-8393. 
Reprinted with permission of the Applied Microbiology Biotechnology. All rights reserved. 
 
72
BIOTECHNOLOGICALLY RELEVANT ENZYMES AND PROTEINS
CYP109E1 is a novel versatile statin and terpene oxidase
from Bacillus megaterium
Natalia Putkaradze1 & Martin Litzenburger1 & Ammar Abdulmughni1 &
Mohammed Milhim1 & Elisa Brill1 & Frank Hannemann1 & Rita Bernhardt1
Received: 31 May 2017 /Revised: 22 August 2017 /Accepted: 26 September 2017 /Published online: 11 October 2017
# Springer-Verlag GmbH Germany 2017
Abstract CYP109E1 is a cytochrome P450 monooxygenase
from Bacillus megaterium with a hydroxylation activity for
testosterone and vitamin D3. This study reports the screening
of a focused library of statins, terpene-derived and steroidal
compounds to explore the substrate spectrum of this enzyme.
Catalytic activity of CYP109E1 towards the statin drug-
precursor compactin and the prodrugs lovastatin and simva-
statin as well as biotechnologically relevant terpene com-
pounds including ionones, nootkatone, isolongifolen-9-one,
damascones, and β-damascenone was found in vitro. The
novel substrates induced a type I spin-shift upon binding to
P450 and thus permitted to determine dissociation constants.
For the identification of conversion products by NMR spec-
troscopy, a B. megaterium whole-cell system was applied.
NMR analysis revealed for the first time the ability of
CYP109E1 to catalyze an industrially highly important reac-
tion, the production of pravastatin from compactin, as well as
regioselective oxidations generating drug metabolites (6′β-
hydroxy-lovastatin, 3′α-hydroxy-simvastatin, and 4″-hy-
droxy-simvastatin) and valuable terpene derivatives (3-
hydroxy-α-ionone, 4-hydroxy-β-ionone, 11,12-epoxy-
nootkatone, 4(R)-hydroxy-isolongifolen-9-one, 3-
hydroxy-α-damascone, 4-hydroxy-β-damascone, and 3,4-
epoxy-β-damascone). Besides that, a novel compound, 2-
hydroxy-β-damascenone, produced by CYP109E1 was iden-
tified. Docking calculations using the crystal structure of
CYP109E1 rationalized the experimentally observed regiose-
lective hydroxylation and identified important amino acid res-
idues for statin and terpene binding.
Keywords Bacillus megaterium . CYP109E1 .
Biotransformation . Pravastatin . Statins . Terpenes
Introduction
Bacillus megaterium is a gram-positive soil bacterium with
industrial importance. The ability of growth on different
low-priced media, the absence of alkaline proteases and endo-
toxins, the stable maintenance of plasmid vectors, and high
protein expression capacity make this microorganism an ex-
cellent biotechnological production host (Rygus and Hillen
1992; Vary et al. 2007). It is used for the production of indus-
trially important enzymes as well as polyhydroxybutyrate and
vitamin B12 (Biedendieck et al. 2010; Korneli et al. 2013;
Kulpreecha et al. 2009; Malten et al. 2005; Stammen et al.
2010). Besides that, the full genome sequencing of two
B. megaterium strains (Eppinger et al. 2011) gave rise to the
identification of several biotechnologically interesting pro-
teins from this bacterium such as cytochromes P450 (P450s)
(Abdulmughni et al. 2017; Brill et al. 2014; Jóźwik et al. 2016;
Kiss et al. 2015; Milhim et al. 2016).
P450s are heme-containing external monooxygenases.
Besides their essential role in steroid hormone biosynthesis
and drug metabolism, several more applications of this en-
zyme class such as bioremediation and implementation of a
great variety of chemical reactions are also described (Sono
et al. 1996). The broad spectrum of substrates and the ability
to perform diverse synthetically challenging reactions under
mild conditions provide a high biotechnological potential of
these enzymes (Bernhardt 2006; Bernhardt and Urlacher
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2014). P450 family members are widely distributed among
different species of life. In contrast to mammalian and plant
P450s, microbial ones have the advantages that they are solu-
ble proteins and exhibit higher stability simplifying their han-
dling (Fulco 1991; Urlacher et al. 2004). Three P450s from
B. megaterium, the self-sufficient fatty acid hydroxylase
CYP102A1 (BM3) and two steroid hydroxylases of the
CYP106 family, CYP106A1 and CYP106A2, have been ex-
tensively studied and described as attractive biocatalysts for
potential biotechnological applications (Berg and Rafter 1981;
Bleif et al. 2011; Brill et al. 2014; Janocha et al. 2016; Kiss
et al. 2015; Putkaradze et al. 2017; Narhi and Fulco 1987;
Schmitz et al. 2014; Urlacher et al. 2006; Virus et al. 2006).
CYP109E1 is a new member of Bacillus P450s, recent-
ly identified by our laboratory, but is not fully character-
ized so far. The crystal structure of CYP109E1 in
substrate-free and substrate-bound state has provided first
insights into the structural background of substrate binding
and activity of this enzyme (Jóźwik et al. 2016). Due to
the close phylogenetic distance of CYP109E1 to the ste-
roid hydroxylase CYP106A1, its potential as steroidogenic
P450 has been investigated. It has been found that
CYP109E1 possesses very low or no catalytic activity
towards steroidal substrates except for testosterone and
vitamin D3 (Abdulmughni et al. 2017; Jóźwik et al.
2016). To extend the substrate range of CYP109E1, a
focused library was screened. The library consisted of ste-
roids, statins, and terpenoids reported to be substrates of
some Bacillus P450s of the 109 family (Furuya et al.
2009; Girhard et al. 2010) (Scheme 1).
Statins are a class of powerful, widely used drugs against
cardiovascular diseases. They effectively reduce plasma LDL-
cholesterol levels and coronary heart disease risk by inhibiting
the key enzyme 3-hydroxy-3-methylglutaryl-coenzyme-A
(HMG-CoA) reductase in the mevalonate pathway (Brown
2007; Endo and Hasumi 1993; Lamon-Fava 2013). The first
discovered statin, the natural product compactin (mevastatin)
undergoes a stereoselective hydroxylation at the position C6′
resu l t ing in the format ion of pravas ta t in (6 ′β -
hydroxycompactin). Pravastatin as well as the naturally occur-
ring statin lovastatin and its semi-synthetic derivative simva-
statin are efficient drugs. The bioconversion of compactin to
pravastatin is one of the successful biotechnological applica-
tions of P450-based systems with only few examples of P450s
described in the literature capable of performing this reaction
(Bernhardt and Urlacher 2014; Matsuoka et al. 1989; McLean
et al. 2015; Milhim et al. 2016; Sakaki 2012).
Terpenes and terpenoids are the most diverse class of
chemicals occurring mainly in plants. These compounds and
their derivatives are important for biotechnology since they
are applied in different fields, such as chemical, pharmaceuti-
cal, or flavor and fragrance industry (Janocha et al. 2015). The
regio- and stereoselective oxyfunctionalization of
terpenes and terpenoids is of high interest but remains to be
a challenging task for synthetic chemistry. Microbial P450
enzymes represent an effective alternative to chemical synthe-
sis since they possess the ability to oxidize diverse biotechno-
logically important terpene and terpenoid compounds in a
highly stereo- and regioselective manner. However, only a
limited number of microbial P450s have been identified as
terpene hydroxylases and epoxidases until now (Janocha
et al. 2015). The well-studied and effective bacterial terpene
hydroxylating-P450s include CYP101A1, CYP108A1, and
CYP111A1 from Pseudomonas species having camphor, ter-
pineol, and linalool as their natural substrates, respectively
(Katagiri et al. 1968; Peterson et al. 1992; Ullah et al. 1990),
as well as enzymes from Novosphingobium aromaticivorans
such as CYP101B1 (Bell and Wong 2007; Hall and Bell
2014). Two P450s fromB.megaterium (CYP106 family) have
been shown to hydroxylate di- and triterpenes (Bleif et al.
2011; Brill et al. 2014; Schmitz et al. 2014).
Here, we report highly regioselective oxidations of three
statins (compactin 1, lovastatin 2, and simvastatin 3) as well as
seven terpenes, including α-ionone 4, β-ionone 5, nootkatone
6, isolongifolen-9-one 7,α-damascone 8,β-damascone 9, and
β-damascenone 10 by CYP109E1. Reconstituted P450 and
B. megaterium whole-cell systems were successfully applied
for the biotransformation of these substrates. Characterization
of the reaction products indicated hydroxylase and epoxidase
activity of CYP109E1, producing an important drug, prava-
statin, as well as known and novel statin drug metabolites and
terpene derivatives.
Materials and methods
Reagents and chemicals
Compactin, lovastatin, simvastatin, medroxyprogesterone ac-
etate, norethisterone, and norethisterone acetate were pur-
chased from TCI chemicals (Eschborn, Germany). (+)-
Nootkatone, (−)-isolongifolen-9-one, and α- and β-ionone
were purchased from Sigma-Aldrich (St. Louis, MI, USA).
α-Damascone, β-damascone, and β-damascenone were pro-
vided from Bell Flavors & Fragrances (Leipzig, Germany).
Bacterial culture media were purchased from Becton,
Dickinson and Company (Franklin Lakes, NJ, USA). All oth-
er chemicals and solvents were obtained from standard
sources and were of the highest purity available.
Strains and plasmids
The E. coli C43 (DE3) cells (Lucigen, Middleton, WI, USA)
transformed with the plasmid pET17b.CYP109E1
(Abdulmughni et al. 2017) were used for the expression of
CYP109E1. B. megaterium MS941 cells (Wittchen and
8380 Appl Microbiol Biotechnol (2017) 101:8379–8393
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Meinhardt 1995) transformed either with the plasmid
pSMF2.1.CYP109E1 (Abdulmughni et al. 2017) or the con-
trol plasmid pSMF2.1 (Bleif et al. 2011) were used for whole-
cell conversions.
Enzyme purification and spectral measurements
E. coli cells were cultured overnight in Luria-Bertani (LB)
medium containing 100 μg/mL ampicillin at 37 °C and
150 rpm in a rotary shaker. Five milliliters of overnight culture
was used to inoculate 500 mL Terrific Broth (TB) medium
containing 100 μg/mL ampicillin in a 2-L baffled shake flask,
and the culture was incubated at 37 °C and 100 rpm. At OD600
of 0.5, the expression of CYP109E1 was induced with 1 mM of
isopropyl-thio-β-D-galactopyranoside (IPTG). Simultaneously,
0.5 mM of δ-aminolevulinic acid (δ-ALA) was added to sup-
port the heme synthesis. After a 24-h expression, the cells were
harvested by centrifugation at 4500×g and stored at − 20 °C
until purification of the enzyme. The purification of CYP109E1
was carried out using immobilized metal ion affinity chroma-
tography (TALON™ Resin, Clontech) as described elsewhere
(Abdulmughni et al. 2017). Fractions containing CYP109E1
were collected, concentrated, and further purified using size
exclusion chromatography (Superdex 75 column, GE
Healthcare Life Sciences) in 50 mM potassium phosphate buff-
er (pH 7.4) with a flow rate of 0.1 mL/min. The purified protein
fractions were collected, concentrated by ultrafiltration, and
stored at − 20 °C. The concentration of purified CYP109E1
was estimated by carbon monoxide difference spectroscopy
using an extinction coefficient (450–490 nm) of
91 mM−1 cm−1 according to the method of Omura and Sato
(1964).
Bovine adrenodoxin reductase (AdR) and a truncated form
of bovine adrenodoxin (Adx4–108) were expressed and puri-
fied as described elsewhere (Sagara et al. 1993; Uhlmann et al.
1992). Protein concentrations were measured spectroscopical-
ly using corresponding molar extinction coefficients as de-
scribed elsewhere (Lisurek et al. 2004).
Scheme 1 Chemical structures of compounds investigated with CYP109E1
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Spin-state shift and estimation of dissociation constant
(Kd)
Spin-state shifts were investigated using a double beam spec-
trophotometer (UV-2101PC, Shimadzu, Japan) and two tan-
dem quartz cuvettes. One chamber of each cuvette contained
10 μM CYP109E1 in 50 mM potassium phosphate buffer
(pH 7.4), while the other chamber was filled with buffer alone.
The substrates were dissolved in DMSO (5 mM stock solu-
tions) and were added into the chamber with CYP109E1 so-
lution of the sample cuvette while an equal amount of each
substrate was also added into the buffer containing a chamber
of the reference cuvette. Difference spectra were recorded be-
tween 350 and 500 nm. Dissociation constant (Kd) was esti-
mated by titrating each substrate (0–200 μM) until saturation.
The data were analyzed by plotting the peak-to-trough differ-
ences against the substrate concentrations and fitting them
(except for lovastatin and simvastatin) with the hyperbolic
function ΔA = ΔAmax × [S] / (Kd + [S]). Lovastatin and sim-
vastatin exhibited tight binding (Kd < 5[E]), and for these
compounds, the data were fitted to the tight binding quadratic
equation: ΔA = (ΔAmax/2[E]) × {(Kd + [E] + [S]) − {(Kd +
[E] + [S])2–4[E][S]}1/2} (Williams and Morrison 1979). ΔA
represents the peak-to-trough absorbance difference,ΔAmax is
the maximum absorbance difference, [E] is the enzyme con-
centration, and [S] is the substrate concentration. The data
processing was done with OriginPro 9.0G software
(OriginLab, MA, USA). All Kd values represent the mean of
three independent measurements with the coefficient of deter-
mination (R2) of 0.99. Spin-state shifts were calculated (to
approximately ± 5%) using theΔAmax value of each substrate
as a percentage of the maximum expected shift for 10 μM
enzyme estimated as described by Luthra et al. (2011).
Measurement of CYP109E1 activity in vitro
The catalytic activity of CYP109E1 towards the selected com-
pounds was investigated using a reconstituted in vitro system
consisting of 0.5 or 1 μM CYP109E1, bovine AdR, and
Adx4–108 with a molar ratio of 1:2:20. The reactions were
carried out in 250 μL of 50 mM potassium phosphate buffer
(pH 7.4) with 10% glycerol. For the sufficient electron supply,
a NADPH regeneration system containing glucose-6-
phosphate-dehydrogenase (1 U), glucose-6-phosphate
(5 mM), and MgCl2 (1 mM) was used. The in vitro reactions
with 100 μM statin 1–3 (20 mM stock solution in DMSO),
200 μM steroidal 11–13 (20 mM stock solution in DMSO),
and terpene 4–10 (50 mM stock solution in ethanol) com-
pounds were started by addition of 1 mM NADPH in
1.5-mL Eppendorf tubes under mixing at 30 °C and 700 rpm
and stopped after 15 min by addition of 250 μL of ethyl
acetate or chloroform. The reaction mixtures were extracted
twice with 500 μL of the organic solvent. The organic phases
were combined, evaporated to dryness, and stored at − 20 °C
until analysis via either high-performance liquid chromatog-
raphy (HPLC) or gas chromatography-mass spectrometry
(GC-MS).
Whole-cell conversion with CYP109E1 in B. megaterium
MS941
The whole-cell conversions were performed in plasmidless
B. megater ium MS941 stra in t ransformed with
pSMF2.1.CYP109E1 shuttle vector by the method of Barg
et al. (2005). As a control of the CYP109E1-based whole-
cell biotransformation, MS941 cells transformed with the
empty vector pSMF2.1 were used. The main cultures were
prepared by inoculating 50 mL of complex medium (24 g/L
yeast extract, 12 g/L soytone, 0.5% glycerol (v/v), 2.31 g/L
KH2PO4 and 12.5 g/L K2HPO4) with overnight culture (1%
of the main culture volume) in 300 mL baffled shake flask
and incubated at 37 °C and 160 rpm in a rotary shaker until
an OD578 of 0.5 was reached. At this time point, the expres-
sion of CYP109E1 was induced by adding 5 g/L xylose.
After 24 h expression at 30 °C, the cultures were harvested
by centrifugation (4500×g, 4 °C), washed, and resuspended
in 50 mM potassium phosphate buffer (pH 7.4) with 2%
glycerol. Whole-cell conversions of 100 μM of statins 1–3
and 200 μM of terpenes 4–10 were carried out in 25 mL
volume in a rotary shaker at 30 °C and 150 rpm. The con-
versions of nootkatone 6, isolongifolen-9-one 7, α-ionone 4,
β-ionone 5, α-damascone 8, β-damascone 9, and β-
damascenone 10 were performed in sealed baffled shake
flasks. Substrate stock solutions were prepared by dissolving
them in DMSO or ethanol. The biotransformation of each
substrate was monitored within 2 h by taking 500-μL culture
samples. The samples were extracted with double volume of
ethyl acetate, dried, and stored at − 20 °C until HPLC anal-
ysis. To obtain sufficient amounts (2–10 mg) of conversion
products for the structure elucidation via NMR, the whole-
cell reactions were scaled up to 0.5–1 L culture volume. The
reactions were stopped after 2 or 4 h and extracted with
double volume of ethyl acetate. The organic phases were
dried over anhydrous MgSO4, concentrated to dryness using
a rotivapor (Büchi R-114), and stored at − 20 °C until puri-
fication via HPLC.
Conversion analysis and product isolation via HPLC
The conversion analysis was performed via reversed phase
HPLC technique using a Jasco system (a Pu-980HPLC pump,
an AS-950 sampler, an UV-975 UV/Vis detector, a LG-980–
02 gradient unit; Jasco, Gross-Umstadt, Germany) and an ec
MN Nucleodur C18 (5 μm, 4.0 × 125 mm) column
(Macherey-Nagel, Bethlehem, PA, USA). For the purification
of conversion products, a preparative ec MN Nucleodur C18
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VP (5 μm, 8.0 × 250 mm) column (Macherey-Nagel,
Bethlehem, PA, USA) was used. The mobile phase consisted
of 10% acetonitrile in water (solvent A) and pure acetonitrile
(solvent B). A gradient from 20 to 80% of solvent B was used
for the separation of α-ionone 4, β-ionone 5, α-damascone 8,
β-damascone 9, β-damascenone 10, compactin 1, and lova-
statin 2 conversions, from 20 to 100% for the analysis of
nootkatone 6 and isolongifolen-9-one 7 conversions and from
0 to 100% for simvastatin 3, medroxyprogesterone acetate 11,
norethisterone 12, and norethisterone acetate 13 conversions.
A flow rate of either 1 mL/min (conversion measurements) or
3.5 mL/min (product isolation) and a temperature of 40 °C
were set during the analysis of all compounds. The UV detec-
tion was accomplished at 236 (statins 1–3), 240 (steroids 11–
13, nootkatone 6, and isolongifolen-9-one 7), 228 (α-ionone
4,α-damascone 8, andβ-damascone 9), 232 (β-damascenone
10), or 296 nm (β-ionone 5).
Conversion analysis via GC-MS and LC-MS
GC-MS measurements were performed with a system
consisting of an AI/AS 3000 autosampler, a DSQ II quadru-
pole, a Focus GC column oven (Thermo Scientific, Waltham,
USA), and a DB-5 column (Agilent) with a length of 25 m,
0.32 mm ID, and 0.52 μm film thickness. The conversions
were analyzed as described elsewhere (Litzenburger and
Bernhardt 2016).
Analytical HPLC-MS was performed on a Thermo Dionex
UltiMate 3000 HPLC using NUCLEOSHELL RP 18plus
(100 × 4.6 mm, 2.7 μm) column (Macherey-Nagel,
Bethlehem, PA, USA) coupled to a Bruker AmaZon SL
ESI-MS system (Bruker, Billerica, MA, USA). The mobile
phase consisted of water with 0.1% formic acid (solvent A)
and pure acetonitrile with 0.1% formic acid (solvent B). A
gradient from 5 to 95% of solvent B was used for the separa-
tion. Mass spectra were acquired in positive mode ranging
from 100 to 600 m/z using UltraScan mode.
Structure elucidation by NMR spectroscopy
NMR spectra were recorded on a Bruker (Rheinstetten,
Germany) DRX 500 NMR spectrometer. A combination of
1H, 13C, 1H,1H-COSY, HSQC, and HMBC experiments was
used for structure elucidation. All chemical shifts are relative
to CHCl3 (δ = 7.24) or CDCl3 (δ = 77.00) using the standard δ
notion in parts per million (ppm).
Molecular docking
For the docking experiments, the recently solved crystal struc-
ture of CYP109E1 was used (Jóźwik et al. 2016). Two struc-
turally different substrates, the statin compactin 1 and the
norisoprenoid compound α-ionone 4, were docked into the
active site of CYP109E1 in its closed conformation (PDB:
5L94) using AutoDock 4.0 (Morris et al. 2009). The
Windows version 1.5.6 of AutoDock Tools was used to com-
pute Kollman charges for the enzyme and Gasteiger-Marsili
charges for the ligands (Sanner 1999). A partial charge of
+ 0.400e was assigned manually to the heme iron, which
corresponds to Fe(II) that was compensated by adjusting the
partial charges of the ligating nitrogen atoms to − 0.348e.
While the protein was kept as rigid, the flexible bonds of the
ligands were assigned automatically and verified by manual
inspection. A cubic grid box with a size of 52 Å × 50Å × 48Å
was fixed above the heme moiety to cover the whole active
site of the enzyme. The spacing between grid points was 0.375
Å. Two hundred docking runs (for each substrate) were car-
ried out applying the Lamarckian genetic algorithm using de-
fault parameter settings. The binding conformations were an-
alyzed according to estimated binding energies and distances
of the target carbon atom to the heme iron.
Results
Substrate binding to CYP109E1
To screen CYP109E1 for potential new substrates, a library of
13 compounds was used. The library contained the steroids
norethisterone 12 and medroxyprogesterone acetate 11,
compactin 1, and the terpenes α-ionone 4, β-ionone 5, and
nootkatone 6, which previously have been identified as sub-
strates of the CYP109 family (Furuya et al. 2009; Girhard
et al. 2010), as well as related compounds with biotechnolog-
ical or pharmaceutical impact (Scheme 1). First, the potential
substrates were investigated for their ability to bind to
CYP109E1. This was done by monitoring the high-spin shift
induction using difference spectroscopy. When a P450 sub-
strate displaces the axial water ligand, it changes the spin-state
of the iron atom from low-spin to high-spin (Schenkman and
Jansson 1998). Spectroscopically, this transition is reflected
by a shift in the absorption maximum from around 420 to
390 nm (type I difference spectrum). Previously, it has been
reported that the spin-shift is not necessary for the catalytic
activity of a P450 (Girhard et al. 2010; Simgen et al. 2000).
On the other hand, a very large type I spin-shift observed for
many bacterial P450s (Bell and Wong 2007) indicating the
ability of its substrates to displace almost all water molecules
in the active site results in an effective electron transfer and
high catalytic activities by substrate-gating mechanism (Sligar
and Gunsalus 1976; Fisher and Sligar 1985; Honeychurch
et al. 1999, Poulos and Raag 1992). Therefore, this spectro-
scopic method remains to be well suitable for screening of
potential P450 substrates as well as inhibitors (Khatri et al.
2016; Schmitz et al. 2012). All here tested compounds, except
for steroids 11–13, were able to induce a type I spin-shift of
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CYP109E1, which allowed us to investigate the substrate
binding spectroscopically (Fig. 1 and S1) and to determine
dissociation constants (Kd). Statin compounds 1–3 showed
tighter binding to P450 than terpene substrates 4–10
(Table 1). Our results indicate that simvastatin 3 binds tighter
to CYP109E1 than the other statins. The Kd of simvastatin 3
[Kd = 4.7 μM] was shown to be approximately 18 times lower
than that of compactin 1 [Kd = 84 μM] and two times lower
than that of lovastatin 2 [Kd = 9.6 μM] (Fig. 1 and S1). The
strongest binding to CYP109E1 among terpenes 4–10 was ob-
served for β-ionone 5 [Kd = 91 μM] and the weakest for
isolongifolen-9-one 7 [Kd = 216 μM] (Fig. S1). Interestingly,
α-ionone 4 (51%) and simvastatin 3 (43%) were able to induce
the highest spin-state shifts among the investigated substrates,
whereas lovastatin 2 shifted the state to a lesser extent (11%).
Biotransformation of medroxyprogesterone acetate,
norethisterone, and norethisterone acetate
Although the tested steroids 11–13 did not show any spec-
tral shift when incubated with CYP109E1, their potential
biotransformation was investigated in vitro. As observed
previously with deoxycorticosterone and testosterone as sub-
strates of CYP106A2 and CYP109B1, respectively, a type I
spectral shift is not a necessary prerequisite for bioconver-
sion (Girhard et al. 2010; Simgen et al. 2000). The steroidal
substrates medroxyprogesterone acetate 11, norethisterone
12, and norethisterone acetate 13 were thus investigated
using a reconstituted P450 system with AdR and Adx4–108
as redox partners. CYP109E1 did not show any activity
towards these compounds (data not shown), and they were,
therefore, not further tested with the CYP109E1 based
whole-cell system in vivo.
Biotransformation of statin substrates
The three statins, compactin 1, lovastatin 2, and simvastatin 3,
identified as CYP109E1 ligands by difference spectroscopy,
were further tested as potential substrates for CYP109E1
in vitro. The activity of CYP109E1 was reconstituted with
bovine AdR and truncated Adx4–108 as described in the
BMaterial and methods^ section. CYP109E1 was found to
convert all three statin compounds 1–3 resulting in one major
reaction product 14, 15 for compactin 1 and lovastatin 2, re-
spectively (Fig. 2a, c) and two products 16, 17 for simvastatin
3 conversion (Fig. 2e). The selectivity of compactin and lov-
astatin conversions (77 and 94%) was found to be remarkably
higher compared to that of simvastatin (Table S1).
Interestingly, the conversion ratio of CYP109E1 towards
compactin 1 was much lower compared with the other statins
resulting in only 11% conversion after 15 min compared with
lovastatin 2 (63%) and simvastatin 3 (72%) (Fig. 2a, c, e and
S2).
To prepare and isolate higher amounts of compactin 1,
lovastatin 2, and simvastatin 3 conversion products for the
analysis via NMR spectroscopy, B. megateriumMS941whole
cells transformed with pSMF2.1.CYP109E1 were used. After
in vivo conversion of statins, the main products of the
compactin 1 and lovastatin 2 conversion (14 and 15, Fig. 2b,
d) as well as two products of simvastatin 3 conversion (16 and
17, Fig. 2f) have been purified in sufficient amounts. NMR
analysis (data S7) revealed that CYP109E1 is able to hydrox-
ylate compactin 1 and lovastatin 2 at position C6′β resulting
in the formation of pravastatin 14 and 6′β-hydroxy-lovastatin
15, respectively (Scheme 2). The simvastatin 3 metabolites
were identified as 3′α-hydroxy-simvastatin 16 and 4″-hy-
droxy-simvastatin 17. The B. megaterium MS941 strain con-
taining the pSMF2.1 vector, which was used as a negative
Fig. 1 The absorbance changes plotted against the corresponding
concentrations of compactin 1 (a) and α-ionone 4 (b) titrated to
CYP109E1 as described in the BMaterial and methods^ section. The
mean values were fitted by hyperbolic regression, and the Kd value was
calculated. The inset shows type I spectral shifts induced by the binding
of the increasing amount of the substrate to CYP109E1. Arrows show the
direction of spectral changes at increasing substrate concentrations
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control for the CYP109E1-dependent conversions, showed no
activity towards the investigated substrates (data not shown).
Biotransformation of terpene substrates
All tested terpenes 4–10 showed type I binding spectra, and
the reactions of CYP109E1 with these compounds were fur-
ther characterized. Similar to statins 1–3, the activity of
CYP109E1 towards the potential terpene substrates α-
ionone 4, β-ionone 5, nootkatone 6, isolongifolen-9-one 7,
α-damascone 8, β-damascone 9, and β-damascenone 10
was initially tested using the reconstituted system.
CYP109E1 showed high conversion within 15 min under
in vitro conditions (95% of α-ionone 4, 96% of β-ionone 5,
70% of nootkatone 6, 91% of isolongifolen-9-one 7, 72% of
α-damascone 8, 70% of β-damascone 9 and β-damascenone
10) (Fig. S2). The reaction selectivity except for β-
damascenone conversion was high (77–93%) yielding one
main product (Table S1). All these substrates were also suc-
cessfully converted by B. megaterium cells overexpressing
CYP109E1, and the product patterns and selectivities were
similar compared to those in vitro. The main products of α-
ionone 4, β-ionone 5, α-damascone 8, and β-damascone 9
were compared with authentic standards by GC-MS
(Litzenburger and Bernhardt 2016) and identified as 3-
hydroxy-α-ionone 18 , 4-hydroxy-β-ionone 19 , 3-
hydroxy-α-damascone 23, and 4-hydroxy-β-damascone 24,
respectively (Fig. 3a, b, e, f and S3–S6). Moreover, 3-
hydroxy-α-ionone 18 and 3-hydroxy-α-damascone 23 were
found to be 3,6-trans-products. The conversion products of
nootkatone 6, isolongifolen-9-one 7, and β-damascenone 10
were isolated via HPLC and elucidated by NMR
spectroscopy. The products of nootkatone 6 and
isolongifolen-9-one 7 conversion were identified as
11(R),12-epoxy-nootkatone 20, 11(S),12-epoxy-nootkatone
21, and 4(R)-hydroxy-isolongifolen-9-one 22, respectively
(Fig. 3c, d). Products of in vivo conversion of β-
damascenone 10 were found to be 3,4-dihydroxy-β-
damascone 27, 2-hydroxy-β-damascenone 25, and 3,4-
epoxy-β-damascone 26 (Fig. 4a). The control strain
B. megaterium MS941 containing only the pSMF2.1 vector
showed low conversion of the investigated terpene substrates
4–10 after 2 h (data not shown), most probably due to the
activity of CYP109E1 encoded in the bacterial genome.
Interestingly, the formation of 3,4-dihydroxy-β-damascone
27 was observed in vivo (Fig. 4a), whereas no corresponding
peak (Fig. 4a, tR = 2.8 min) was detectable in vitro using the
reconstituted CYP109E1-based system (data not shown). For
further characterization, the in vivo conversion was monitored
over time. TheHPLC results showed significant changes in prod-
uct distribution within 4 h. After 1 h of conversion, 3,4-epoxy-β-
damascone 26 and 3,4-dihydroxy-β-damascone 27 were found
to be the major and minor products with 34 and 8% of total
shares, respectively. The amount of 3,4-dihydroxy-β-damascone
27 increased up to 45% after 4 h of conversion, and the increase
was correlated with a decrease of 3,4-epoxy-β-damascone 26
(Fig. 4b). Thus, the time-dependent data suggested that the dou-
ble hydroxylated product is formed from 3,4-epoxy-β-
damascone 26 by a CYP109E1-independent reaction.
Molecular docking
The crystal structure of CYP109E1 in its closed form was
used to investigate the enzyme-substrate interaction and ob-
served regioselectivity of hydroxylation for two of the nov-
el substrates, compactin 1 and α-ionone 4, by docking of
these structurally different substances into the active site of
CYP109E1. Both substrates appeared in docking positions
allowing hydroxylation at experimentally identified posi-
tions, C6′ (distance ~ 4.4 Å) for compactin 1 and C3
(distance ~ 4 Å) for α-ionone 4, respectively. Eight amino
acid residues including Ile85, Leu238, Ile241, Ala242,
Thr246, Ala291, Leu292, and His293 were found to form
the binding pocket of CYP109E1 with compactin 1 where-
as only six (Arg69, Ile85, Ala242, Val289, Leu292,
His293) were predicted to interact with the smaller sub-
strate α-ionone 4 (Fig. 5). The results predicted that both
substrates were bound by van der Waals forces and hydro-
phobic interactions. Active site residues with predicted hy-
drophobic interactions with both substrates are Ile85 (BC-
loop, SRS1), Ala242 (I-helix, SRS4), and Leu292 (K-β5-
loop, SRS5). Considering the electrostatic interactions with
the substrates, only His293 was predicted to form a hydro-
gen bond with compactin 1 and α-ionone 4 (Fig. 5).
Table 1 Binding of different compounds to CYP109E1
Compound Spin-state shift [%]a Kd [μM]
b
Compactin 17 84 ± 13
Lovastatin 11 9.6 ± 3.5
Simvastatin 43 4.7 ± 1.8
α-Ionone 51 178 ± 6
β-Ionone 23 91 ± 9
Nootkatone 22 129 ± 8
Isolongifolen-9-one 24 216 ± 18
α-Damascone 27 161 ± 8
β-Damascone 20 167 ± 7
β-Damascenone 17 154 ± 7
Medroxyprogesterone acetate – –
Norethisterone – –
Norethisterone acetate – –
Kd dissociation constant, − no spin-state shift observed
a Estimated to approximately ± 5%
bEstimated with a coefficient of determination (R2 ) ≥ 0.99
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Discussion
Various P450s from B. megaterium attract interest due to their
ability to perform the biotransformation of a broad spectrum of
highly interesting compounds such as steroids (Berg and Rafter
1981; Kiss et al. 2015; Putkaradze et al. 2017; Rauschenbach
et al. 1993), di- and triterpenes (Bleif et al. 2011; Brill et al. 2014;
Schmitz et al. 2014), as well as sesquiterpenes (Sowden et al.
2005), fatty acids, amides, and alcohols (Miura and Fulco 1975).
CYP109E1 is a newly identified member of this group, and
therefore, elucidation of its substrate range is of great interest.
During the initial study on CYP109E1, the crystal structure was
solved revealing a highly dynamic active site (Jóźwik et al.
2016). Phylogenetically, CYP109E1 was found to be related to
Fig. 2 HPLC chromatograms of in vitro (a, c, e) and in vivo (b, d, f)
conversion of statins 1–3. 14, 15, 16, and 17 represent products of
compactin 1, lovastatin 2, and simvastatin 3 conversion by CYP109E1,
respectively, which have been isolated and characterized. The minor
products are labeled with Bx^ (masses are provided in Table S1) and
impurities with asterisk
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the steroid hydroxylase CYP106A1 and, therefore, a focused
library of important steroids was tested as its potential substrates.
The study revealed that among the 13 tested steroidal com-
pounds, only testosterone was converted by CYP109E1
resulting in the corresponding 16β-hydroxy product (Jóźwik
et al. 2016). Another important compound which was recently
identified as substrate of CYP109E1 is the secosteroid vitamin
D3 (Abdulmughni et al. 2017). The enzyme showed 25- and 24-
hydroxylase activities towards vitamin D3 generating the valu-
able compound 25-hydroxy vitamin D3 and two new metabo-
lites hydroxylated at position C24(S) and C25 (Abdulmughni
et al. 2017).
In order to further characterize CYP109E1, we aimed to ex-
tend the substrate spectrum by investigating its activity towards a
focused library of biotechnologically valuable compounds. The
enzyme showed no activity for the three tested steroidal com-
pounds 11–13, whereas several statins 1–3 and terpenes 4–10
were successfully converted (Scheme 1). Compactin 1, lovastatin
2, and simvastatin 3, identified as novel substrates of CYP109E1
during our study, belong to the group of statins, effective phar-
maceutical agents widely used against lipid disorders. In several
studies, a broad range of pleiotropic effects of statins was also
described proposing their application for the treatment of inflam-
matory and neurological diseases as well as tumors (Gazzerro
et al. 2012). All three compoundswere able to shift the heme iron
of CYP109E1 into the high-spin state. Dissociation constants
determined by substrate titrations showed strongest binding for
simvastatin 3 to CYP109E1, with a Kd of 4.7 ± 1.8 μM com-
pared to 9.6 ± 3.5 μM and 84 ± 13 μM for lovastatin 2 and
compactin 1, respectively. Investigated statin compounds 1–3
were successfully converted by CYP109E1 into one main prod-
uct, and the activity of the P450 towards lovastatin 2 and simva-
statin 3 was higher than that towards compactin 1 using the
heterologous redox partners AdR and Adx4–108 (Fig. 2a, c, e).
The CYP109E1-based reactions were further investigated
in vivo in a mutant of B. megaterium DSM319, MS941, exten-
sively investigated by our group to generate pharmaceutically
important metabolites (Abdulmughni et al. 2017; Kiss et al.
Scheme 2 Chemical structures
of the statin conversion products
14–17 identified via NMR
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2015; Putkaradze et al. 2017). The observed product patterns of
statins in vitro and in vivo (Fig. 2) were very similar and allowed
us to scale up the whole-cell reactions to isolate sufficient
amounts of the main products for structure identification via
NMR spectroscopy. The data revealed that CYP109E1 hydrox-
ylates compactin 1 with a high stereoselectivity at the C6′ posi-
tion forming the biologically active form of the widely used
pharmaceutical pravastatin 14 and this way characterizing
CYP109E1 as a novel pravastatin synthase. To the best of our
knowledge, so far only two other non-mutated P450
monooxygenases are known being able to convert compactin 1
to active pravastatin variant. The CYP109E1-based whole-cell
system produced up to 14 mg/L pravastatin 14 after 4 h of bio-
transformation which is comparable to the previously described
Fig. 3 HPLC chromatograms of in vivo conversions of α-ionone 4 (a),
β-ionone 5 (b), nootkatone 6 (c), isolongifolen-9-one 7 (d),α-damascone
8 (e), and β-damascone 9 (f) with the identified products shown close to
the peaks. Masses of the minor products detected in vitro as well as
in vivo are provided in Table S1
8388 Appl Microbiol Biotechnol (2017) 101:8379–8393
82
E. coli systemswith P450sca-2 (12.9mg/Lwithin 21 h) (Ba et al.
2013) and CYP107DY1 (13.2 mg/L within 20 h) (Milhim et al.
2016) but provides much higher space-time yield. The activity of
this industrially relevant P450 system for pravastatin 14 produc-
tion might be further optimized by identification of a more effec-
tive redox chain, by more suitable production hosts, and by a
rational or semi-rational design of the enzyme (Ba et al. 2013;
McLean et al. 2015;Milhim et al. 2016). Moreover, to overcome
known limitations of cytochrome P450 whole-cell systems on
industrial scale, such as substrate solubility, toxicity, and uptake
from the cells, expression of CYP109E1 by compactin-
producing Penicillium chrysogenum similar to the expression
of P450Prava (McLean et al. 2015) might be promising. Besides
compactin 1, lovastatin 2 was also converted into the C6′β-hy-
droxylated product byCYP109E1while simvastatin 3was found
to be hydroxylated at the C3′α and C4″ positions (Scheme 2).
6′β-Hydroxy-lovastatin 15 and 3′α-hydroxy-simvastatin 16 are
human liver metabolites of the statin drugs formed by P450
enzymes, whereas 4″-hydroxy-simvastatin 17 is a synthetic drug
derivative. None of these compounds are commercially available
although they are highly required in larger quantities for activity
and safety studies, particularly due to the reported improved
pharmacokinetic properties of some statin metabolites (Kandel
et al. 2014) and the known drug-drug interactions of statin phar-
maceuticals (Kellick et al. 2014). There are few reports describ-
ing the generation of these metabolites, such as chemical
synthesis of 3′α-hydroxy-simvastatin 16, electrochemical oxida-
tion, and biotransformation of lovastatin 2 and simvastatin 3with
CYP3A4 or CYP102A1 mutants (Khera and Hu 2013; Kim
et al. 2011; Stokker 1994). However, CYP109E1 seems to be a
perfect candidate for the production of these metabolites through
mild and cost-effective biocatalysis with much higher selectiv-
ities and higher product yields compared to previously
established methods. Moreover, CYP109E1 represents the first
enzyme that is able to introduce a hydroxyl group at the C4″
position into the simvastatin molecule.
In addition to statins 1–3, seven terpene compounds 4–10
were identified as novel substrates of CYP109E1 and their bio-
transformation was further investigated. Terpene and terpenoid
hydroxylation and epoxidation bymicrobial P450 enzymes have
been reported in the literature (Çelik et al. 2005; Hall and Bell
2014; Litzenburger and Bernhardt 2016; Schifrin et al. 2015).
However, the high demand of valuable terpene derivatives and
their mostly unselective and low-yield production via chemical
synthesis makes exploration of new effective biocatalysts for
terpene oxyfunctionalization highly important. Here, α-ionone
4,β-ionone 5,α-damascone 8,β-damascone 9,β-damascenone
10, nootkatone 6, and isolongifolen-9-one 7were found to serve
as substrates for CYP109E1 identifying this P450 as a novel
terpene hydroxylase and epoxidase. All compounds were able
to bind to the enzyme and induce a type I difference spectrum of
CYP109E1. Concerning dissociation constants, terpenes 4–10
Fig. 4 HPLC chromatogram of
β-damascenone 10 conversion by
the B. megateriumMS941 cells
overexpressing CYP109E1 (a)
and time-dependent in vivo con-
version within 4 h (b). The minor
products are labeled with Bx^
(masses are provided in Table S1)
and impurities with asterisk
Fig. 5 Docking orientations of
compactin 1 (a) and α-ionone 4
(b) shown in yellow in the active
site of CYP109E1 capable of hy-
droxylation at C6′ and C3, re-
spectively. The distance of the
corresponding carbon atom from
the heme iron is given in ang-
strom. Amino acids forming the
active site in the presence of each
substrate are shown and named
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showed weaker binding to the active site of CYP109E1 than
statin substrates 1–3. However, they have been converted by
CYP109E1 with high efficiencies and regioselectivities in vitro
as well as in vivo. The reaction products of α-ionone 4,
β-ionone 5,α-damascone 8, andβ-damascone 9were identified
as 3-hydroxy-α-ionone 18, 4-hydroxy-β-ionone 19, 3-
hydroxy-α-damascone 23, and 4-hydroxy-β-damascone 24, re-
spectively. Thus, CYP109E1 hydroxylates preferably at allylic
positions which are energetically favorable and also preferred by
other P450s converting these compounds (Çelik et al. 2005; Hall
and Bell 2014; Khatri et al. 2010; Litzenburger and Bernhardt
2016). The resulting hydroxylated ionones and damascones are
important compounds which might be used as precursors or
building blocks in chemical synthesis of fragrance constituents
due to their floral and fruity scents as well as in bioassays due to
their bioactive properties. For example, the 4-hydroxy derivative
of β-ionone 5 has been reported to be a versatile synthon (More
and Bhat 2013) whereas 4-hydroxy-β-damascone 24was found
to possess very strong antifeedant properties against lesser meal-
worm Alphitobius diaperinus (Gliszczyńska et al. 2016). The
CYP109E1-based B. megaterium system used in our study is
very suitable for the production of thesemetabolites. To compare
it with the previously established P450-based production sys-
tems, whole-cell experiments using higher substrate concentra-
tions and longer incubation times are necessary. However, based
on the observed fast conversion of up to 200 μM substrate
within 2 h under non-optimized conditions, the whole-cell sys-
tem used in our study seems to be efficient for the production of
these valuable metabolites. The NMR data of nootkatone 6 and
β-damascenone 10 conversion products revealed for the first
time the epoxidation activity of CYP109E1 resulting in the for-
mation of 11(R),12-epoxy-nootkatone 20, 11(S),12-epoxy-
nootkatone 21, and 3,4-epoxy-β-damascone 26, respectively.
3,4-Epoxy-β-damascone 26 has been previously reported to be
a conversion product of β-damascone 9 by CYP101C1 from
N. aromaticivorans DSM12444 (Ma et al. 2011), whereas
11,12-epoxy-nootkatone has been described to be produced by
CYP102A1 mutants as well as unknown fungal proteins. It
showed antiproliferative activity against leukemia cell line HL-
60 (Gliszczyńska et al. 2011; Sowden et al. 2005). In our studies,
3,4-epoxy-β-damascone 26 was further metabolized in vivo to
3,4-dihydroxy-β-damascone 27 by a CYP109E1-independent
reaction proposed to be catalyzed by an unknown epoxide hy-
drolase from the DSM319 as described for other B. megaterium
strains (Michaels et al. 1980; Tang et al. 2001; Zhang et al.
2010). Besides 3,4-epoxy-β-damascone 26, a novel compound,
2-hydroxy-β-damascenone 25, was identified as conversion
product of CYP109E1. Its properties are unknown and need to
be investigated. Isolongifolen-9-one 7 was hydroxylated regio-
and stereoselectively at C4 by CYP109E1 yielding 4(R)-hy-
droxy-isolongofilen-9-one 22. This compound has been de-
scribed in the literature as conversion product of isolongifolen-
9-one 7 by four fungal cultures, and it has been shown to have an
inhibitory activity on tyrosinase, the key enzyme for melanin
biosynthesis (Choudhary et al. 2003). In another study, the sup-
pressive effect of 4(R)-hydroxy-isolongofilen-9-one 22 against
chemical mutagen-induced SOS response in Salmonella
typhimurium TA1535/pSK1002 has been reported (Sakata
et al. 2010).
In addition to the in vitro and in vivo characterization of
CYP109E1, in silico experiments were performed using the
crystal structure of this enzyme in order to predict residues re-
sponsible for substrate binding and to understand the structural
basis of the observed hydroxylation regioselectivity. The molec-
ular docking of the two selected structurally different novel sub-
strates, compactin 1 and α-ionone 4, into CYP109E1 indicated
the presence of common as well as specific residues interacting
with each substrate. The obtained docking orientations of these
substrates in the active site supported experimental results, 6′β-
hydroxylation of compactin 1 and 3-hydroxylation in the cyclo-
hexene ring of α-ionone 4 (Fig. 5).
Taken together, we were able to characterize CYP109E1
from B. megaterium for the first time as a novel and highly
regioselective statin and terpene hydroxylase as well as ter-
pene epoxidase. Thus, CYP109E1 might be used to generate
pharmaceutically and biotechnologically interesting com-
pounds, such as the drug pravastatin 14 and the human statin
drug metabolites 6′β-hydroxy-lovastatin 15 and 3′α-hydroxy-
simvastatin 16 as well as several valuable terpene derivatives.
Besides that, 4″-hydroxy-simvastatin 17 and a novel com-
pound, 2-hydroxy-β-damascenone 25, were obtained using
CYP109E1 as biocatalyst, and are now available for further
investigations. Finally, our B. megaterium whole-cell system
was successfully utilized for the production of the statin and
terpene metabolites in milligram scale. The established
CYP109E1 system is a good candidate for improvement to-
wards industrial scale.
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Fig. S1 The absorbance changes plotted against the corresponding concentrations of lovastatin 2 (a), 
simvastatin 3 (b), β-ionone 5 (c), nootkatone 6 (d), isolongifolen-9-one 7 (e), α-damascone 8 (f), β-
damascone 9 (g) and β-damascenone 10 (h) titrated to CYP109E1 as described in ’’Material and 
methods’’. The mean values were fitted by either tight binding equation or hyperbolic regression and the 
Kd value was calculated. The inset shows type I spectral shifts induced by the binding of the increasing 
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amount of the substrate to CYP109E1. Arrows show the direction of spectral changes at increasing 
substrate concentrations 
 
 
 
 
 
 
 
Fig. S2 Conversion ratio of 100 µM compactin 1, lovastatin 2 and simvastatin 3 and 200 µM of other 
substrates 4-10 after 15 min in vitro in the presence of CYP109E1 using AdR and Adx4-108 as redox 
partners 
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Fig. S3 GC-MS data of the α-ionone 4 conversion product by CYP109E1 (a and b) and by CYP267B1 (c 
and d) identified as 3-hydroxy-α-ionone 18 (Litzenburger et al. 2016). 1-5 are the minor products with 
known masses (Table S1) 
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Fig. S4 GC-MS data of the β-ionone 5 conversion product by CYP109E1 (a and b) and by CYP267B1 (c 
and d) identified as 4-hydroxy-β-ionone 19 (Litzenburger et al. 2016). 1-5 are the minor products with 
known masses (Table S1) 
   
 
92
6 
 
 
Fig. S5 GC-MS data of the α-damascone 8 conversion product by CYP109E1 (a and b) and by 
CYP267B1 (c and d) identified as 3-hydroxy-α-damascone 23 (Litzenburger et al. 2016). 1-5 are the 
minor products with known masses (Table S1). Impurity is labelled with “*” 
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Fig. S6 GC-MS data of the β-damascone 9 conversion product by CYP109E1 (a and b) and by 
CYP267B1 (c and d) identified as 4-hydroxy-β-damascone 24 (Litzenburger et al. 2016). 1-4 are the 
minor products with known masses (Table S1). Impurity is labelled with “*”  
Table S1 Selectivity of the CYP109E1-catalyzed reactions in vitro and masses of the reaction products. 
Minor products are numbered and labelled. “*” indicates impurities 
Compound  product tR 
[min] 
Δm/z Selectivity 
[%] 
 
 
 
 
α-ionone 
 
 
 
 
1 13.5 +16 1.1 
2 13.6 +16 5.2 
3 13.9 +14 6.2 
4 14.1 +16 1.4 
5 14.4 +16 1.1 
3-hydroxy-α-ionone 13.7  +16 85 
 
94
8 
 
 
 
 
 
β-ionone 
 
 
 
1 13.0 +16 0.6 
2 13.7 +16 0.7 
3 13.9 +16 2.6 
4 14.4 +16 1.3 
5 14.5 +16 10.2 
4-hydroxy-β-ionone 14.2 +16 84.5 
 
 
 
 
 
 
 
 
 
 
α-damascone 
 
 
 
 
 
1 12.8 +16 3.6 
2 13.0 +16 7.4 
3 13.6 +16 0.6 
4 13.7 +14 2.1 
5 13.9 +16 0.8 
3-hydroxy-α-damascone 13.3 +16 85.4 
 
 
 
 
 
 
 
 
 
 
 
 
β-damascone 
 
 
 
 
 
1 13.0 +16 1.6 
2 13.2 +14 2.7 
3 13.5 +16 0.4 
4 13.6 +16 2.4 
4-hydroxy-β-damascone 13.3 +16 92.8 
 
 
 
 
compactin 
 
 
 
 
 
1 10.6 +16 23 
pravastatin 8.9 +16 77 
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lovastatin 
 
 
 
 
 
 
 
 
 
1 9.1 +16 6 
6’β-hydroxy-lovastatin 9.8 +16 94 
 
 
 
 
 
 
 
 
 
 
 
 
simvastatin 
 
 
 
1 13.3 +16 4.7 
2 14.4 +16 5 
3 14.6 +14 3 
3’α-hydroxy-simvastatin 13.8 +16 23 
4’’-hydroxy-simvastatin 15.2 +16 64 
 
 
 
 
nootkatone 
 
 
 
1 5.2 +16 1.2 
2 5.9 +16 6.2 
11,12-epoxy-nootkatone 7.4 +16 92.6 
 
 
 
 
 
 
isolongifolen-9-one 
 
 
 
1 6.3 +16 6.5 
2 6.4 +16 10.6 
3 6.6 +16 4.4 
4 8.1 +14 1.3 
4(R)-hydroxy-
isolongifolen-9-one 
5.3 +16 77.2 
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β-damascenone 
 
 
1 3.8 +32 1.6 
2 4.1 +32 0.8 
3 4.4 +32 2 
4 4.5 +32 3 
5 5.3 +18 1.6 
6 5.9 +14 0.5 
7 6.6 +16 3 
8 7.7 +16 3.6 
2-hydroxy-β-
damascenone 
6.4 +16 35.3 
3,4-epoxy β-damascone 8.7 +16 48.7 
 
 
Data S7: NMR data of investigated compounds 
3,4-dihydroxy-β-damascone 27: 1H NMR (CDCl3, 500 MHz): 6.74 (dq, 1H, J= 15.8, 6.9 Hz, H9), 6.13 
(dq, 1H, J= 15.8, 1.6 Hz, H8), 3.94 (d, 1H, J= 7.9 Hz, H4), 3.87 (ddd, 1H, J= 12.2, 8.1, 3.8 Hz, H3), 1.91 
(dd, 3H, J= 6.9, 1.6 Hz, H10), 1.74-1.63 (m, 2H, H2a and H2b), 1.60 (d, 3H, J= 1.0 Hz, C5-Me), 1.17 (s, 
3H, C1-Me), 0.96 (s, 3H, C1-Me); 
13
C NMR (CDCl3, 125 MHz): 200.23 (C7), 146.77 (C9), 142.14 (C6), 
133.81 (C8), 129.89 (C5), 76.88 (C4), 71.08 (C3), 44.88 (C2), 36.15 (C1), 29.85 (C1-Me), 28.70 (C1-
Me), 18.46 (C10), 15.88 (C5-Me).  
 
2-hydroxy-β-damascenone 25: 1H NMR (CDCl3, 500 MHz): 6.81 (dq, 1H, J= 15.7, 6.9 Hz, H9), 6.17 
(dq, 1H, J= 15.7, 1.6 Hz, H8), 5.97 (dd, 1H, J= 9.5 Hz, 4.7 Hz, H3), 5.87 (d, 1H, J= 9.5 Hz, H4), 3.80 (d, 
1H, J= 4.8 Hz, H2), 1.92 (dd, 3H, J= 6.9 Hz, 1.6 Hz, H10), 1.65 (s, 3H, C5-Me), 1.08 (s, 6H, C1-Me 
(2x)); 
13
C NMR (CDCl3, 125 MHz): 200.34 (C7), 146.98 (C9), 140.05 (C6), 134.28 (C8), 129.15 (C3), 
129.06 (C4), 126.80 (C5), 73.79 (H2), 39.21 (C1), 24.69 (C1-Me), 19.37 (C1-Me), 19.24 (C5-Me), 18.93 
(C10). 
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3,4-epoxy β-damascone 26: 1H NMR (CDCl3, 500 MHz): 6.73 (dq, 1H, J= 15.7, 6.9 Hz, H9), 6.13 (dq, 
1H, J= 15.7, 1.6 Hz, H8), 3.50 (ddd, J=6.6, 4.3, 2.3 Hz, H3), 3.13 (d, 1H, J= 4.3 Hz, H4), 1.98 (dd, J= 
14.6, 2.5 Hz, 1H, H2a),  1.91 (dd, 3H, J= 7.0, 1.5 Hz, H10), 1.74-1.63 (m, 1H, H2b), 1.61 (d, 3H, J= 1.0 
Hz, C5-Me), 1.16 (s, 3H, C1-Me), 0.96 (s, 3H, C1-Me); 
13
C NMR (CDCl3, 125 MHz): 200.14 (C7), 
147.59 (C9), 144.74 (C6), 133.89 (C8), 127.03 (C5), 54.24 (C4), 51.20 (C3), 37.90 (C2), 33.95 (C1), 
32.12 (C1-Me), 29.55 (C1-Me), 19.83 (C10), 18.50 (C5-Me).  
 
Pravastatin 14: 
1
H NMR (500 MHz, CDCl3): 5.98 (d, 1H, J=9.7 Hz, H4’), 5.87 (dd, 1H, J= 9.7, 5.9 Hz, 
H3’), 5.55 (br s, 1H, H5’), 5.39 (br s, 1H, H8’), 4.62-4.56 (m, 1H, H6), 4.42-4.34 (m, 2H, H6’, H4), 2.72 
(dd, 1H, J= 17.6, 5.1 Hz, H3a), 2.60 (ddd, J= 17.6, 3.7, 1.6 Hz, H3b), 2.55 (m, 1H, H7), 2.40-2.30 (m, 3H, 
H2’, H8’a, H2’’), 1.93-1.90 (m, 1H, H5a), 1.85 (m, 1H, H7a), 1.70-1.62 (m, 3H, H1’, H5b, H3’’a), 1.44-
1.37 (m, 3H, H8, H3’’b), 1.28-1.24 (m, 1H, H7b), 1.09 (d, 3H, J=7.0 Hz, C2’’-Me), 0.88 (d, 3H, J= 7.0 
Hz, C2’-Me), 0.87 (t, 3H, J=7.4 Hz, H4’’); 13C NMR (125 MHz, CDCl3): 176.29 (C1’’), 169.94 (C2), 
135.79 (C3’), 135.29 (C4’a), 127.39 (C4’), 126.12 (C5’), 75.93 (C6), 69.04 (C8’), 65.04 (C6’), 62.75 
(C4), 41.58 (C2’’), 38.59 (C3), 37.60 (C8’a), 36.69 (C7’), 36.60 (C1’), 36.18 (C5), 32.75 (C7), 30.95 
(C2’), 26.64 (C3’’), 23.76 (C8), 16.80 (C2’’-Me), 13.56 (C2’-Me), 11.76 (C4’’). 
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6’β-hydroxy-lovastatin 15: 1H NMR (500 MHz, CDCl3): 5.96 (d, 1H, J= 10.0 Hz, H4’), 5.89 (dd, 1H, J= 
10.0, 6.1 Hz, H3’), 5.43 (br s, 1H, H5’), 5.39 (m, 1H, H8’), 4.62-4.55 (m, 1H, H6’), 4.37-4.32 (m, 1H, 
H4), 2.70 (dd, 1H, J= 17.6, 5.1 Hz, H3a), 2.60 (ddd, 1H, J= 17.6, 3.8, 1.7 Hz, H3b), 2.42-2.29 (m, 5H, 
H7’, H2’, H8’a, H2’’), 1.96-1.80 (m, 2H, H5a, H7a), 1.70-1.60 (m, 3H, H1’, H5b, H3’’a), 1.44-1.38 (m, 
3H, H8, H3’’b), 1.32 (s, 3H, C6’-Me), 1.29-1.24 (m, 1H, H7b), 1.10 (d, 3H, J=6.9 Hz, C2’’-Me), 0.87 (d, 
3H, J= 7.2 Hz, C2’-Me), 0.86 (t, 3H, J=7.4 Hz, H4’’); 13C NMR (125 MHz, CDCl3): 176.41 (C1’’), 
170.12 (C2), 135.88 (C3’), 133.48 (C4’a), 129.64 (C5’), 127.58 (C4’), 76.05 (C6), 68.92 (C8’a), 68.77 
(C6’), 62.71 (C4), 42.18 (C7’), 41.41 (C2’’), 38.54 (C3), 37.41 (C8’a), 36.34 (C5), 36.17 (C6), 32.69 
(C7), 30.75 (C6’-Me), 30.55 (C2’), 26.82 (C3’’), 24.00 (C8), 16.25 (C2’’-Me),  13.55 (C2’-Me), 11.71 
(C4’’).  
 
3’α-hydroxy-simvastatin 16: 1H NMR (500 MHz, CDCl3): 5.87 (s, 1H, H5’), 5.60 (d, 1H, J= 4.7 Hz, 
H4’), 5.37 (d, 1H, J=2.6 Hz, H8’), 4.67-4.60 (m, 1H, H6), 4.38-4.34 (m, 1H, H4), 3.92 (d, 1H, J= 4.7 Hz, 
H3’), 2.72 (dd, 1H, J= 17.6, 5.1 Hz, H3a), 2.60 (ddd, 1H, J= 17.6, 3.8, 1.6 Hz, H3b), 2.38 (d, 1H, J= 17.1 
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Hz, H7’a), 2.21 (dd, 1H, J= 18.9, 1.9 Hz, H7’b), 2.02-1.91 (m, 3H, H5a, H2’ H8’a), 1.80-1.65 (m, 4H, 
H5b, H1’, H8a, H7a), 1.71 (s, 3H, C6’-Me), 1.54-1.44 (m, 4H, H7b, H8b, H3’’), 1.07 (s, 3H, C2’’-Me), 
1.06 (s, 3H, C2’’-Me), 0.76 (t, 3H, J=7.5 Hz, C4’’), 0.74 (d, 3H, J=7.2 Hz, C2’-Me); 13C NMR (125 
MHz, CDCl3): 177.75 (C1’’), 170.24 (C2), 137.52 (C6’), 134.06 (C4’a), 124.24 (C5’), 122.38 (C4’), 
76.12 (C6), 70.11 (C3’), 67.46 (C8’), 62.76 (C4), 42.93 (C2’’), 39.69 (C8’a), 38.58 (C3), 36.37 (C5), 
36.33 (C7’), 35.48 (C2’), 33.23 (C7), 33.19 (C3’’), 31.33 (C1’), 24.93 (C2’’-Me), 24.93 (C8) 24.38 
(C2’’-Me), 23.29 (C6’-Me), 10.57 (C2’-Me), 9.26 (C4’’). 
 
4’’-hydroxy-simvastatin 17: 1H NMR (500 MHz, CDCl3): 5.97 (d, 1H, J= 9.7 Hz, H4’), 5.76 (dd, 1H, J= 
9.6, 6.1 Hz, H3’), 5.49 (br s, 1H, H5’), 5.33 (q, 1H, J= 3.3, 2.9 Hz, H8’), 4.65-4.59 (m, 1H, H6), 4.33-
4.30 (m, 1H, H4), 3.70-3.65 (m, 1H, H4’’), 3.64- 3.59 (m, 1H, H4’’), 2.74 (dd, 1H, J= 17.7, 5.4 Hz, 
H3a),2.58 (ddd, 1H, J=17.7, 4.1, 1.5 Hz, H3b), 2.43-2.39 (m, 1H, H6’), 2.37-2.32 (m, 1H, H2’), 2.25 (dd, 
1H, J= 11.8, 2.6 Hz, H8’a), 1.98-1.89 (m, 4H, H7’, H5a, H3’’a), 1.96-1.89 (m, 1H, H7a), 1.79-1.66 (m, 
3H, H5b , H1’, H3’’b), 1.48 -1.39 (m, 1H, H8a), 1.38-1.34 (m, 2 H, H8b, H7b), 1.18 (s, 3H, C2’’-Me), 
1.16 (s, 3H, C2’’-Me), 1.06 (d, 3H, J= 7.4 Hz, C6’-Me), 0.86 (d, 3H, J= 7.0, C2’-Me); 13C NMR (125 
MHz, CDCl3): 178.58 (C1’’), 170.64 (C2), 132.93 (C3’), 131.39 (C4’a), 129.62 (C5’), 128.32 (C4’), 
76.29 (C6), 68.87 (C8’), 62.44 (C4), 59.42 (C4’’), 42.54 (C3’’), 41.53 (C2’’), 38.46 (C3), 37.39 (C8’a), 
36.88 (C1’), 35.88 (C5), 32.59 (C7’), 32.56 (C7), 30.61 (C2’), 27.23 (C6’), 26.23 (C2’’-Me), 24.93 (C2’’-
Me), 24.19 (C8), 23.08 (C6’-Me), 13.81 (C2’-Me). 
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4(R)-hydroxy-isolongifolen-9-one 22: 
1
H NMR (CDCl3, 500 MHz): 5.70 (s, 1H, H10), 4.31 (brd, 1H, 
J=6.6 Hz, H4), 2.31 (d, 1H, J= 16.2 Hz, H8a), 2.06 (dd, 1H, J= 16.2, 0.8 Hz, H8b), 1.95 (brs, 1H, H3), 
1.80 (ddd, 1H, J= 13.0, 6.6, 2.6 Hz, H5a), 1.73 (ddd, 1H, J= 13.0, 2.1, 1.0 Hz, H5b), 1.59 (m, 2H, H11), 
1.11 (s, 3H, C2-Me), 1.09 (s, 3H, C2-Me), 1.06 (s, 3H, C7-Me), 0.97 (s, 3H, C7-Me); 
13
C NMR (CDCl3, 
125 MHz): 199.81 (C9), 181.71 (C1), 117.58 (C10), 70.30 (C4), 57.96 (C6), 54.42 (C3), 49.81 (C8), 
42.10 (C2), 40.16 (C5), 34.10 (C7), 32.82 (C11), 27.20 (C2-Me), 25.90 (C7-Me), 25.28 (C7-Me), 24.25 
(C2-Me). 
 
11(R), 12-epoxy-nootkatone 20: 
1
H NMR (CDCl3, 500 MHz): 5.73 (brs, 1H, H1), 2.62 (m, 1H, H12a), 
2.56 (m, 1H, H12b), 2.42 (m, 1H, H9a), 2.35 (m, 1H, H9b), 2.23 (m, 2H, H3), 2.02 (m, 1H, H6a), 1.99 
(m, 1H, H7), 1.88 (m, 1H, H8a), 1.60 (m, 1H, H4), 1.22 (m, 1H, H8b), 1.22 (s, 3H, H13), 1.10 (m, 1H, 
H6b), 1.04 (s, 3H, C5-Me), 0.96 (d, 3H, J=6.7 Hz, C4-Me); 
13
C NMR (CDCl3, 125 MHz): 199.50 (C2), 
168.80 (C10), 124.87 (C1), 58.91 (C11), 53.33 (C12), 42.01 (C3), 40.50 (C7), 40.43 (C6), 39.60 (C4) 
39.01 (C5), 32.43 (C9), 28.79 (C8), 17.73 (C13), 16.74 (C5-Me), 14.89 (C4-Me). 
11(S), 12-epoxy-nootkatone 21: 
1
H NMR (CDCl3, 500 MHz): 5.73 (brs, 1H, H1), 2.63 (m, 1H, H12a), 
2.57 (m, 1H, H12b), 2.42 (m, 1H, H9a), 2.35 (m, 1H, H9b), 2.23 (m, 2H, H3), 1.99 (m, 1H, H7), 1.97 (m, 
1H, H8a), 1.90 (m, 1H, H6a), 1.58 (m, 1H, H4), 1.29 (m, 1H, H8b), 1.24 (s, 3H, H13), 1.04 (s, 3H, C5-
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Me), 1.00 (m, 1H, H6b), 0.94 (d, 3H, J=6.7 Hz, C4-Me); 
13
C NMR (CDCl3, 125 MHz): 199.40 (C2), 
168.87 (C10), 124.87 (C1), 59.13 (C11), 53.65 (C12), 42.01 (C3), 40.74 (C6), 40.44 (C7), 39.42 (C4) 
38.97 (C5), 32.38 (C9), 28.37 (C8), 18.04 (C13), 16.74 (C5-Me), 14.89 (C4-Me). 
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3. General discussion  
Cytochrome P450 enzymes (P450) are present in all domains of life (Nelson, 2011). They 
are involved in important metabolic processes, including biosynthesis of steroids and fatty 
acids, drug metabolism and detoxification (Bernhardt, 2006). In recent years, there has been 
recognition of the P450s potential for the industrial production of bulk chemicals and 
pharmaceuticals. Therefore, there is an increasing interest in the identification, 
characterization and optimization of P450 enzymes in order to use them for industrial 
applications. Previously, the genome of Bacillus megaterium strain DSM319 was 
sequenced. This strain has a 5.1 Mbp genome with 5300 open reading frames (Eppinger et 
al., 2011). Besides the well-studied CYP102A1 (BM3), three genes encoding for 
cytochrome P450 enzymes have been reported (CYP106A2, CYP109E1 and CYP109A2) 
(Eppinger et al., 2011; Brill et al., 2014). The focus of the present work lies on CYP109E1 
and CYP109A2. 
Concerning the substrate spectrum of CYP109E1 and CYP109A2, it has been previously 
shown that testosterone and nootkatone are converted by CYP109E1 (Brill, 2013). In 
addition, the catalytic activity towards vitamin D3 was described for both enzymes (Brill, 
2013). The substrate spectrum of these P450s has been further extended in this work. As 
described in publication 2.4, CYP109E1 shows a catalytic activity towards statins 
(compactin, lovastatin and simvastatin) and terpenes (α- and β-ionone, isolongifolen-9-one 
as well as α- and β- damascone), producing pharmaceutically interesting compounds, such 
as the LDL-cholesterol-lowering drug pravastatin and different statin drug metabolites as 
well as valuable terpene derivatives (Putkaradze et al., 2017).  In addition, the potential of 
CYP109A2 as steroid hydroxylase has been investigated. In an in vitro reconstituted system 
containing CYP109A2, diflavin reductase (BmCPR) and ferredoxin (Fdx2), the substrate 
testosterone was converted into one major (P2) and two minor products (P1 and P3) (Fig. 
S1). The product profile of CYP109A2-dependent testosterone conversion is comparable to 
that of CYP109E1, showing identical retention times of the major product (P2) and one of 
the minor products (P3), that have been previously identified by NMR spectroscopy as 16β-
hydroxytestosterone and androstenedione (publication 2.3), respectively. However, the 
formation of P1 was not detectable in case of CYP109E1 reaction (Fig. S1).  
Among the identified substrates for both enzymes, our focus was on vitamin D3. Vitamin D3 
plays a substantial role in human health and, therefore, a variety of diseases are associated 
with vitamin D3 deficiency. Because of that, vitamin D3 is used for the treatment of different 
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health issues, such as chronic renal failure, different cancers, diabetes and neuromuscular 
dysfunction. The pharmaceutical relevance of vitamin D3 is based on its active metabolites, 
where the most active metabolite is a hydroxylated metaboilte at C-25 and C-1 (1α,25-
dihydroxyvitamin D3). The chemical synthesis of hydroxylated vitamin D3 is a challenging, 
multistep procedure with low yields (Kametani and Furuyama, 1987), limiting their 
application in industrial production and, therefore, there is extraordinary interest in 
biotechnological production of vitamin D3 hydroxylated products. 
The usage of mammalian vitamin D3 hydroxylases in biotechnological production is limited 
due to their membrane-binding nature, low activity and expression level as well as their 
instability (Kumar, 2010). Therefore, there is a great interest in bacterial vitamin D3 
hydroxylases. Nevertheless, only a few bacterial P450 enzymes are employed in the 
bioconversion of vitamin D3 (Sakaki et al., 2011). The most investigated bacterial P450s 
acting as vitamin D3 hydroxylase are CYP105A1 form Streptomyces griseolus (Sawada et 
al., 2004) and CYP107 (known as Vdh) from Pseudonocardia autotrophica (Fujii et al., 
2009). The results of this work extend the tool box of bacterial vitamin D3 hydroxylases by a 
new P450 family, namely CYP109 family. Using protein engineering, the yield of specific 
products has been further optimized, in particular 25(OH)VD3. In the next sections, the 
potential of CYP109E1 and CYP109A2 as vitamin D3 hydroxylase is discussed and 
compared with that of the most investigated bacterial P450 vitamin D3 hydroxylases, 
CYP105A1 and CYP107.       
3.1 Bioconversion of vitamin D3 by CYP109E1 and CYP109A2 
It has been found that both enzymes have similar Km values, indicating their similar affinity 
for vitamin D3. Through comparison with the known bacterial vitamin D3 hydroxylase 
(CYP105A1 and Vdh), it becomes clear that CYP109E1 and CYP109A2 have a rather low 
affinity to vitamin D3 (Table 3.1). On the other hand, the two CYP109 enzymes showed a 
higher turnover number (kcat), in particular CYP109E1, compared to CYP105A1 and Vdh. 
As a result, the catalytic efficiencies (kcat /Km) of CYP109 enzymes towards vitamin D3 
conversion are significantly higher in comparison to CYP105A2 or Vdh (Table 3.1), 
demonstrating the potential of these two P450s as vitamin D3 hydroxylase. 
In terms of the regio-selectivity, our results demonstrate the superiority of CYP109A2 over 
CYP109E1. It has been shown that CYP109A2 converts vitamin D3 into two products; the 
metabolite 25(OH)VD3 (90%) and one minor product (10%) (publication 2.2). On the other 
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hand, the product profile of CYP109E1-dependent vitamin D3 conversion consists of seven 
different products (publication 2.1). Among the other known bacterial vitamin D3 
hydroxylase (CYP105A1 and CYP107), CYP109A2 shows the highest regio-selectivity 
towards vitamin D3 25-hydroxylation, demonstrating the advantage of this enzyme to act as 
a vitamin D3 25-hydroxylase in biotechnological processes.  
By analyzing the product profile of CYP109E1, we were able to confirm the hydroxylation 
of vitamin D3 at C-24 and C-25, resulting in the formation of 24S(OH)VD3 and 25(OH)VD3 
(publication 2.1). Furthermore, it was shown that 24S(OH)VD3 is produced during the 
reaction as intermediate, which is further converted by CYP109E1 to produce 
24S,25(OH)2VD3, confirming the 25-hydroxylation activity of CYP109E1 towards vitamin 
D3 as well as 24S(OH)VD3. To the best of our knowledge the formation of 24S,25(OH)2VD3 
from vitamin D3 via 24S(OH)VD3  is a novel pathway.  
 
  Table 3.1. Kinetic parameters of known bacterial vitamin D3 hydroxylase. 
 
Although the reactions catalyzed by P450s are diverse, their application for commercial 
purposes is still limited due to some properties of these enzymes (Bernhardt, 2006; 
Bernhardt and Urlacher, 2014). The reaction cycle of P450s is dependent on an equimolar 
amount of the expensive cofactor NAD(P)H and electron carrier proteins. This limitation 
can be overcome by using of whole-cell systems. 
Since many decades, Bacillus megaterium has been used in industrial processes. Many of its 
industrial applications have been reviewed in detail (Vary, 1992, 1994). It offers a great 
potential as a source and expression host (Vary et al., 2007). In contrast to E. coli, B. 
megaterium does not produce endotoxins and, therefore, is a safe host for applications in the 
pharmaceutical and food industry. In addition, the ability of B. megaterium cells to 
metabolize various cheap carbon sources and to maintain the stability of recombinant 
CPY Km [µM] kcat  [min
-1
] kcat /Km Reference 
CYP109E1 45.3 23 0.5 (Brill, 2013) 
CYP109A2 49 3.4 0.06 Publication 2.2 
CYP105A1 0.54 0.016 0.029 (Sawada et al., 2004) 
CYP107 
(Vdh) 
13.5 0.29 0.021 (Fujii et al., 2009) 
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plasmids make them of great interest for biotechnological processes (Biedendieck, 2016; 
Stammen et al., 2010). Previously, a whole-cell system in B. megaterium has been used in 
our laboratory for the bioconversion of steroid hormones and valuable pharmaceuticals 
(Bleif et al., 2012; Brill et al., 2014; Ehrhardt et al., 2016; Kiss et al., 2015). In this work, the 
whole-cell conversions were performed using B. megaterium MS941.  
 
The obtained results show clearly that CYP109A2-based whole-cell system using B. 
megaterium is an efficient route for the production of 25(OH)VD3 in comparison to other 
known P450-based whole-cell systems (Table 3.2). In the literature, only Vdh expressed in 
P. autotrophica was reported to provide a higher 25(OH)VD3 yield than CYP109A2 being 
137 mg/L. However, it should be noted that this value was obtained after 72 h, whereas in 
case of CYP109A2, 54.9 mg/L were obtained already after 24 h. A comparable yield to that 
of CYP109A2 was obtained using CYP109E1 mutants, I85A or I85W (Table 3.2). More 
details about these mutants are given in section ’Engineering of CYP109E1’. CYP109E1-
based system, in addition, offers the opportunity to produce high amounts of the natural 
product 24S,25(OH)2VD3 (28.6 mg/L/day). Although the biological activity of 
24(S),25(OH)2VD3 is, in general, significantly below that of its isomer 24R,25(OH)2VD3 
(Kato et al., 1998), its utility as an antitumor agent is patented by Kureha Chemical Industry 
CO (Seino et al., 1997). In this context, the production of this metabolite using CYP109E1-
based system could be of great interest for the pharmaceutical industry. In addition, the 
V169A- and I241A-based systems showed an optimization in the production of 
24S(OH)VD3, producing 23 and 25 mg/L/day, respectively (see publication 2.1). It should 
be noted that 24S(OH)VD3 can be used as precursor for different active vitamin D3 
metabolites such as 20S,24S(OH)2VD3 and 1α,20S,24S(OH)3VD3, which exhibit a 
therapeutic potential as antiproliferative agents (Lin et al., 2015). 
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     Table 3.2. The yield of 25(OH)VD3 achieved by different P450-based whole-cell systems. 
 
Despite the promising results obtained with the whole-cell systems presented in this work, 
further optimization can be obtained. It should be noticed that no heterologous redox 
partners were co-expressed with the P450s in B. megaterium, leaving only the so far 
unknown endogenous B. megaterium redox proteins to support the activity of CYP109E1 
and CYP109A2 (and their mutants). Co-expression of redox partners has been previously 
shown to increase the production of hydrocortisone in CYP11B1 expressing fission yeast 
Schizosaccharomyces pombe (Hakki et al., 2008).  
CYP Source Expression Yield of  
25(OH)VD3 
[mg/L] 
Reaction 
time [h] 
Ref. 
CYP109A2 B. 
megaterium 
B. 
megaterium 
54.9 24 Publication 
2.2 
CYP109E1 B. 
megaterium 
B. 
megaterium 
24.5 24 Publication 
2.1 
CYP109E1 
(I85A) 
B. 
megaterium 
B. 
megaterium 
45 24 Publication 
2.1  
CYP109E1  
(I85W) 
 
B. 
megaterium 
B. 
megaterium 
53 24 This work 
CYP105A2 P. 
autotrophica 
P. 
autotrophica 
8.3 120 (Sasaki et 
al., 1992) 
CYP105A2 P. 
autotrophica 
S. lividans 20 72 (Kawauchi 
et al., 1994) 
CYP105A1 
(R73V/R84A) 
S. griseolus S. lividans 7.8 24 (Hayashi et 
al., 2010) 
CYP107BR1 
(Vdh) 
P. 
autotrphica 
P. 
autotrophica 
137 72 (Takeda et 
al., 1994) 
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Therefore, we suggest that the identification and co-expression of the endogenous (or 
suitable heterologous) redox partners in B. megaterium can enhance the conversion of 
vitamin D3. Further enhancement can be achieved by feeding the culture with the heme 
precursor δ-aminolevulinic acid (δ-ALA). In our laboratory, it has been observed that the 
conversion of progesterone in CYP17 expressing B. megaterium is further optimized by 
addition of δ-ALA (data not published). 
 
3.2. Structural aspects of CYP109E1 and CYP109A2 
The crystal structures of CYP109E1 and CYP109A2 have been determined in collaboration 
with the laboratory of biophysical chemistry at the University of Groningen, which allowed 
the analysis of the active site geometry, providing the basis for future efforts to investigate 
these two enzymes (see publications 2.2 and 2.3). The structural comparison showed 
differences between these two enzymes, especially in functionally relevant regions such as 
BC loop and access channel, as reported in publication 2.2. The polar BC loop and the 
restricted access channel of CYP109A2, compared to CYP109E1, might decrease the 
number of stabilized conformation of the hydrophobic vitamin D3 in the active site resulting 
in the experimentally observed higher regio-selectivity of CYP109A2. 
Unfortunately, the complex of CYP109E1 and CYP109A2 with vitamin D3 as substrate has 
not been obtained. In the absence of the vitamin D3-bound crystal structure, it remains 
unknown how is vitamin D3 binding and which residues interact with in the active site of 
these two P450s. Molecular docking is a practical alternative for the study of substrate-
enzyme complexes, providing significant information on the positioning/orientation and 
interaction of the substrate within the catalytic pocket.  Fortunately, the closed conformation 
of CYP109E1 was determined in complex with the substrate testosterone (publication 2.3), 
providing the functionally active form of this enzyme and, therefore, this structure was used 
for docking experiments. The structurally different substrates (vitamin D3, compactin and α-
ionone) were docked into the active site of CYP109E1. The results obtained thus revealed 
that vitamin D3 exhibits a conformation in the CYP109E1 active site similar to the 
experimentally observed one in CYP107 (Vdh), as described in publication 2.1. The 
obtained results combined with site-directed mutagenesis enabled us to create CYP109E1 
variants with optimized regio-selectivity as well as to identify functionally relevant residues 
responsible for the catalytic activity and substrate specificity (see publications 2.1, 2.3 and 
section ‘Engineering of CYP109E1’). 
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Furthermore, our docking calculations predicted the orientation of compactin and α-ionone 
in CYP109E1 active site, confirming the experimentally observed regio-selectivity of the 
enzyme concerning the identified substrates (publication 2.4). In addition, the docking 
experiments allowed us to predict which active site residues interact with compactin and\or 
α-ionone, whose functional relevance should be investigated in future attempts. 
In case of CYP109A2, the docking experiments were not performed, as the functionally 
relevant crystal structure (closed conformation) of the enzyme is still unknown. However, 
the comparison of vitamin D3 binding residues in the active site of CYP109E1 or Vdh to 
their structural equivalents in CYP109A2 revealed a significant degree of conservation, 
supporting the suggestion of overall binding mode of vitamin D3 suitable for 25-
hydroxylation in these three enzymes, as reported in publication 2.2.  
The observed structural similarity between CYP109E1 and CYP109A2 gives hints for 
similar functions and, therefore, it is recommended to investigate if CYP109A2 can also 
convert the other substrates of CYP109E1 (compactin, lovastatin simvastatin, α- and β-
ionone, isolongifolen-9-one as well as α- and β- damascone). 
 
3.3. Engineering of CYP109E1 
Some enzyme properties have to be improved before enzymes can be employed in industrial 
biotransformation. From an economic point of view, the formation of side or undesirable 
products reduces the added value of the biotechnological process, especially when these 
undesirable products are less valuable than the target product. Moreover, the separation of 
the target product from other side products (downstream process) drives the costs up and is 
both time-consuming and technically difficult. Therefore, enzyme specificity and selectivity 
are crucial properties that affect the whole process. In general, the usage of P450s is often 
limited due to their poor regio- and stereo-selectivities, requiring the employment of protein 
engineering methods to overcome such limitations. 
As mentioned above, CYP109E1 catalyzes a multiple hydroxylation of vitamin D3 
producing 7 different products. Among them, our interest was focused on calcidiol 
(25(OH)VD3), which is produced with a ratio of 37% of total products. Therefore, our next 
aim was the creation of mutants with a higher regio-selectivity towards 25-hydroxylation. 
Using docking experiments and site-directed mutagenesis, we determined the functional 
importance of selected residues in the active site of the enzyme (described in publications 
2.1 and 2.3). 
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Concerning our target product (25(OH)VD3), an approximately 2-fold increase was achieved 
by the mutant I85A, compared to the wild type. This enhancement of 25(OH)VD3 yield is 
based on the improvement of the regio-selectivity towards 25-hydroxylation of vitamin D3 
(see publication 2.1). The residue I85 of CYP109E1 is located closest to the heme on the BC 
loop (SRS1), which is one of the most flexible regions in P450s. Previous studies have 
shown the critical role of the corresponding position (standard position 87 in P450 amino 
acid sequences (Gricman et al., 2015)) in terms of enzyme selectivity (Li et al., 2001; Liu et 
al., 2004). The impact of this position in CYP109E1 was further examined by semi-saturated 
mutagenesis.  In total, 10 different residues were introduced at position 85, creating the 
following CYP109E1 variants (CYP109E1-I85X, where X refers to: A, L, V, M, W, F, H, E, 
D or R). Interestingly, it has been found that all substitutions at position 85 yielded an 
improved regio-selectivity towards vitamin D3 compared to the wild type enzyme (Figure 
3.1 and Table 3.3). Hereby, 25(OH)VD3 was produced as the major product. Furthermore, 
it has been found that the replacement of the hydrophobic residue isoleucine at position 85 
by other hydrophobic residues (W, A, M, L, V, and F), results in comparable or slightly 
lower conversion of vitamin D3 compared to the wild type. On the other hand, the 
introduction of charged residues (R, E, D and H) causes a significant decrease in vitamin D3 
conversion (Table 3.3), demonstrating the important role of a hydrophobic side chain at 
position 85 for vitamin D3 conversion. It can be supposed that substitution at this position 
causes conformational changes, promoting a higher regio-selectivity towards vitamin D3 25-
hydroxylation and, therefore, the elucidation of the 3D-structures of CYP109E1 mutants is 
of great interest. In particular I85W mutant, which shows the highest regio-selectivity 
towards 25-hydroxylation (81%) (Table 3.3). 
 
In addition, it has been shown that the active site residues V169 (SRS2) and I241 (SRS4) are 
substrate-specificity determining residues as their substitution with alanine led to an 
abolishment of enzyme activity towards testosterone, while the activity towards vitamin D3 
is still maintained (publication 2.1 and 2.2). Vitamin D3 conversion by these two mutants 
has been, however, changed compared to the wild type enzyme. It was observed that these 
two mutants, in contrast to the wild type, show a significant decrease in 25-hydroxylation 
activity towards the intermediate product 24S(OH)VD3, resulting in the accumulation of this 
metabolite, in particular when using mutant V169A. Furthermore, differences between these 
two mutants have been observed in terms of their regio-selectivity.  
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While the mutant V169A showed the same ratio for 24- and 25-hydroxylation, the 24-
hydroxylation of vitamin D3 was preferred in the reaction of the mutant I241A (publication 
2.1). These results indicate the functional key role of these two active site residues and, 
therefore, further investigations of position 169 and 241 in CYP109E1 are highly 
recommended. 
 
 
Figure 3.1. HPLC chromatograms of 24 h whole-cell conversion of vitamin D3 by 
CYP109E1 and its mutants with one point mutation at position 85. The reactions 
were performed in B. megaterium MS941 overexpressing the corresponding P450 
variants. Vitamin D3 and its derivatives are labeld here by VD3 and P1-P7, 
respectively. P4 refers here to as 25(OH)VD3. 
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                     Table 3.3.  Vitamin D3 conversion by different variant of CYP109E1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Engineering of CYP109A2 
Previously, CYP109A2 was cloned and expressed based on an open reading frame (ORF) 
producing a protein of 426 amino acids (Brill, 2013). Using the genome data and depending 
on ribosomal binding site (RBS) analysis, it has been found in our recent studies that the 
correct start codon of CYP109A2 is located 69 nucleotides downstream the previously used 
start codon (Brill, 2013). The new open reading frame was cloned and expressed in E. coli 
leading to a protein with 403 amino acids. Spectral characterization of the purified 
“truncated” form of CYP109A2 (see publication 2.2) showed the characteristic peak at 450 
nm identical with the previously identified form of CYP109A2. The activity of the 
“truncated” form towards vitamin D3 was compared with that of the full-length form. 
Interestingly, a higher in vitro conversion of vitamin D3 (36 ±4 %) was reached with the new 
form of CYP109A2 (see publication 2.2), which is significantly higher than the conversion 
using the previously investigated form of the enzyme (conversion of <5%) (Brill, 2013). It 
should be mentioned that the previously (as full-length) identified form, in contrast to the 
new form (truncated), was not able to convert testosterone (Brill, 2013). Therefore, further 
Enzyme variant Conversion [%] Selectivity towards 25-
hydroxylation [%] 
WT 95 ± 3 36± 2 
I85W 92 ± 2 81± 3 
I85A 87 ± 4 64± 2 
I85M 83 ± 4 73± 1 
I85L 90 ± 2 48± 4 
I85V 89 ± 3 57± 1 
I85F 69 ± 5 71± 4 
I85H 59 ± 7 64± 1 
I85E 27 ± 4 48± 3 
I85R 31 ± 6 40± 4 
I85D 23 ± 8 40± 3 
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investigations of this P450 were performed with the “truncated” form, which is for the 
simplicity named as CYP109A2. 
 
CYP109A2 was studied by X-ray crystallography providing the typical organization of P450 
domains (Publication 2.2). Unfortunately, only the substrate-free structure of CYP109A2 
was obtained so far. Hereby, structural comparison can be useful to predict the substrate 
binding residues and functionally relevant regions. As reported in publication 2.2, 
CYP109A2 shows the highest structural similarity with the open form of CYP109E1 (PDP: 
5L91) and the structure of Vdh from P. autotrophica (PDB: 3A4G). It should be membered 
that the conversion of vitamin D3 by CYP109A2 is lower than that of CYP109E1 and 
CYP107. Through structural comparison, differences in the amino acid composition were 
observed in the active sites of these three enzymes, which lead to different charge 
distributions in the corresponding active sites. In comparison to CYP109E1 and CYP107, 
the charged amino acids R74, R78 and E81 (BC loop) of CYP109A2 form a highly polar 
surface, providing no optimal environment for the binding of highly hydrophobic substrates 
like vitamin D3. Therefore, these charged amino acids in CYP109A2 were mutated in order 
to get a less polar BC loop (more hydrophobic).   R74V, R78V and E81L mutants have been 
created and the whole-cell conversion of vitamin D3 with these mutants was performed. 
Unfortunately, the achieved conversion of vitamin D3 was not as good as expected. The 
E78V and E81L mutants showed a decreased conversion (44% and 52%) compared to wild 
type (75%). More interesting is the almost complete abolishment of the catalytic activity of 
the R74V mutant towards vitamin D3 (below 15% of added substrate were converted after 
24h), suggesting the importance of the R74 residue for the catalytic activity towards vitamin 
D3 (Figure S2). Conversely, the whole-cell conversion of testosterone using the mutant 
R74V was comparable with that of the wild type enzyme. Hence, further investigations of 
this mutant were performed. The R74V mutant was successfully expressed and purified in E. 
coli, showing the characteristic peak at 450 nm. In an in vitro reconstituted system 
containing the mutant R74V, the diflavin reductase BmCPR and the ferredoxin Fdx2, no 
activity towards testosterone or vitamin D3 was observed (data not shown). Since a sufficient 
sequential delivery of electrons from NAD(P)H via redox partners is needed for the catalytic 
activity of P450 enzymes, we aimed to examine the functional interaction between the 
electron transfer carriers and this mutant by recording the NADPH reduced CO-complex at 
peak 450 nm, as described previously (Milhim et al., 2016). 
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While CYP109A2 wild type produced a typical reduced CO spectrum with a Soret peak at 
450 nm, the mutant R74V did not show this Soret peak, demonstrating the disruption of the 
electron transfer to the mutant enzyme. 
This result explains the missing in vitro activity of R74V mutant when BmCPR and Fdx2 
are used as electron transfer proteins. It is known that R74 is not a part of the redox partner-
binding site of CYP109A2. However, we suggest that on one site the substitution of this 
residue might cause conformational changes in the whole structure that may affect the 
interaction between electron transfer protein and CYP109A2. On the other hand, it is also 
possible that the redox potential of this mutant has been changed compared to that of the 
wild type and, therefore, the electron transfer from the redox partner to this mutant becomes 
thermodynamically unfavorable. Summarizing, these results suggest that the mutant R74V 
strictly needs its endogenous redox partner to perform its catalytic activity, while this 
requirement is relaxed for the wild type enzyme. It should be noted that the observed in vivo 
activities of CYP109A2 and its mutants, including R74V mutant, are supported by the 
endogenous redox partners, which are still unknown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Reduction of CYP109A2 wild type (WT) and its mutant 
R74V using the autologous electron transfer protein BmCPR and Fdx2. 
NADPH reduced CO-difference spectra of CYP109A2 wild type (in blue) 
and R74V mutant (in red). The dithionite reduced CO-difference 
spectrum of the mutant R74V (black). The NADPH (1 mM) reduced CO-
difference spectra were recorded in a 400 μL mixture of 
CYP/ferredoxin/reductase with a 1:20:3 molar ratio in 50 mM potassium 
phosphate buffer pH 7.4 containing 20% glycerol. 
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Further attempts have been made in this work to increase vitamin D3 conversion by 
CYP109A2. It has been previously shown that a single mutation at the ferredoxin binding 
site of Vdh results in the highly active mutant T107A (Yasutake et al., 2013). The residue 
T103 of CYP109A2 was identified as corresponding residue to T107 of Vdh and, therefore, 
we aimed to investigate the role of T103 in CYP109A2. Our results showed that the 
substitution T103A lead to a slight increase of vitamin D3 conversion (85%), compared to 
wild type (75%) (Figure 3.3). Furthermore, the role of the neighboring residues of T103 
(P104, R105 and R106) were tested, as it was observed that both CYP109A2 and Vdh have 
a certain similarity in this region. P104A, R105A, R105K and A106R mutants of 
CYP109A2 were created and tested in terms of their activity towards vitamin D3. Our results 
showed that the substitution P104A does not affect the activity of CYP109A2 towards 
vitamin D3, while the substitution R105A led to a decrease in vitamin D3 conversion. 
Interestingly, the substitution of R105 with the positively charged residue lysine showed the 
same conversion as the wild type enzyme, indicating the relevance of positive charged 
residue at position of 105 in CYP109A2. In contrary, replacement of A106 with arginine led 
to a decrease in the vitamin D3 conversion. Based on these results, we suggest that the 
positions 103-106 in CYP109A2 form a functionally important region, which should be 
investigated in more details using single and a combination of two or more mutations. 
Previously, it has been shown that double and triple mutants of P450s (for example in case 
of Vdh and CYP105A1) showed a collective effect on enzymatic activity compared to single 
mutants (Fujii et al., 2009; Hayashi et al., 2010). 
  
 
 
 
 
 
 
 
Figure 3.3. HPLC-chromatogram of vitamin D3 conversion in B. 
megaterium MS941 ovrexpressing the wild type of CYP109A2 (WT) and its 
mutant T103A. The reactions were performed as described in publication 2.1 
and 2.2. 
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Taken together, the high potential of CYP109E1 and CYP109A2 as vitamin D3 
hydroxylases has been shown in this work. In comparison to the known whole-cell systems 
used for the bioconversion of vitamin D3, B. megaterium cells overexpressing CYP109E1 or 
CYP109A2 provide a high promising route to produce the valuable metabolite 25(OH)VD3. 
The elucidation of both, CYP109E1 and CYP109A2, crystal structures offers the first 
insights into the geometry of these two P450s. Furthermore, protein engineering has been 
successfully applied in this work to optimize the regio-selectivity and/or activity of 
CYP109E1 and CYP109A2. Besides the generation of enzyme mutants with improved 
properties compared to the wild type, the functional role of some residues in CYP109E1 and 
CYP109A2 has been determined using site-directed mutagenesis. 
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During the last years, the enzymatic oxyfunctionalization of unactivated carbons in organic 
compounds has gained interest, since chemical synthesis often consists of multistep-
procedures with environmentally unfriendly conditions. P450 monooxygenases can be the 
ideal biocatalysts for interesting industrial reactions and, therefore, the identification and 
characterization of novel P450 enzymes was and is still a main target for scientist. 
This work demonstrates the optimization and application of two members of CYP109 family 
for the conversion of vitamin D3. The obtained results demonstrate clearly the promising 
potential of CYP109A2- and CYP109E1-based whole-cell systems, providing a competitive 
offer for the production of 25(OH)VD3. Further enhancement of the system’s productivity, 
however, has to be achieved by optimization of the electron transfer, substrate solubility and 
substrate uptake. Hereby, site-directed mutagenesis performed in this work offers starting 
points for further mutations in order to optimize the redox-binding sites, in particular for 
CYP109A2 as the surface residues R105 and R106 seem to be implicated in the catalytic 
activity of this P450. In addition, the identification of the natural redox partner proteins of 
CYP109E1 and CYP109A2 is highly important and meaningful. Another point that can be 
further optimized is the poor solubility of vitamin D3 in aqueous solutions. Hereby, 
cyclodextrins have been shown to enhance enzymatic conversions of lipophilic substrates 
due to its lipophilic interior and hydrophilic outer surface (Harper et al., 2000). Previously, 
the Enhancement of androstadienedione production from progesterone was achieved by 
complexation of progesterone with 2-hydroxypropyl-β-cyclodextrin (HPCD) (Manosroi et 
al., 2008). Although HPCD has been successfully used in the present work to increase the 
solubility of the hydrophobic vitamin D3, previous studies have shown that the usage of 
partially-methylated-β-cyclodextrin (PMCD) is superior among other cyclodextrins 
derivatives for the bioconversion of vitamin D3 (Takeda et al., 1994). In this context, the 
effect of PMCD on vitamin D3 conversion should be investigated in future efforts with the 
established whole-cell system. In addition, to overcome the cellular membrane boundaries is 
an important problem that should be considered. To increase cell membrane permeability, 
the permeabilizing detergent saponin was used in this work to perform vitamin D3 in vivo 
conversion. However, other permeabilizing agents should be tested, too. Hereby, it has been 
reported that the antibiotic Nisin enhances vitamin D3 bioconversion in Rhodococcus 
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erythropolis through pore formation in the membrane and the disruption of cell wall 
biosynthesis (Imoto et al., 2011). 
The elucidation of the crystal structure of CYP109E1 in its closed conformation laid the 
basics for docking experiments and the subsequent site-directed mutagenesis investigations, 
which led to the creation of mutants with optimized regio-selectivity towards vitamin D3 25-
hydroxylation. Since only the open form of CYP109A2 was obtained, it is highly 
recommended to crystallize this P450 in its functionally active form (closed form), if 
possible in complex with vitamin D3. Moreover, the interesting mutants of CYP109E1 
(I85W) and CYP109A2 (R74V) deserve to be examined by X-ray protein crystallography. 
We believe that such structural information will improve our understanding for both, 
CYP109A2 and CYP109E1, and guide their further optimization processes. 
We were able to identify two novel vitamin D3 metabolites (24S(OH)VD3 and 
24S,25(OH)2VD3), whose physiological function has not been fully clarified and, therefore, 
relevant laboratory experiments should be performed to explore their physiological 
relevance. 
Finally, we suggest that the substrate spectrum of both enzymes, in particular of CYP109A2, 
can be further expanded and, thus, it would be beneficial to apply high-throughput methods 
to identify new substrates such as drugs and fatty acids. Some mutants of CYP109E1 and 
CYP109A2 show different substrate specificity compared to the corresponding wild type, 
hence, these mutants should be also taken into account for substrate screening. 
 
118
5. Appendix 
 
5.1. Plasmids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
119
Appendix 
5.2. Proteins 
> CYP109E1 (BMD_3874)| 
MKTERENGIVRQVNTIQTKEERFNPFSWYEEMRNTAPVQWDEERQVWDVFHYDGVKEVLEQKNIFS
SDRRPPQNQRQTALGTSLINIDPPKHAEMRALVNKAFTPKAMKAWEPKIARITNELLQEVEHLEDIDIV
EHLSYPLPVMVIADILGVPIEDQRQFKDWSDIIVAGPSNNERETLEKLQQEKMKANDELETYFYRIIEE
KRTRPGDDIISVLLQAKEEGKQLTDEEIVGFSILLLIAGNETTTNLISNTIYCLMEDKASFERLKREKELL
PSGIEEVLRYRSPVQALHRIVKEDVTLAGKKLKAGEHVVPWMGSAHRDAEYFEDPEVFKIDRKPNVH
MAFGRGIHFCLGAPLARIEAKIMLAELIDRYPQMDWSPSFELKPIESTFVYGLKELLIRKNV 
> CYP109A2 (BMD_2035) 
MNPKAVKRENRYANLIPMQEIKSVEQQLYPFDIYNSLRQEAPIRYDESRNCWDVFDYETVKYILKNPS
LFSSKRAMEERQESILMMDPPKHTKLRNLVNKAFTPRAIQHLEGHIEEIADYLLDEVSSKEKFDIVEDF
AGPLPIIVIAELLGVPIQDRALFKKYSDDLVSGAENNSDEAFAKMMQKRNEGVIFLQGYFKEIIAERQQ
NKQEDLISLLLEAEIDGEHLTEEEVLGFCILLLVAGNETTTNLITNGVRYMTEDVDVQNEVRRDISLVP
NLVEETLRYYPPIQAIGRIAAEDVELGECKIKRGQQVISWAASANRDSAKFEWPDTFVVHRKTNPHVS
FGFGIHFCLGAPLARMEGKIAFTKLLEKGGFSKVQNQSLKPIDSPFVFGVKKYEIAFNNA 
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Figure S1. HPLC chromatogram of testosterone conversion 
by CYP109A2 compared to CYP109E1-dependent 
conversion. Diflavin reductase (BmCPR) and ferredoxin 
(Fdx2) were used as redox partners. Testosterone and P450s 
were added in end concentrations of 200 µM and 1µM, 
respectively. The reactions were performed in potassium 
phosphate buffer at 30 °C for 1h. 
Figure S2. HPLC chromatogram of vitamin D3 whole-cell 
conversion using B. megaterium cells overexpressing 
CYP109A2 wild type and CYP109A2 mutant R74V.  
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6. Abbreviations 
 
 
 
AdR Adrenodoxin reductase 
Adx Adrenodoxin 
B. megaterium Bacillus megtaerium 
BmCPR Bacillus megaterium cytochrome P450 reductase 
CYP/P450 Cytochrome P450 
δ-aminolevulinic acid δ-ALA 
E. coli Escherichia coli 
FAD Flavine adenine dinucleotide 
Fdx2 Ferredoxin 2 from B. megaterium DSM319 
FMN Flavine mononucleotide 
HPLC High performance liquid chromatography 
HPCD 2-hydroxypropyl-β-cyclodextrin 
L Liter 
M Molar 
mg Milligram 
µM Micormolar 
NAD(P)H Nicotinamide adenine dinucleotide (phosphate) 
ORF Open reading frame 
P. autotrophica Pseudonocardia autotrophica 
S. griseolus Streptomyces griseolus 
S. lividans Streptomyces lividans 
SRS Substrate recognition site 
Vdh Vitamin D3 hydroxylase CYP107 from P. autotrophica 
VD3 Vitamin D3 
VDREs Vitamin D3 response elements 
25(OH)VD3 25-hydroxyvitamin D3 
1α,25(OH)2VD3 1α ,25-dihydroxyvitamin D3 
UV/Vis Ultraviolet–visible spectroscope 
WT Wild type 
 
122
7. References 
 
Abdulmughni, A., Jóźwik, I.K., Putkaradze, N., Brill, E., Zapp, J., Thunnissen, A.-M.W.H., 
Hannemann, F., Bernhardt, R., 2017a. Characterization of cytochrome P450 CYP109E1 from 
Bacillus megaterium as a novel vitamin D3 hydroxylase. J. Biotechnol. 243, 38–47. 
Abdulmughni, A., Jóźwik, I.K., Brill, E., Hannemann, F., Thunnissen, A.-M.W.H., Bernhardt, R., 
2017b. Biochemical and structural characterization of CYP109A2, a vitamin D3 25-
hydroxylase from Bacillus megaterium. FEBS J. 284, 3881–3894. 
Abe, E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K., Yamazaki, T., Yoshiki, S., Suda, T., 
1981. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-
dihydroxyvitamin D3. Proc. Natl. Acad. Sci. U. S. A. 78, 4990–4994. 
Arnold, F.H., 2017. Directed Evolution: Bringing New Chemistry to Life. Angew. Chem. Int. Ed Engl. 
Barletta, F., Freedman, L.P., Christakos, S., 2002. Enhancement of VDR-mediated transcription by 
phosphorylation: correlation with increased interaction between the VDR and DRIP205, a 
subunit of the VDR-interacting protein coactivator complex. Mol. Endocrinol. Baltim. Md 16, 
301–314. 
Bernhardt, R., 1996. Cytochrome P450: structure, function, and generation of reactive oxygen species. 
Rev. Physiol. Biochem. Pharmacol. 127, 137–221. 
Bernhardt, R., 2006. Cytochromes P450 as versatile biocatalysts. J. Biotechnol. 124, 128–145. 
Bernhardt, R., Urlacher, V.B., 2014. Cytochromes P450 as promising catalysts for biotechnological 
application: chances and limitations. Appl. Microbiol. Biotechnol. 98, 6185–6203. 
Biedendieck, R., 2016. A Bacillus megaterium System for the Production of Recombinant Proteins 
and Protein Complexes. Adv. Exp. Med. Biol. 896, 97–113. 
Bischoff-Ferrari, H.A., Giovannucci, E., Willett, W.C., Dietrich, T., Dawson-Hughes, B., 2006. 
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health 
outcomes. Am. J. Clin. Nutr. 84, 18–28. 
Bleif, S., Hannemann, F., Zapp, J., Hartmann, D., Jauch, J., Bernhardt, R., 2012. A new Bacillus 
megaterium whole-cell catalyst for the hydroxylation of the pentacyclic triterpene 11-keto-β-
boswellic acid (KBA) based on a recombinant cytochrome P450 system. Appl. Microbiol. 
Biotechnol. 93, 1135–1146. 
Böttcher, D., Bornscheuer, U.T., 2010. Protein engineering of microbial enzymes. Curr. Opin. 
Microbiol., Ecology and industrial microbiology • Special section: Systems biology 13, 274–
282. 
Brill, E., 2013. Identifizierung und Charakterisierung neuer Cytochrom P450 Systeme  aus Bacillus 
megaterium DSM319. Universität des Saarlandes. 
Brill, E., Hannemann, F., Zapp, J., Brüning, G., Jauch, J., Bernhardt, R., 2014. A new cytochrome 
P450 system from Bacillus megaterium DSM319 for the hydroxylation of 11-keto-β-boswellic 
acid (KBA). Appl. Microbiol. Biotechnol. 98, 1701–1717. 
Brown, A.J., Dusso, A.S., Slatopolsky, E., 2002. Renal failure and vitamin D. Clin. Calcium 12, 711–
723. 
Buchholz, K., Kasche, V., Bornscheuer, U.T., 2005. Biocatalysts and enzyme technology. Wiley-
VCH, Weinheim. 
Calvo, M.S., Whiting, S.J., Barton, C.N., 2005. Vitamin D intake: a global perspective of current 
status. J. Nutr. 135, 310–316. 
Cheng, J.B., Levine, M.A., Bell, N.H., Mangelsdorf, D.J., Russell, D.W., 2004. Genetic evidence that 
the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. U. S. 
A. 101, 7711–7715. 
123
References 
 
Declerck, N., Machius, M., Wiegand, G., Huber, R., Gaillardin, C., 2000. Probing structural 
determinants specifying high thermostability in Bacillus licheniformis α-amylase. Edited by 
A. R. Fersht. J. Mol. Biol. 301, 1041–1057. 
DeLuca, H.F., 2004. Overview of general physiologic features and functions of vitamin D. Am. J. 
Clin. Nutr. 80, 1689S–1696S. 
Deluca, H.F., Cantorna, M.T., 2001. Vitamin D: its role and uses in immunology. FASEB J. Off. Publ. 
Fed. Am. Soc. Exp. Biol. 15, 2579–2585. 
Denisov, I.G., Makris, T.M., Sligar, S.G., Schlichting, I., 2005. Structure and chemistry of cytochrome 
P450. Chem. Rev. 105, 2253–2277. 
Di Rosa, M., Malaguarnera, M., Nicoletti, F., Malaguarnera, L., 2011. Vitamin D3: a helpful immuno-
modulator. Immunology 134, 123–139. 
Duso, A., Brown AJ., Slatopolsky E., 2004. Vitamin D. - PubMed - NCBI. Am. Physiol. Soc. 289.  
Ehrhardt, M., Gerber, A., Hannemann, F., Bernhardt, R., 2016. Expression of human CYP27A1 in B. 
megaterium for the efficient hydroxylation of cholesterol, vitamin D3 and 7-
dehydrocholesterol. J. Biotechnol. 218, 34–40. 
Ener, M.E., Lee, Y.-T., Winkler, J.R., Gray, H.B., Cheruzel, L., 2010. Photooxidation of cytochrome 
P450-BM3. Proc. Natl. Acad. Sci. 107, 18783–18786. 
Eppinger, M., Bunk, B., Johns, M.A., Edirisinghe, J.N., Kutumbaka, K.K., Koenig, S.S.K., Creasy, 
H.H., Rosovitz, M.J., Riley, D.R., Daugherty, S., Martin, M., Elbourne, L.D.H., Paulsen, I., 
Biedendieck, R., Braun, C., Grayburn, S., Dhingra, S., Lukyanchuk, V., Ball, B., Ul-Qamar, 
R., Seibel, J., Bremer, E., Jahn, D., Ravel, J., Vary, P.S., 2011. Genome sequences of the 
biotechnologically important Bacillus megaterium strains QM B1551 and DSM319. J. 
Bacteriol. 193, 4199–4213. 
Fujii, Y., Kabumoto, H., Nishimura, K., Fujii, T., Yanai, S., Takeda, K., Tamura, N., Arisawa, A., 
Tamura, T., 2009. Purification, characterization, and directed evolution study of a vitamin D3 
hydroxylase from Pseudonocardia autotrophica. Biochem. Biophys. Res. Commun. 385, 
170–175. 
Gamble, M.J., Freedman, L.P., 2002. A coactivator code for transcription. Trends Biochem. Sci. 27, 
165–167. 
Garfinkel, D., 1958. Studies on pig liver microsomes. I. Enzymic and pigment composition of 
different microsomal fractions. Arch. Biochem. Biophys. 77, 493–509. 
Gillam, E.M.J., 2008. Engineering cytochrome p450 enzymes. Chem. Res. Toxicol. 21, 220–
231. 
Gotoh, O., 1992. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred 
from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 
267, 83–90. 
Graham, S.E., Peterson, J.A., 1999. How similar are P450s and what can their differences teach us? 
Arch. Biochem. Biophys. 369, 24–29. 
Grant, W.B., 2002. An estimate of premature cancer mortality in the U.S. due to inadequate doses of 
solar ultraviolet-B radiation. Cancer 94, 1867–1875. 
Gricman, Ł., Vogel, C., Pleiss, J., 2015. Identification of universal selectivity-determining positions in 
cytochrome P450 monooxygenases by systematic sequence-based literature mining. Proteins 
Struct. Funct. Bioinforma. 83, 1593–1603. 
Groves, J.T., 2006. High-valent iron in chemical and biological oxidations. J. Inorg. Biochem. 100, 
434–447. 
Guengerich, F.P., Munro, A.W., 2013. Unusual cytochrome p450 enzymes and reactions. J. Biol. 
Chem. 288, 17065–17073. 
124
References 
 
Hakki, T., Zearo, S., Drăgan, C.-A., Bureik, M., Bernhardt, R., 2008. Coexpression of redox partners 
increases the hydrocortisone (cortisol) production efficiency in CYP11B1 expressing fission 
yeast Schizosaccharomyces pombe. J. Biotechnol. 133, 351–359. 
Hannemann, F., Bichet, A., Ewen, K.M., Bernhardt, R., 2007. Cytochrome P450 systems--biological 
variations of electron transport chains. Biochim. Biophys. Acta 1770, 330–344. 
Harper, J.B., Easton, C.J., Lincoln, S.F., 2000. Cyclodextrins to Increase the Utility of Enzymes in 
Organic Synthesis | BenthamScience. Curr. Org. Chem. 4, 429–454. 
Haussler, M.R., Whitfield, G.K., Haussler, C.A., Hsieh, J.C., Thompson, P.D., Selznick, S.H., 
Dominguez, C.E., Jurutka, P.W., 1998. The nuclear vitamin D receptor: biological and 
molecular regulatory properties revealed. J. Bone Miner. Res. 13, 325–349. 
Hayashi, K., Sugimoto, H., Shinkyo, R., Yamada, M., Ikeda, S., Ikushiro, S., Kamakura, M., Shiro, Y., 
Sakaki, T., 2008. Structure-based design of a highly active vitamin D hydroxylase from 
Streptomyces griseolus CYP105A1. Biochemistry (Mosc.) 47, 11964–11972. 
Hayashi, K., Yasuda, K., Sugimoto, H., Ikushiro, S., Kamakura, M., Kittaka, A., Horst, R.L., Chen, 
T.C., Ohta, M., Shiro, Y., Sakaki, T., 2010. Three-step hydroxylation of vitamin D3 by a 
genetically engineered CYP105A1. FEBS J. 277, 3999–4009. 
Hazel M Girvan & Andrew W Munro, 2016. Applications of microbial cytochrome P450 enzymes in 
biotechnology and synthetic biology 31, 136–145. 
Heaney, R.P., Dowell, M.S., Hale, C.A., Bendich, A., 2003. Calcium absorption varies within the 
reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr. 22, 142–146. 
Hebeda, R.E., Styrlund, C.R., Teague, W.M., 1988. Benefits of Bacillus megaterium Amylase in 
Dextrose Production. Starch - Stärke 40, 33–36. 
Holick, M.F., 2007. Vitamin D deficiency. N. Engl. J. Med. 357, 266–281. 
Holick, M.F., 2004. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, 
and osteoporosis. Am. J. Clin. Nutr. 79, 362–371. 
Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., 
Murad, M.H., Weaver, C.M., Endocrine Society, 2011. Evaluation, treatment, and prevention 
of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. 
Metab. 96, 1911–1930. 
Holick, M.F., DeLuca, H.F., Avioli, L.V., 1972. Isolation and identification of 25-
hydroxycholecalciferol from human plasma. Arch. Intern. Med. 129, 56–61. 
Holick, M.F., Frommer, J.E., McNeill, S.C., Richtand, N.M., Henley, J.W., Potts, J.T., 1977. 
Photometabolism of 7-dehydrocholesterol to previtamin D3 in skin. Biochem. Biophys. Res. 
Commun. 76, 107–114. 
Holick, M.F., MacLaughlin, J.A., Clark, M.B., Holick, S.A., Potts, J.T., Anderson, R.R., Blank, I.H., 
Parrish, J.A., Elias, P., 1980. Photosynthesis of previtamin D3 in human skin and the 
physiologic consequences. Science 210, 203–205. 
Hollmann, R., Deckwer, W.-D., 2004. Pyruvate formation and suppression in recombinant 
Bacillus megaterium cultivation. J. Biotechnol. 111, 89–96.Horsting, M., DeLuca, H.F., 
1969. In vitro production of 25-hydroxycholecalciferol. Biochem. Biophys. Res. Commun. 36, 
251–256. 
Hossein-nezhad, A., Holick, M.F., 2013. Vitamin D for Health: A Global Perspective. Mayo Clin. 
Proc. Mayo Clin. 88, 720–755. 
Illanes, A., Cauerhff, A., Wilson, L., Castro, G.R., 2012. Recent trends in biocatalysis engineering. 
Bioresour. Technol., Biocatalysis 115, 48–57. 
Imai, M., Shimada, H., Watanabe, Y., Matsushima-Hibiya, Y., Makino, R., Koga, H., Horiuchi, T., 
Ishimura, Y., 1989. Uncoupling of the cytochrome P-450cam monooxygenase reaction by a 
single mutation, threonine-252 to alanine or valine: possible role of the hydroxy amino acid in 
oxygen activation. Proc. Natl. Acad. Sci. U. S. A. 86, 7823–7827. 
125
References 
 
Imoto, N., Nishioka, T., Tamura, T., 2011. Permeabilization induced by lipid II-targeting lantibiotic 
nisin and its effect on the bioconversion of vitamin D3 to 25-hydroxyvitamin D3 by 
Rhodococcus erythropolis. Biochem. Biophys. Res. Commun. 405, 393–398. 
Jean, G., Terrat, J.-C., Vanel, T., Hurot, J.-M., Lorriaux, C., Mayor, B., Chazot, C., 2008. Daily oral 
25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis 
patients: effects on mineral metabolism and bone markers. Nephrol. Dial. Transplant. 23, 
3670–3676. 
Julsing, M.K., Cornelissen, S., Bühler, B., Schmid, A., 2008. Heme-iron oxygenases: powerful 
industrial biocatalysts? Curr. Opin. Chem. Biol. 12, 177–186. 
Kametani, T., Furuyama, H., 1987. Synthesis of vitamin D3 and related compounds. Med. Res. Rev. 7, 
147–171. 
Kawauchi, H., Sasaki, J., Adachi, T., Hanada, K., Beppu, T., Horinouchi, S., 1994. Cloning and 
nucleotide sequence of a bacterial cytochrome P-450VD25 gene encoding vitamin D-3 25-
hydroxylase. Biochim. Biophys. Acta BBA - Gene Struct. Expr. 1219, 179–183. 
Kiss, F.M., Khatri, Y., Zapp, J., Bernhardt, R., 2015. Identification of new substrates for the 
CYP106A1-mediated 11-oxidation and investigation of the reaction mechanism. FEBS Lett. 
589, 2320–2326. 
Kittsteiner-Eberle, R., Ogbomo, I., Schmidt, H.-L., 1989. Biosensing devices for the semi-automated 
control of dehydrogenase substrates in fermentations. Biosensors 4, 75–85. 
Klingenberg, M., 1958. Pigments of rat liver microsomes. Arch. Biochem. Biophys. 75, 376–386. 
Kumar, S., 2010. Engineering Cytochrome P450 Biocatalysts for Biotechnology, Medicine, and 
Bioremediation. Expert Opin. Drug Metab. Toxicol. 6, 115–131. 
Leichtmann, G.A., Bengoa, J.M., Bolt, M.J., Sitrin, M.D., 1991. Intestinal absorption of 
cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and 
intestinal resection. Am. J. Clin. Nutr. 54, 548–552. 
Li, H., Poulos, T.L., 1997. The structure of the cytochrome p450BM-3 haem domain complexed with 
the fatty acid substrate, palmitoleic acid. Nat. Struct. Biol. 4, 140–146. 
Li, Q.S., Ogawa, J., Schmid, R.D., Shimizu, S., 2001. Residue size at position 87 of cytochrome P450 
BM-3 determines its stereoselectivity in propylbenzene and 3-chlorostyrene oxidation. FEBS 
Lett. 508, 249–252. 
Li, Y., Cirino, P.C., 2014. Recent advances in engineering proteins for biocatalysis. Biotechnol. 
Bioeng. 111, 1273–1287. 
Li, Y.C., 2003. Vitamin D regulation of the renin-angiotensin system. J. Cell. Biochem. 88, 327–331. 
Lin, Z., Marepally, S.R., Ma, D., Myers, L.K., Postlethwaite, A.E., Tuckey, R.C., Cheng, C.Y.S., Kim, 
T.-K., Yue, J., Slominski, A.T., Miller, D.D., Li, W., 2015. Chemical Synthesis and Biological 
Activities of 20S,24S/R-Dihydroxyvitamin D3 Epimers and Their 1α-Hydroxyl Derivatives. J. 
Med. Chem. 58, 7881–7887. 
Liu, J., Ericksen, S.S., Sivaneri, M., Besspiata, D., Fisher, C.W., Szklarz, G.D., 2004. The effect of 
reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin 
metabolism. Arch. Biochem. Biophys. 424, 33–43. 
Lu, A.Y., Junk, K.W., Coon, M.J., 1969. Resolution of the cytochrome P-450-containing omega-
hydroxylation system of liver microsomes into three components. J. Biol. Chem. 244, 3714–
3721. 
Manosroi, A., Saowakhon, S., Manosroi, J., 2008. Enhancement of androstadienedione production 
from progesterone by biotransformation using the hydroxypropyl-β-cyclodextrin 
complexation technique. J. Steroid Biochem. Mol. Biol. 108, 132–136. 
Martín, L., Prieto, M.A., Cortés, E., García, J.L., 1995. Cloning and sequencing of the pac gene 
encoding the penicillin G acylase of Bacillus megaterium ATCC 14945. FEMS Microbiol. 
Lett. 125, 287–292. 
126
References 
 
Martinis, S.A., Atkins, W.M., Stayton, P.S., Sligar, S.G., 1989. A conserved residue of cytochrome P-
450 is involved in heme-oxygen stability and activation. J. Am. Chem. Soc. 111, 9252–9253. 
McIntosh, J.A., Farwell, C.C., Arnold, F.H., 2014. Expanding P450 catalytic reaction space 
through evolution and engineering. Curr. Opin. Chem. Biol. 19, 126–134.  
Milhim, M., Putkaradze, N., Abdulmughni, A., Kern, F., Hartz, P., Bernhardt, R., 2016. Identification 
of a new plasmid-encoded cytochrome P450 CYP107DY1 from Bacillus megaterium with a 
catalytic activity towards mevastatin. J. Biotechnol. 240, 68–75. 
Munetsuna, E., Kawanami, R., Nishikawa, M., Ikeda, S., Nakabayashi, S., Yasuda, K., Ohta, M., 
Kamakura, M., Ikushiro, S., Sakaki, T., 2014. Anti-proliferative activity of 25-hydroxyvitamin 
D3 in human prostate cells. Mol. Cell. Endocrinol. 382, 960–970.  
Nelson, D.R., 2011. Progress in tracing the evolutionary paths of cytochrome P450. Biochim. 
Biophys. Acta BBA - Proteins Proteomics, Cytochrome P450: Structure, biodiversity and 
potential for application 1814, 14–18.  
Nelson, D.R., 2009. The Cytochrome P450 Homepage. Hum. Genomics 4, 59–65. 
Nordblom, G.D., White, R.E., Coon, M.J., 1976. Studies on hydroperoxide-dependent substrate 
hydroxylation by purified liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 175, 
524–533. 
Okano, T., Yasumura, M., Mizuno, K., Kobayashi, T., 1977. Photochemical conversion of 7-
dehydrocholesterol into vitamin D3 in rat skins. J. Nutr. Sci. Vitaminol. (Tokyo) 23, 165–168. 
Oliver, C.F., Modi, S., Sutcliffe, M.J., Primrose, W.U., Lian, L.Y., Roberts, G.C., 1997. A single 
mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate 
and the regiospecificity of hydroxylation. Biochemistry (Mosc.) 36, 1567–1572. 
Omura, T., Sanders, E., Estabrook, R.W., Cooper, D.Y., Rosenthal, O., 1966. Isolation from adrenal 
cortex of a nonheme iron protein and a flavoprotein functional as a reduced 
triphosphopyridine nucleotide-cytochrome P-450 reductase. Arch. Biochem. Biophys. 117, 
660–673. 
Omura, T., Sato, R., 1964. The carbon Monoxide-binding Pigment of liver Microsomes. J. Biol. 
Chem. 239, 2370–2378. 
Ozono, K., Liao, J., Kerner, S.A., Scott, R.A., Pike, J.W., 1990. The vitamin D-responsive element in 
the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. J. Biol. 
Chem. 265, 21881–21888. 
Pike, J.W., Meyer, M.B., 2010. The Vitamin D Receptor: New Paradigms for the Regulation of Gene 
Expression by 1,25-Dihydroxyvitamin D3. Endocrinol. Metab. Clin. North Am. 39, 255–269.  
Prosser, D.E., Jones, G., 2004. Enzymes involved in the activation and inactivation of vitamin D. 
Trends Biochem. Sci. 29, 664–673.  
Putkaradze, N., Litzenburger, M., Abdulmughni, A., Milhim, M., Brill, E., Hannemann, F., Bernhardt, 
R., 2017. CYP109E1 is a novel versatile statin and terpene oxidase from Bacillus megaterium. 
Appl. Microbiol. Biotechnol. 
Raux, E., Lanois, A., Warren, M.J., Rambach, A., Thermes, C., 1998. Cobalamin (vitamin B12) 
biosynthesis: identification and characterization of a Bacillus megaterium cobI operon. 
Biochem. J. 335 ( Pt 1), 159–166. 
Rojkova, A.M., Galkin, A.G., Kulakova, L.B., Serov, A.E., Savitsky, P.A., Fedorchuk, V.V., Tishkov, 
V.I., 1999. Bacterial formate dehydrogenase. Increasing the enzyme thermal stability by 
hydrophobization of alpha-helices. FEBS Lett. 445, 183–188.  
Röthlisberger, D., Khersonsky, O., Wollacott, A.M., Jiang, L., DeChancie, J., Betker, J., Gallaher, 
J.L., Althoff, E.A., Zanghellini, A., Dym, O., Albeck, S., Houk, K.N., Tawfik, D.S., Baker, 
D., 2008. Kemp elimination catalysts by computational enzyme design. Nature 453, 190–195. 
Sakaki, T., 2012. Practical application of cytochrome P450. Biol. Pharm. Bull. 35, 844–849. 
127
References 
 
Sakaki, T., Sugimoto, H., Hayashi, K., Yasuda, K., Munetsuna, E., Kamakura, M., Ikushiro, S., Shiro, 
Y., 2011. Bioconversion of vitamin D to its active form by bacterial or mammalian 
cytochrome P450. Biochim. Biophys. Acta BBA - Proteins Proteomics 1814, 249–256. 
Sasaki, J., Mikami, A., Mizoue, K., Omura, S., 1991. Transformation of 25- and 1 alpha-
hydroxyvitamin D3 to 1 alpha, 25-dihydroxyvitamin D3 by using Streptomyces sp. strains. 
Appl. Environ. Microbiol. 57, 2841–2846. 
Sasaki, J., Miyazaki, A., Saito, M., Adachi, T., Mizoue, K., Hanada, K., Omura, S., 1992. 
Transformation of vitamin D3 to 1 alpha,25-dihydroxyvitamin D3 via 25-hydroxyvitamin D3 
using Amycolata sp. strains. Appl. Microbiol. Biotechnol. 38, 152–157. 
Sawada, N., Sakaki, T., Yoneda, S., Kusudo, T., Shinkyo, R., Ohta, M., Inouye, K., 2004. Conversion 
of vitamin D3 to 1α,25-dihydroxyvitamin D3 by Streptomyces griseolus cytochrome P450SU-
1. Biochem. Biophys. Res. Commun. 320, 156–164. 
Schuster, I., 2011. Cytochromes P450 are essential players in the vitamin D signaling system. 
Biochim. Biophys. Acta 1814, 186–199. 
Seino, Y., Tanaka, H., Nagai, Y., 1997. Use of 24,25-dihydroxyvitamin D3 for the manufacture of a 
medicament for the treatment of rickets. EP0575974. 
Seo, E.G., Einhorn, T.A., Norman, A.W., 1997. 24R,25-dihydroxyvitamin D3: an essential vitamin D3 
metabolite for both normal bone integrity and healing of tibial fracture in chicks. 
Endocrinology 138, 3864–3872. 
Soares, J.H., Kerr, J.M., Gray, R.W., 1995. 25-hydroxycholecalciferol in poultry nutrition. Poult. Sci. 
74, 1919–1934. 
Sono, M., Roach, M.P., Coulter, E.D., Dawson, J.H., 1996. Heme-Containing Oxygenases. Chem. 
Rev. 96, 2841–2888. 
Spiro, A., Buttriss, J.L., 2014. Vitamin D: An overview of vitamin D status and intake in Europe. 
Nutr. Bull. Bnf 39, 322–350. 
Stammen, S., Müller, B.K., Korneli, C., Biedendieck, R., Gamer, M., Franco-Lara, E., Jahn, D., 2010. 
High-Yield Intra- and Extracellular Protein Production Using Bacillus megaterium. Appl. 
Environ. Microbiol. 76, 4037–4046. 
Sutton, A.L.M., MacDonald, P.N., 2003. Vitamin D: more than a “bone-a-fide” hormone. Mol. 
Endocrinol. Baltim. Md 17, 777–791. 
Takeda, K., Asou, T., Matsuda, A., Kimura, K., Okamura, K., Okamoto, R., Sasaki, J., Adachi, T., 
Omura, S., 1994. Application of cyclodextrin to microbial transformation of vitamin D3 to 25-
hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3. J. Ferment. Bioeng. 78, 380–382. 
Tsai, M.J., O’Malley, B.W., 1994. Molecular mechanisms of action of steroid/thyroid receptor 
superfamily members. Annu. Rev. Biochem. 63, 451–486. 
Tucker, G., Gagnon, R.E., Haussler, M.R., 1973. Vitamin D3-25-hydroxylase: Tissue occurrence and 
apparent lack of regulation. Arch. Biochem. Biophys. 155, 47–57. 
Underwood, J.L., DeLuca, H.F., 1984. Vitamin D is not directly necessary for bone growth and 
mineralization. Am. J. Physiol. 246, E493-498. 
Urlacher, V.B., Lutz-Wahl, S., Schmid, R.D., 2004. Microbial P450 enzymes in biotechnology. Appl. 
Microbiol. Biotechnol. 64, 317–325. 
Vary, P., 1992. Development of genetic engineering in Bacillus megaterium. Biotechnol. Read. Mass 
22, 251–310. 
Vary, P.S., 1994. Prime time for Bacillus megaterium. Microbiol. Read. Engl. 140 ( Pt 5), 1001–1013. 
Vary, P.S., Biedendieck, R., Fuerch, T., Meinhardt, F., Rohde, M., Deckwer, W.-D., Jahn, D., 2007. 
Bacillus megaterium—from simple soil bacterium to industrial protein production host. Appl. 
Microbiol. Biotechnol. 76, 957–967. 
128
References 
 
Wagner, N., Wagner, K.-D., Schley, G., Badiali, L., Theres, H., Scholz, H., 2003. 1,25-
dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal 
changes of Bcl-2 and bax. Exp. Eye Res. 77, 1–9. 
Watanabe, I., Nara, F., Serizawa, N., 1995. Cloning, characterization and expression of the gene 
encoding cytochrome P-450sca-in2 from Streptomyces carbophilus involved in production of 
pravastatin, a specific HMG-CoA reductase inhibitor. Gene 163, 81–85. 
Whitehouse, C.J.C., Bell, S.G., Wong, L.-L., 2012. P450 (BM3) (CYP102A1): connecting the dots. 
Chem. Soc. Rev. 41, 1218–1260. 
Yano, J.K., Koo, L.S., Schuller, D.J., Li, H., Ortiz de Montellano, P.R., Poulos, T.L., 2000. Crystal 
structure of a thermophilic cytochrome P450 from the archaeon Sulfolobus solfataricus. J. 
Biol. Chem. 275, 31086–31092.  
Yasutake, Y., Nishioka, T., Imoto, N., Tamura, T., 2013. A single mutation at the ferredoxin binding 
site of P450 Vdh enables efficient biocatalytic production of 25-hydroxyvitamin D(3). 
Chembiochem Eur. J. Chem. Biol. 14, 2284–2291. 
Yasuda, K., Sugimoto, H., Hayashi, K., Takita, T., Yasukawa, K., Ohta, M., Kamakura, M., 
Ikushiro, S., Shiro, Y., Sakaki, T., 2018. Protein engineering of CYP105s for their 
industrial uses. Biochim. Biophys. Acta 1866, 23–31. 
Zhao, H., Chockalingam, K., Chen, Z., 2002. Directed evolution of enzymes and pathways for 
industrial biocatalysis. Curr. Opin. Biotechnol. 13, 104–110. 
129
